Official Protocol Title:  
NCT number:  [STUDY_ID_REMOVED] 
Document Date:  11-May-2020A Phase 1/Phase 2, Randomized, Double-blind Study to Evaluate 
the Safety, Tolerability, and Immunogenicity of a Polyvalent 
Pneumococcal Conjugate Vaccine in Adults.
PRODUCT: V116  1
PROTOCOL/AMENDMENT N O.:001-01 
V116 -001-01FINAL PROTOCOL 11-MAY -2020
Title Page
THIS PROTOCOL AMENDMENT AND ALL OF THE INFORMATION RELATING 
TO IT ARE CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK 
SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC., NJ, U.S.A. 
(MSD) .
Protocol Title: A Phase 1/Phase 2, Randomized, Double -blind Study  to Evaluate the Safety , 
Tolerability , and Immunogenicity  of a Poly valent Pneumococcal Conjugate Vaccine in 
Adults.
Protocol Number: 001-01
Compound Number: V116
Sponsor Name:
[CONTACT_19519] & Dohme Corp., a subsidiary  of [COMPANY_006] & Co., Inc.
(hereafter referred to as the Sponsor or MSD)
Legal Registered Address:
One [COMPANY_006] Drive
[PO_BOX]
Whitehouse Station, New Jersey , [ZIP_CODE]- 0100, U.S.A.
Regulatory Agency Identifying Number(s):
IND [ZIP_CODE]
Approval Date: 11May [ADDRESS_1214509]: V116  2
PROTOCOL/AMENDMENT N O.:001-01 
V116 -001-01FINAL PROTOCOL 11-MAY -2020
Sponsor Signatory
Typed Name:
[CONTACT_1641]:Date
Protocol -specific Sponsor c ontact information can be found in the Investigator Study
File Binder (or equivalent).
Investigator Signatory
I agree to conduct this clinical study in accordance with the design outlined in this protocol 
and to abide b y all provisions of this protocol.
Typed Name:
[CONTACT_1641]:DateÂ 
Â  05H6VD
07XD6Y
PRODUCT: V116  3
PROTOCOL/AMENDMENT N O.:001-[ADDRESS_1214510]: V116  4
PROTOCOL/AMENDMENT N O.:001-01 
V116 -001-01FINAL PROTOCOL 11-MAY -2020
PROTOCOL AMENDMENT S UMMARY OF CHANGES
Amendment: 01
Overall Rationale for the Amendments:
The primary  purpose of this amendment is to include definitions forsolicited and unsolicited adverse events.
Summary of Changes Table:
Section # and Name [CONTACT_11029]  
8.1.[ADDRESS_1214511] (VRC)
8.3.4 Postvaccination 
Observation Period
8.4.8 Adverse Events 
Reported on the VRC
10.3.1 Definition of AEDetails related to AEs reported on the 
VRC were moved from Section 8.1.9 to 
Section 8.4.8.
The previous Section 8.3.4 (Safet y 
Assessments and Use of the VRC/eVRC) 
was split into 2 sections: Section 8.3.[ADDRESS_1214512]: V116  5
PROTOCOL/AMENDMENT N O.:001-01 
V116 -001-01FINAL PROTOCOL 11-MAY -2020
Section # and Name [CONTACT_11029]  
5.1 Inclusion Criteria
10.5.2 Contraception 
RequirementsUpdated inclusion criterion No. 4 to 
include different contraception 
requirements for Phase 1 and Phase 2.
Added subsections to Appendix 3 
(Section 10.5.2) to define different 
contraception requirements for Phase 1 
(Section [IP_ADDRESS]) and Phase 2 
(Section [IP_ADDRESS]).Based on assessment of additional nonclinical data, 
contraception requirements for Phase 2 were made less 
restrictive compared wi th Phase 1.
1.2.2 Schema for Phase 2
1.3.2 Schedule of 
Activities for Phase 2
8 Study  Assessments and 
Procedures (Table 4: 
Approximate Blood 
Volumes Drawn b y Study  
Visit and Sample Ty pe 
[Phase 2])Added visit numbers for the telephone 
contacts in Phase 2:
ï‚·Visit 2 (Day  [ADDRESS_1214513])
ï‚·Visit 4 (Day [ADDRESS_1214514])
ï‚·Visit 5 (Day [ADDRESS_1214515])
The Day 30 site visit in Phase 2 
(previousl y Visit 2)was renumbered to 
Visit 3Visit numbers were added for telephone contacts.
1.3.[ADDRESS_1214516]: V116  6
PROTOCOL/AMENDMENT N O.:001-01 
V116 -001-01FINAL PROTOCOL 11-MAY -2020
Section # and Name [CONTACT_11029]  
[IP_ADDRESS] Future Biomedical 
Researc h
[IP_ADDRESS] Consent and 
Collection of Specimens 
for Future Biomedical 
Research
10.6 Appendix 6: 
Collection and 
Management of Specimens 
for Future Biomedical 
ResearchRemoved the word â€œsubstudy â€ from the 
description of future biomedical research.Future biome dical research is not a separate substudy .
8.1.13 Participant 
Blinding/UnblindingAdded the following text to clarify  
emergency  unblinding procedures:
Once an emergency  unblinding has taken 
place, the investigator, site personnel, and 
Sponsor personnel may  be unblinded so 
that the appropriate follow -up medical 
care can be provided to the participant.Revisions were made for clarity .
Throughout Editorial revisions . Minor editorial changes to the text.Â 
Â  05H6VD
07XD6Y
PRODUCT: V116  7
PROTOCOL/AMENDMENT N O.:001-01 
V116 -001-01FINAL PROTOCOL 11-MAY -2020
Table of Contents
DOCUMENT HISTORY ........................................................................................................ 3
PROTOCOL AMENDMENT S UMMARY OF CHANGES ............................................... 4
1 PROTOCOL SUMMARY ............................................................................................ 14
1.1 Synopsis ................................................................................................................. 14
1.2 Schema .................................................................................................................. 18
1.2.1 Schema for Phase 1 ...................................................................................... 18
1.2.2 Schema for Phase 2 ...................................................................................... 19
1.3 Schedule of Activities ........................................................................................... 20
1.3.1 Schedule of Activities for Phase 1 ............................................................... 20
1.3.2 Schedule of Activities for Phase 2 ............................................................... 23
2 INTRODUCTION .......................................................................................................... 26
2.1 Study Rationale ....................................................................................................26
2.2 Background .......................................................................................................... 26
2.2.1 Pharmaceutical and Therapeutic Background ............................................. 26
2.2.2 Preclinical and Clinical Studies ...................................................................27
2.2.3 Information on Other Study -related Therap y.............................................. 27
[IP_ADDRESS] PNEUMOVAXâ„¢23 .......................................................................... 27
2.3 Benefit/Risk Assessment ...................................................................................... 28
3 HYPOTHESES, OBJECTIVES, AND ENDPOINTS ................................................ 28
4 STUDY DESIGN ............................................................................................................ 31
4.1 Overall Design ......................................................................................................31
4.2 Scientific Rationale for Study Design ................................................................ .32
4.2.1 Rationale for Endpoints ............................................................................... 32
[IP_ADDRESS] Immunogenicit y Endpoints ................................................................ 32
[IP_ADDRESS] Safety  Endpoints ................................................................................ 33
[IP_ADDRESS] Future Biomedical Research .............................................................. [ADDRESS_1214517]: V116  8
PROTOCOL/AMENDMENT N O.:001-01 
V116 -001-01FINAL PROTOCOL 11-MAY -2020
5.4 Screen Failures ..................................................................................................... 39
5.5 Participant Replacement Strategy ......................................................................39
6 STUDY INTERVENTION ............................................................................................ 39
6.1 Study Intervention(s) Administered ...................................................................40
6.2 Preparation/Handling/Storage/Accountability ................................................. 43
6.2.1 Dose Preparation .......................................................................................... 43
6.2.2 Handling, Storage, and Accountability ........................................................ 43
6.3 Measures to Minimize Bias: Randomization and Blinding .............................. [ADDRESS_1214518] to Follow -up................................................................................................ .47
8 STUDY ASSESSMENTS AND PROCEDURES ........................................................ 47
8.1 Administrative and General Procedures ........................................................... 49
8.1.1 Informed Consent ......................................................................................... 49
[IP_ADDRESS] General Informed Consent ................................................................ .49
[IP_ADDRESS] Consent and Collection of Specimens for Future Biomedical 
Research ............................................................................................. 50
[IP_ADDRESS] Consent and Collection of Blood Samples for Optional Assay  
Development ...................................................................................... 50
8.1.2 Inclusion/Exclusion Criteria ........................................................................[ADDRESS_1214519] .....................................................................50
8.1.4 Medical History ........................................................................................... 50
8.1.5 Prior and Concomitant Medications Review ............................................... 51
[IP_ADDRESS] Prior Medications ............................................................................... 51
[IP_ADDRESS] Concomitant Medications ..................................................................51
8.1.6 Assignment of Screening Number ............................................................... 51
8.1.7 Assignment of Treatment/Randomization Number .....................................[ADDRESS_1214520]: V116  9
PROTOCOL/AMENDMENT N O.:001-01 
V116 -001-01FINAL PROTOCOL 11-MAY -2020
8.1.8 Study  Intervention Administration .............................................................. 51
[IP_ADDRESS] Timing of Dose Administration ......................................................... [ADDRESS_1214521] (VRC) ..................................................................[ADDRESS_1214522] Questionnaire on Day  90 and Day  180......................... 53
8.1.12 Discontinuation and Withdrawal ................................................................ .53
[IP_ADDRESS] Withdrawal From Future Biomedical Research ................................ 53
8.1.13 Participant Blinding/Unblinding ..................................................................54
8.1.14 Calibration of Equipment ............................................................................. 54
8.2 Immunogenicity Assessments ............................................................................. 55
8.2.1 Multiplex Opsonophagocytic Assay  (MOPA) ............................................. 55
8.2.2 Pneumococcal Electrochemiluminescence (PnECL) ...................................[ADDRESS_1214523] ............................................................................................. 56
8.3.3 Body Temperature Measurement ................................................................ .56
8.3.4 Postvaccination Observation Period ............................................................ 56
8.3.5 Clinical Safety  Laboratory  Assessments ..................................................... 57
8.4 Adverse Events, Serious Adverse Events, and Other Reportable Safety 
Events .................................................................................................................... 57
8.4.1 Time Period and Frequency  for Collecting AE, SAE, and Other 
Reportable Safet y Event Information .......................................................... 58
8.4.2 Method of Detecting AEs, SAEs, and Other Reportable Safet y Events ......60
8.4.3 Follow -up of AE, SAE, and Other Reportable Safety  Event Information ...60
8.4.4 Regulatory  Reporting Requirements for SAE ............................................. 60
8.4.5 Pregnancy  and Exposure During Breastfeeding .......................................... 60
8.4.6 Disease -related Events and/or Disease -related Outcomes Not Qualifying 
as AEs or SAEs ............................................................................................ [ADDRESS_1214524] ............................................................................ 61
8.4.8 Adverse Events Reported on the VRC ......................................................... 61
[IP_ADDRESS] Solicited Adverse Events ...................................................................61
[IP_ADDRESS] Unsolicited Adverse Events ............................................................... [ADDRESS_1214525]: V116  10
PROTOCOL/AMENDMENT N O.:001-01 
V116 -001-01FINAL PROTOCOL 11-MAY -2020
8.11 Medical Resource Utilization and Health Economics ....................................... 63
8.12 Visit Requirements ............................................................................................... 64
8.12.1 Screening......................................................................................................64
8.12.2 Treatment Period/Vaccination Visit ............................................................ 64
9 STATISTICAL ANALYSIS PLAN ............................................................................. 64
9.1 Statistical Analysis Plan Summary.....................................................................64
9.2 Responsibility for Analyse s/In-house Blinding ................................................. 67
9.3 Hypotheses/Estimation ........................................................................................ 68
9.4 Analysis Endpoints ............................................................................................... 68
9.4.1 Immunogenicit y Endpoints in Phase 1 ........................................................ 68
9.4.2 Immunogeni city Endpoints in Phase 2 ........................................................ 68
9.4.3 Safety  Endpoints in Phase 1 and Phase 2 ..................................................... 69
9.5 Analysis Populations ............................................................................................ 69
9.5.1 Immunogenicit y Analysis Populations ........................................................ 69
9.5.2 Safety Anal ysis Populations ........................................................................70
9.6 Statistical Methods ............................................................................................... 70
9.6.1 Statistical Methods for Immunogenicit y Anal yses in Phase 1 ..................... 70
9.6.2 Statistical Methods for Immunogenicit y Anal yses in Phase 2 ..................... 71
9.6.3 Statistical Methods for Safet y Anal ysis (Phase 1 and Phase 2) ................... 74
9.6.4 Summaries of Demographic and Baseline Characteristics .......................... 76
9.7 Interim Analyses ..................................................................................................77
9.7.1 Phase 1 Interim Anal ysis............................................................................. 77
9.7.2 Phase 2 Interim Anal ysis............................................................................. 78
9.8 Multiplicity ........................................................................................................... 78
9.9 Sample Size and Power Calculations ................................................................ .78
9.9.1 Immunogenicit y Analyses ........................................................................... 78
9.9.2 Safety Anal yses............................................................................................ 79
9.10 Subgroup Analyses ............................................................................................... 80
9.11 Compliance (Medication Adherence) ................................................................ .80
9.12 Extent of Exposure ............................................................................................... 80
10 SUPPORTING DOCUMENTATION AND OPERATIONAL
CONSIDERATIONS .....................................................................................................81
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ........[ADDRESS_1214526] for Clinical Trials ............................................................. 81
10.1.2 Financial Disclosure ..................................................................................... 83
10.1.3 Data Protection ............................................................................................. 84
[IP_ADDRESS] Confidentiality  of Data ......................................................................84
[IP_ADDRESS] Confidentiality  of Participant Records ............................................... [ADDRESS_1214527]: V116  11
PROTOCOL/AMENDMENT N O.:001-01 
V116 -001-01FINAL PROTOCOL 11-MAY -2020
[IP_ADDRESS] Confidentiality  of IRB/IEC I nformation ............................................ 84
10.1.4 Committees Structure ................................................................................... 85
[IP_ADDRESS] Internal Data Monitoring Committee ................................................. 85
10.1.5 Publication Policy ........................................................................................ 85
10.1.6 Compliance with Study  Registration and Results Posting Requiremen ts...85
10.1.7 Compliance with Law, Audit, and Debarment ............................................ 86
10.1.8 Data Qualit y Assurance ............................................................................... 86
10.1.9 Source Documents ....................................................................................... 87
10.1.10 Study  and Site Closure ................................................................................. 87
10.2 Appendix 2: Clinical Laboratory Tests .............................................................. 89
10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting ............................................................... 91
10.3.1 Definition of AE .......................................................................................... 91
10.3.2 Definition of SAE ........................................................................................ 92
10.3.3 Additional Events Reported ......................................................................... 93
10.3.4 Recording AE and SAE ............................................................................... 94
10.3.5 Reporting of AEs, SAEs, and Other Reportable Safety Events to the 
Sponsor ........................................................................................................99
10.4 Appendix 4: Device Events, Adverse Device Events, and Medical Device 
Incidents: Definitions, Collection, and Documentation ..................................100
10.5 Appendix 5: Contraceptive Guidance .............................................................. 101
10.5.1 Definitions ..................................................................................................101
10.5.2 Contraception Requirements ......................................................................102
[IP_ADDRESS] Contraception Requirements in Phase 1 .......................................... 102
[IP_ADDRESS] Contraception Requirements in Phase 2 .......................................... 103
10.6 Appendix 6: Collection and Management of Specimens for Future 
Biomedical Research .......................................................................................... 105
10.7 Appendix 7: Country -specific Requirements .................................................. 110
10.8 Appendix 8: Abbreviations ............................................................................... [ADDRESS_1214528]: V116  12
PROTOCOL/AMENDMENT N O.:001-[ADDRESS_1214529] OF TABLES
Table 1 Study  Interventions for Phase 1................................................................ .41
Table 2 Study  Interventions for Phase 2................................................................ .42
Table 3 Approximate Blood Volumes Drawn b y Stud y Visit and by [CONTACT_870017] (Phase 1)........................................................................................... 48
Table 4 Approximate Blood Volumes Drawn b y Stud y Visit and by [CONTACT_870017] (Phase 2)........................................................................................... 49
Table 5 Reporting Time Periods and Time Frames for Adverse Events and 
Other Reportable Safet y Events ................................................................ .59
Table 6 Solicited Adverse Events for V116 -001.................................................... 62
Table 7 Analy sis Strategy  for Key  Immunogenicit y Variables in Phase 1............. 71
Table 8 Analy sis Strategy  for Key  Immunogenicit y Variables in Phase 2............. 74
Table 9 Analy sis Strategy for Safety  Parameters .................................................... 76
Table 10 Differences in the Incidence of Adverse Event Rates Between the 
2Vaccination Groups in Phase 2 That Can be Detected With 
Approximately  80% Probability ................................................................ [ADDRESS_1214530]: V116  13
PROTOCOL/AMENDMENT N O.:001-[ADDRESS_1214531] OF FIGURES
Figure 1 V116 -001 Study  Design: Phase 1 .............................................................. 18
Figure 2 V116 -001 Study  Design: Phase [ADDRESS_1214532]: V116  14
PROTOCOL/AMENDMENT N O.:001-01 
V116 -001-01FINAL PROTOCOL 11-MAY -2020
1 PROTOCOL SUMMARY
1.1 Syno psis
Protocol Title: A Phase 1/Phase 2, Randomized, Double -blind Study  to Evaluate the Safety , 
Tolerability , and Immunogenicity  of a Poly valent Pneumococcal Conjugate Vaccine in 
Adults.
Short Title: Phase 1/Phase 2 Study  ofa pPCV in Adults
Acronym:
Hypotheses, Objectives ,and Endpoints :
There are no h ypotheses for Phase 1 of this study . For Phase 2, hypotheses are aligned with 
objectives in the Objectives and Endpoints table.
In Phase 1, objectives and endpoints will be evaluated in pneumococcal vaccine -naÃ¯ve adults 
18to 49 years of age who are administered a single dose of pPCV -1, pPCV -2, or 
PNEUMOVAXâ„¢23.
In Phase 2, objectives and endpoints will be evaluated in pneumococcal v accine -naÃ¯ve adults 
â‰¥50years of age who are administered a single dose of pPCV or PNEUMOVAXâ„¢23.
Primary  Objectives Primary  Endpoints
Phase 1
-Objective: To evaluate the safet y and 
tolerability  of pPCV -[ADDRESS_1214533] to the proportion of part icipants with 
AEs.-Solicited injection -site AEs
-Solicited sy stemic AEs
-Vaccine -related SAEs
Phase 2
-Objective: To evaluate the safet y and 
tolerability  of pPCV with respect to the 
proportion of participants with AEs.-Solicited injection -site AEs
-Solicited sy stemic AEs
-Vaccine -related SAEsÂ 
Â  05H6VD
07XD6Y
PRODUCT: V116  15
PROTOCOL/AMENDMENT N O.:001-01 
V116 -001-01FINAL PROTOCOL 11-MAY -2020
Phase 2
-Objective: To evaluate the serot ype-specific 
OPA GMTs at 30 days postvaccination.
Hypothesis (H1): pPCV is noninferior to 
PNEUMOVAXâ„¢23 as measured b y the 
seroty pe-specific OPA GMTs for the 
comm on seroty pes at 30 days 
postvaccination. 
Hypothesis (H2): The seroty pe-specific OPA 
GMTs for the unique seroty pes in pPCV at 
30days postvaccination are statisticall y 
significantl y greater following vaccination 
with pPCV than those following vaccination 
with PNEUMOVAXâ„¢23.-Seroty pe-specific OPA responses
Secondary  Objectives Secondary  Endpoints
Phase 1
-Objective: To describe the serot ype-specific 
OPA GMTs and IgG GMCs as measured at 
30days postvaccination.-Seroty pe-specific OPA and IgG responses
Phase 1
-Objective: To describe the serot ype-specific 
GMFR from prevaccination (Day 1) to 
30days postvaccination (Day 30) for both 
OPA and IgG responses -Seroty pe-specific OPA and IgG responses
Phase 2
-Objective: To evaluate seroty pe-specific 
IgG GM Cs at 30 days postvaccination.
Hypothesis (H3): pPCV is noninferior to 
PNEUMOVAXâ„¢23 as measured b y the 
seroty pe-specific IgG GMCs for the common 
seroty pes at 30 days postvaccination. 
Hypothesis (H4): The seroty pe-specific IgG 
GMCs for the unique seroty pesin pPCV at 
30days postvaccination are statisticall y 
significantl y greater following vaccination 
with pPCV than those following vaccination 
with PNEUMOVAXâ„¢23.-Seroty pe-specific IgG responses
Phase 2
-Objective: To evaluate seroty pe-specific 
GMFR from prevaccination (Day 1) to 
30days postvaccination (Day  30) for both 
OPA and IgG responses -Seroty pe-specific OPA and IgG responses.Â 
Â  05H6VD
07XD6Y
PRODUCT: V116  16
PROTOCOL/AMENDMENT N O.:001-01 
V116 -001-01FINAL PROTOCOL 11-MAY -2020
Phase 2
-Objective: To evaluate the proportion of 
participants who achieve a â‰¥4-fold increase 
in seroty pe-specific OPA r esponses from 
prevaccination (Day 1) to 30 days 
postvaccination (Day 30)-Seroty pe-specific OPA responses
Overall Desig n:
Study  Phase Phase 1/Phase 2
Primary  Purpose Prevention
Indication Pneumococcal infection
Population Phase 1: A dults 18 to 49 years of age
Phase 2: A dults [ADDRESS_1214534] participantâ€™s last 
study-related telephone call or visit.
For purposes of analy sis and reporting, the overall study  
ends when the Sponsor receives the last laboratory result or 
at the time of final contact [CONTACT_26355], 
whichever comes last.Â 
Â  05H6VD
07XD6Y
PRODUCT: V116  17
PROTOCOL/AMENDMENT N O.:001-01 
V116 -001-01FINAL PROTOCOL 11-MAY -2020
Number of Participant s:
Approximately  590 total participants (90 participants in Phase 1 and 500 participants in 
Phase 2) will be enrolled as detailed in Section 9.9.
Intervention Groups and Du ration :
Intervention 
Group sStudy  Interventions for Phase 1:
Intervention 
Group Name [CONTACT_870044] -1 pPCVRefer to 
IBSingle 
DoseIMSingle Dose 
at Visit 1 
(Day 1)Experimental
pPCV -2 pPCVRefer to 
IBSingle 
DoseIMSingle Dose 
at Visit 1 
(Day 1)Experimental
PNEUMOVAXâ„¢23 PNEUMOVAXâ„¢23Refer to 
product 
labelingSingle 
DoseIMSingle Dose 
at Visit 1 
(Day 1)Experimental
Abbreviations: Admin = administration; I B = I nvestigatorâ€™s Brochure; I M = intramuscular; pPCV =polyvalent 
pneumococcal conjugate vaccine.
Study  Interventions for Phase 2:
Intervention Group 
Name [CONTACT_870045] 1 
(Day 1)Experimental
PNEUMOVAXâ„¢23 PNEUMOVAXâ„¢23Refer to 
product 
labelingSingle 
DoseIMSingle Dose 
at Visit 1 
(Day 1)Experimental
Abbreviations: Admin = administration; I B = I nvestigatorâ€™s Brochure; I M = intramuscular; pPCV =polyvalent 
pneumococcal conjugate vaccine.
Total 
Number5total intervention groups (3 groups in Phase 1 and 2 groups in Phase 2)
Duration of 
ParticipationEach participant will participate in the study  for approximately  6months from 
the time the participant signs the Informed Consent Form through the final 
contact.Â 
Â  05H6VD
07XD6Y
PRODUCT: V116  18
PROTOCOL/AMENDMENT N O.:001-01 
V116 -001-01FINAL PROTOCOL 11-MAY -2020
Study Governance Committees:
Steering Committee No
Executive Oversight Committee No
Data Monitoring Committee Yes
Clinical Adjudication Committee No
Study  governance considerations are outlined in Appendix 1.
Study Accepts Healthy Volunteers :Yes
A list of abbreviations used in this document can be found in Appendix 8.
1.2 Schema
1.2.1 Schema for Phase 1
The Phase 1 study  design is depi[INVESTIGATOR_6517] 1.
Figure 1V116 -001 Study  Design: Phase [ADDRESS_1214535]: V116  19
PROTOCOL/AMENDMENT N O.:001-01 
V116 -001-01FINAL PROTOCOL 11-MAY -2020
1.2.2 Schema for Phase 2
The Phase 2 stud y design is depi[INVESTIGATOR_6517] 2.
Figure 2V116 -001 Study  Design: Phase [ADDRESS_1214536]: V116  20
PROTOCOL/AMENDMENT N O.:001-01 
V116 -001-01FINAL PROTOCOL 11-MAY -2020
1.3 Schedule of Activities
1.3.1 Schedule of Activities for Phase 1
Study Period: Intervention Notes
Visit Number: 1Telephone 
Contact2Telephone 
Contact[CONTACT_870018]: Day 1 Day 15 Day 30 Day 90 Day 180
Visit Window: -Day [ADDRESS_1214537] be obtained before the 
blood sample (DNA sample) is collected.
Assignment of Screening Number X
Inclusion/Exclusion Criteria XPrior to randomization, r eview of prior 
medications/vaccinations, medical history, a 
complete physical examination, and temperature 
measurement are required at Visit 1 to determine 
eligibility. If Day 1 is rescheduled (see 
Section 5.2), these activities must be repeated 
prior to vaccination.
Medical History XThe participantâ€™s relevant medical history for the 
5years prior to study e ntry will be reviewed. 
History of tobacco use will also be collected for 
all participants .
Postrandomization Procedures
Assignment of Randomization Number X
Participant Identification Card X
Prior/Concomitant Medication and Nonstudy 
Vaccination ReviewX X XÂ 
Â  05H6VD
07XD6Y
PRODUCT: V116  21
PROTOCOL/AMENDMENT N O.:001-01 
V116 -001-01FINAL PROTOCOL 11-MAY -2020
Study Period: Intervention Notes
Visit Number: 1Telephone 
Contact2Telephone 
Contact[CONTACT_870018]: Day 1 Day 15 Day 30 Day 90 Day 180
Visit Window: -Day 15 to 
Day 19Day 30 to 
Day 44Day 76 to 
Day 104Day 166to 
Day 194
pPCV -1/pPCV -2/PNEUMOVAXâ„¢23 
Administration (blinded)XParticipants will receive a single dose of either 
pPCV -1, pPCV -2, or PNEUMOVAXâ„¢23. Study 
vaccine will be administered by [CONTACT_870019] (see Section 6.3.3). The unblinded study 
site staff must not perform any other visit 
procedures.
Provide Paper Vaccination Report Card (VRC) X See Section 8.1.[ADDRESS_1214538] ( if applicable) X XA pregnancy test consistent with local 
requirements (sensitive to at least 25 IU beta 
human chorionic gonadotropin [ Î²-hCG]) must be 
performed before administration of study vaccine 
in females who are of reproductive potential (see 
Section 8.3.2 and Appendix 5 for details).
Body Temperature Measurement XEach participantâ€™s body temperature must be 
taken before vaccination (see Section 8.3.3 for 
details). Participants who have febrile illness 
occurring at or within [ADDRESS_1214539] their Day 1 Visit 
rescheduled (see Section 5.2 for det ails).
Postvaccination Observation Period. XParticipants will be observed for at least 
30minutes postvaccination (see Section 8.3.4 for 
details).
Hematology X XDay [ADDRESS_1214540]: V116  22
PROTOCOL/AMENDMENT N O.:001-01 
V116 -001-01FINAL PROTOCOL 11-MAY -2020
Study Period: Intervention Notes
Visit Number: 1Telephone 
Contact2Telephone 
Contact[CONTACT_870018]: Day 1 Day 15 Day 30 Day 90 Day 180
Visit Window: -Day 15 to 
Day 19Day 30 to 
Day 44Day 76 to 
Day 104Day 166to 
Day 194
Chemistry X XDay 1 blood samples should be collected before 
vaccination.
AE Monitoring X X X X XNonserious AEs are to be reported from Day 1 
through Day 30 following vaccination. Serious 
adverse events (S AEs)and deaths are to be 
reported from Day 1 through the duration of an 
individualâ€™s study participation (see Section 8.4.1 
for details).
Immunogenicity Procedures
Serum for Immunogenicity Assays (Including 
Retention Serum)X XDay [ADDRESS_1214541] be collected before 
vaccination (see Section 4.1 and Section 8.9 for 
details).
Future Biomedical Research
Blood (DNA) for Future Biomedical Research XSample will be collected from randomized 
participants who provide consent for future 
biomedical research (see Section 8.9). The sample 
should be obtained at Day 1 before vaccine is 
administered , or at a later date as soon as the 
informed consent is obtained .
Assay Development Samples
Serum for Optional Assay Development X XSamples will be collected from randomized 
participants who provide consent for assay 
development sample collection (see Section 8.10).
Day [ADDRESS_1214542]: V116  23
PROTOCOL/AMENDMENT N O.:001-01 
V116 -001-01FINAL PROTOCOL 11-MAY -2020
1.3.2 Schedule of Activities for Phase 2
Study Period: Intervention Notes
Visit Number: [ADDRESS_1214543]
Scheduled Time: Day 1 Day 15 Day 30 Day 90 Day 180
Visit Window: -Day [ADDRESS_1214544] be obtained before the 
blood sample (DNA sample) is collected.
Assignment of Screening Number X
Inclusion/Exclusion Criteria XPrior to randomization, review of prior 
medications/vaccinations, medical history, a 
complete physical examination, and temperature 
measurement are required at Visit 1 to determine 
eligibility. If Day 1 is rescheduled (see 
Section 5.2), these activities must be repeated 
prior to vaccination.
Medical History XThe participantâ€™s relevant medical history for the 
5years prior to study entry will be reviewed. 
History of tobacco use will also be collected for 
all participants.
Postrandomization Procedures
Assignment of Randomization Number X
Participant Identification Card XÂ 
Â  05H6VD
07XD6Y
PRODUCT: V116  24
PROTOCOL/AMENDMENT N O.:001-01 
V116 -001-01FINAL PROTOCOL 11-MAY -2020
Study Period: Intervention Notes
Visit Number: [ADDRESS_1214545]
Scheduled Time: Day 1 Day 15 Day 30 Day 90 Day 180
Visit Window: -Day 15 to 
Day 19Day 30 to 
Day 44Day 76 to 
Day 104Day 166to 
Day 194
Prior/Concomitant Medication and Nonstudy 
Vaccination ReviewX X X
pPCV /PNEUMOVAXâ„¢23 Administration (blinded) XParticipants will receive a single dose of either 
pPCV or PNEUMOVAXâ„¢23 .Study vaccine will 
be administered by [CONTACT_870020] (see 
Section 6.3.3). The unblinded study site staff must 
not perform any other visit procedures.
Provide electronic Vaccination Report Card (eVRC) X See Section 8.1.[ADDRESS_1214546] ( if applicable) X XA pregnancy test consistent with local 
requirements (sensitive to at least 25 IU beta 
human chorionic gonadotropin [ Î²-hCG]) must be 
performed before administration of study vaccine 
in females who are of reproductive potential (see 
Section 8.3.2 and Appendix 5 for details).
Body Temperature Measurement XEach participantâ€™s body temperature must be taken 
before vaccination (see Section 8.3.3 for details). 
Participants who have febrile illness occurring at 
or within [ADDRESS_1214547] 
their Day 1 Visit rescheduled (see Section 5.2 for 
details).
Postvaccination Observation Period XParticipants will be observed for at least 
30minutes postvaccination (see Section 8.3.4 for 
details).Â 
Â  05H6VD
07XD6Y
PRODUCT: V116  25
PROTOCOL/AMENDMENT N O.:001-01 
V116 -001-01FINAL PROTOCOL 11-MAY -2020
Study Period: Intervention Notes
Visit Number: [ADDRESS_1214548]
Scheduled Time: Day 1 Day 15 Day 30 Day 90 Day 180
Visit Window: -Day 15 to 
Day 19Day 30 to 
Day 44Day 76 to 
Day 104Day 166to 
Day 194
AE Monitoring X X X X XNonserious AEs are to be reported from Day 1 
through Day 30 following vaccination. Serious 
adverse events ( SAEs )and deaths are to be 
reported from Day 1 through the duration of an 
individualâ€™s study participation (see Section 8.4.1 
for details).
Immunogenicity Procedures
Serum for Immunogenicity Assays (Including 
Retention Serum)X XDay [ADDRESS_1214549] be collected before 
vaccination (see Section 4.1 and Section 8.9 for 
details).
Future Biomedical Research
Blood (DNA) for Future Biomedical Research XSample will be collected from randomized 
participants who provide consent for future 
biomedical research (see Section 8.9). The sample 
should be obtained at Day 1 before vaccine is 
administered , or at a later date as soon as the 
informed consent is obtaine d.
Assay Development Samples
Serum for Optional Assay Development X XSamples will be collected from randomized 
participants who provide consent for assay 
development sample collection (see Section 8.10).
Day [ADDRESS_1214550]: V116  26
PROTOCOL/AMENDMENT N O.:001-01 
V116 -001-01FINAL PROTOCOL 11-MAY -2020
2 INTRODUCTION
[COMPANY_006] Sharp & Dohme Corp. is developi[INVESTIGATOR_870006] ( V116, 
hereafter referred to as pPCV ) for the prevention of pneumococcal disease caused b y the 
seroty pes in the vaccine.
2.1 Study Rationale
Pneumococcal disease, specificall y residual d isease in adults, remains an unmet medical 
need. To address the burden of residual pneumococcal disease in adults, pPCV is designed to 
target serot ypes that account for the majority  of IPD in adults and includes seroty pes not 
currentl y contained in any lic ensed pneumococcal vaccine .
This Phase 1/Phase 2 clinical study  is designed to evaluate the safet y, tolerability , and 
immunogenicit y of pPCV compared with PNEUMOVAXâ„¢23 in adults.
The Phase 1 portion of this study  will be conducted in a population of adults 18 to 49years 
of age .This population is in general good health and, based on age, is not at increased risk 
for pneumococcal disease.
The Phase 2 portion of this study  will be conducted i n a population of adults â‰¥50 years of 
age. This population is at elevated risk for pneumococcal disease and associated morbidity  
and mortality  due to aging -related ph ysiological changes in the respi[INVESTIGATOR_870007] [Drijkoningen, J. J 2014] [Janssens, J. P. 2004] .
2.2 Background
Refer to the IBfor detailed background information on pPCV , including information on 
pneumococcal disease burden.
2.2.1 Pharmaceutical and Therapeutic Background
Pneumococcal disease ( ie, disease caused b y Streptococcus pneumoniae) is the single largest 
vaccine -preventable cause of death in children and older adults ( â‰¥65years of age) 
worldwide . Direct vaccination of children with PCV shas decreased the incidence of disease 
caused b y vaccine serot ypes and has led to herd protection in unvaccinated individuals from 
other age groups , referred to as an indirect effect . This indirect effect of childhood 
vaccination with PCVs has resulted in a decrease in hospi[INVESTIGATOR_870008] â‰¥65years of age , with an estimated 29% and 34% reduction in IPD and 
non-invasive pneumococcal pneumonia admissions ,respectivel y[Simonsen, L ., et al 2014] . 
Additionally , in some countries, including the US , this indirect effect led to the 
recommendation to vaccinate adults with PCV s. However, current surveillance does not 
definitively  support that a reduction of disease has been observed due to direct vaccination of 
adults with currently licensed PCVs . Asignificant burden of pneumococcal disease remains 
with an estimated 24cases of IPD per 100,000 in adults >65 years of age in the US ,and 
surveillance data estimates serot ypes included in currentl y licensed PCVs account for only  Â 
Â  05H6VD
07XD6Y
352'8&7 9 
[ZIP_CODE]&2/$0(1'0(1712 
9 ),1$/[ZIP_CODE]&2/ 0$<
DSSUR[LPDWHO\RIWKHVHFDVHV >&HQWUHIRU'LVHDVH&RQWURODQG 3UHYHQWLRQ@>&HQWHUV
IRU'LVHDVH&RQWURODQG3UHYHQWLRQ@
7KLV UHVLGXDOEXUGHQRIGLVHDVHLQDGXOWV UHIOHFWVWKHGLIIHUHQFH LQVHURW\SHGLVWULEXWLRQLQ
DGXOWVFRPSDUHGZLWK LQIDQWVDQGFKLOGUHQ,PSRUWDQWO\ LQIDQWYD FFLQDWLRQZLWK3&9VKDVOHG
WRDQLQFUHDVLQJLQFLGHQFHRIGLVHDVHGXHWRVHURW\SHVQRWLQFO XGHGLQWKHOLFHQVHG3&9V
SDUWLFXODUO\LQDGXOWV >0LOOHU(OL]DEHWKHWDO@>0RRUH0 5HWDO@>3LOLVKYLOL7
@>YDQGHU/LQGHQ0HWDO@>*ROGHQ$5HWDO @,QFUHDVHVLQ,3'FDVHVGXH
WRFHUWDLQVHURW\SHV)DQG$DIWHULPSOHPHQWDWLRQRI3U HYQDUÂŒ)DQG)
IROORZLQJZLGHVSUHDGXVDJHRI3UHYQDUÂŒZHUHQRWHGLQERWKSHG LDWULF DQGDGXOW
Â• \HDUVRIDJHSRSXODWLRQVLQWKH86 >+LFNV/$HWDO @>3LOLVKYLOL7DPDUDHWDO
@>:DLJKW3$HWDO@>0RRUH05HWDO@>' HPF]XN:+%HWDO
@6LPLODUO\LQWKH(8GXHWRWKHOLPLWHGVHURW\SHFRYHUDJ HRIWKHFXUUHQWO\OLFHQVHG
YDFFLQHVVHURW\SHUHSODFHPHQWLVEHLQJREVHUYHGDQGPD\GHFUHD VHWKHSRWHQWLDODGGLWLRQDO
EHQHILWRIYDFFLQDWLRQZLWKFXUUHQWO\DYDLODEOH3&9V LQWKHHOGHU O\>(XURSHDQ&HQWHUIRU
'LVHDVH3UHYHQWLRQDQG&RQWURO@
7RDGGUHVVWKLVUHVLGXDOEXUGHQ RIGLVHDVHLQDGXOWVVHURW\SHV ZHUHVHOHFWHGIRULQFOXVLRQLQ
S3&9EDVHGRQDYDLODEOHJOREDOHSLGHPLRORJ\GDWDZLWKDSULPDU\ IRFXVRQGDWDIURPWKH
HOGHUO\Â• \HDUVRIDJHLQWKH86DQG(8:LWKWKHLQWHQWWR SURYLGHEURDGFRYHUDJH
DJDLQVWWKHOHDGLQJVHURW\SHVDVVRFLDWHGZLWKSQHXPRFRFFDOGLVH DVHWKHVHURW\SHVVHOHFWHG
IRULQFOXVLRQLQS3&9DFFRXQWIRUDSSUR[LPDWHO\RIDOOFDVH VRI,3'LQWKH86LQDGXOWV
Â• \HDUVRIDJHEDVHGRQ  VXUYHLOODQFHGDWD
:LWKWKHDERYHFRQVLGHUDWLRQVLQPLQGS3&9LVGHVLJQHGWRWDUJ HWVHURW\SHVWKDWDFFRXQWIRU
WKHPDMRULW\RI,3'LQDGXOWVLQFOXGLQJVHURW\SHVQRWFXUUHQWO\ FRQWDLQHGLQDQ\OLFHQVHG
SQHXPRFRFFDOYDFFLQH DVZHOODVDGGUHVVLQJWKHLQIOXHQFHRIVHU RW\SHUHSODFHPHQWRI
FLUFXODWLQJVWUDLQVWKHUHE\DGGUHVVLQJWKHXQPHWPHGLFDOQHHGRI UHVLGXDOSQHXPRFRFFDO
GLVHDVHLQDGXOWV
 3UHFOLQLFDODQG&OLQLFDO6WXGLHV5HIHUWRWKH,%IRULQIRUPDWLRQRQFRPSOHWHGSUHFOLQLFDOVWXGLH VFRQGXFWHGZLWKS3&9
7KLVLVWKHILUVWFOLQLFDOVWXG\FRQGXFWHGZLWKS3&9 ,QIRUPDWLRQRQ2WKHU6WXG\UHODWHG7KHUDS\ 31(8029$;ÂŒ5HIHUWRWKHDSSURYHGODEHOLQJIRUGHWDLOHGEDFNJURXQGLQIRUPDW LRQRQ31(8029$;ÂŒ
31(8029$;ÂŒ LVFRPSULVHGRIWKHSRO\VDFFKDULGHVIURP RIWKHP RVWLPSRUWDQW
VHURW\SHVFDXVLQJGLVHDVHLQDGXOWV%) 19$$)%
 +9'CCI
CCI
;'<
PRODUCT: V116  28
PROTOCOL/AMENDMENT N O.:001-01 
V116 -001-01FINAL PROTOCOL 11-MAY -2020
17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F). The formulatio n is not adjuvanted and no 
carrier protein is used.
In the US, PNEUMOVAXâ„¢23 is recommended by  [CONTACT_528869] â‰¥65 years of age [Kobayashi, M., et al 2015] . PNEUMOVAXâ„¢23
is also recommended in the USfor use in adults aged 19 to 64 years of age with underly ing 
medical conditions that increase the risk for serious pneumococcal infection [Centers for 
Disease Control and Prevention 2010] and in immunocompromised adults â‰¥19years of age
as part of a sequential regimen with Prevnar 13â„¢ [Kobay ashi, M., et al 2015] . Children 2 to 
18years of age with underly ing medical conditions are recommended to receive 
PNEUMOVAXâ„¢23 after completing all recommended Prevnar 13â„¢ doses [Centers for 
Disease Control and Prevention (CDC) 2013] .
Many  countries follow similar age -based and/or risk-based recommendations for the use of 
PNEUMOVAXâ„¢23 [Castiglia P. 2014] .
2.3 Benefit/Risk Asse ssment
It cannot be guaranteed that participants in clinical studies will directly  benefit from 
vaccination with pPCV during participation, as clinical studies are designed to provide 
information about the safety  and effectiveness of an investigational medicine.
Approximately  33% of participants in Phase 1and 50% of participants in Phase 2 will 
receive PNEUMOVAXâ„¢23, a pneumococcal vacc ine for the prevention of pneumococcal 
disease that is licensed in the US, EU, and other regions. pPCV is expected to provide 
comparable immune responses to PNEUMOVAXâ„¢[ADDRESS_1214551] the same clinical benefit as PNEUMOVAXâ„¢ 23.
Additional details regarding specific benefits and risks for participants participating in this 
clinical study  may  be found in the accompan ying IB and informed consent documents.
3 HYPOTHESE S, OBJECTIVES ,AND ENDPOINTS
There are no h ypotheses for Phase 1 of this study . For Phase 2, hypotheses are aligned with 
objectives in the Objectives and Endpoints table.
In Phase 1, objectives and endpoints will be evaluated in pneumococcal vaccine -naÃ¯ve adults 
18to 49 years of age who are administered a single dose of pPCV -1, pPCV -2, or 
PNEUMOVAXâ„¢23.
In Phase 2, objectives and endpoints will be evaluated in pneumococcal vaccine -naÃ¯ve adults 
â‰¥50years of age who are administered a single dose of pPCV or PNEUMOVAXâ„¢23.Â 
Â  05H6VD
07XD6Y
PRODUCT: V116  29
PROTOCOL/AMENDMENT N O.:001-01 
V116 -001-01FINAL PROTOCOL 11-MAY -2020
Objectives Endpoints
Primary
Phase 1
â€¢Objective : To evaluate the safet y and 
tolerability  of pPCV -[ADDRESS_1214552] to the proportion of participants 
with AEs.â€¢Solicited injection -site AEs
â€¢Solicited sy stemic AEs
â€¢Vaccine -related SAEs
Phase 2
â€¢Objective : To evaluate the safet y and 
tolerability  of pPCV with respect to the 
proportion of participants with AEs.â€¢Solicited injection -site AEs
â€¢Solicited sy stemic AEs
â€¢Vaccine -related SAEs
Phase 2
â€¢Objective : To evaluate the 
seroty pe-specific OPA GMTs at 30 days
postvaccination.
Hypothesis (H1) : pPCV is noninferior to 
PNEUMOVAXâ„¢ 23 as measured b y the 
seroty pe-specific OPA GMTs for the 
common seroty pes at 30 days 
postvaccination.
Hypothesis (H2) : The seroty pe-specific 
OPA GMTs for the unique serot ypes in 
pPCV at 30 days postvaccination are 
statistically  significantly  greater 
following vaccination with pPCV than
those following vaccination with 
PNEUMOVAXâ„¢23 .â€¢Seroty pe-specific OPA responses
Secondary
Phase 1
â€¢Objective : To describe the
seroty pe-specific OPA GMTs and IgG 
GMCs as measured at 30 days
postvaccination.â€¢Seroty pe-specific OPA and IgG
responsesÂ 
Â  05H6VD
07XD6Y
PRODUCT: V116  30
PROTOCOL/AMENDMENT N O.:001-01 
V116 -001-01FINAL PROTOCOL 11-MAY -2020
Objectives Endpoints
Phase 1
â€¢Objective: To describe the
seroty pe-specific GMFR from 
prevaccination (Day 1) to 30 days 
postvaccination (Day 30) for both OPA 
and IgG responses â€¢Seroty pe-specific OPA and IgG
responses
Phase 2
â€¢Objective : To evaluate seroty pe-specific 
IgG GMCs at 30 dayspostvaccination.
Hypothesis (H3) : pPCV is noninferior to 
PNEUMOVAXâ„¢23 as measured b y the
seroty pe-specific IgG GMCs for the 
common seroty pes at 30 days 
postvaccination.
Hypothesis (H4) : The seroty pe-specific 
IgG GMCs for the unique serot ypes in 
pPCV at 30 days postvaccination are 
statistically  significantly  greater 
following vaccination with pPCV than 
those following vaccination with 
PNEUMOVAXâ„¢23 .â€¢Seroty pe-specific IgGresponses
Phase 2
â€¢Objective: To evaluate seroty pe-specific 
GMFR from prevaccination (Day 1) to 
30days postvaccination (Day  30) for both 
OPA and IgG responses â€¢Seroty pe-specific OPA and IgG
responses .
Phase 2
â€¢Objective: To evaluate the proportion of 
participants who achieve a â‰¥4-fold 
increase in serot ype-specific OPA 
responses from prevaccination (Day 1) to 
30days postvaccination (Day 30)â€¢Seroty pe-specific OPA responsesÂ 
Â  05H6VD
07XD6Y
PRODUCT: V116  31
PROTOCOL/AMENDMENT N O.:001-01 
V116 -001-01FINAL PROTOCOL 11-MAY -2020
4 S TUDY DESIGN
4.1 Overall Design
This is a 2- part, randomized, active -controlled, parallel- group, multi -site, double -blind (with 
in-house blinding) stud y of pPCV in adults who have not previousl y received an y 
pneumococcal vaccine .
In the Phase 1 portion of the study ,approximately  90participants 18 to 49 years of age 
(inclusive) who have not previously  received an y pneumococcal vaccine (vaccine naÃ¯ve) will 
be randoml y assigned in a 1:1:1 ratio to recei ve a single dose of either pPCV -1 
(30participants), pPCV -2 (30 participants), or PNEUMOVAXâ„¢23 (30participants) at 
Visit 1 (Day 1).pPCV -[ADDRESS_1214553] will occur at 90 and 180 days postvaccination. An siDMC 
will review the safet y and tolerability data throughout Phase 1 and Phase 2.The siDMC is a 
standing, internal Sponsor committee established to monitor earl y phase clinical studies. 
Additional details are provided in Appendix 1 and in the siDMC charter.
An interim anal ysis will be performed once the primary  30-day postvaccination safet y and 
immunogenicit y data are available for all Phase 1 participants. At this point , the database will 
be locked and an analy sis will be performed to summarize the safet y and immunogenicit y 
data. The siDMC will review all safet y and immunogenicity  data to evaluate the benefit risk 
profile and to make a recommendation regarding proceeding to Phase 2.The Sponsor study  
team will also review the unblinded agg regate data and,in conjunction with the 
recommendation of thesiDMC, a decision will be made whether to proceed to Phase 2, and 
which dose should be selected for further evaluation .If the decision is made to proce edto 
Phase 2,enrollment will commence immediatel y.
In the Phase 2 portion of the study , approximately 500participants â‰¥[ADDRESS_1214554] not previousl y received an y pneumococcal vaccine (vaccine naÃ¯ve) will be randomly  
assigned in a 1:1 ratio to receive a single dose of either pPCV (250 participants) or 
PNEUMOVAXâ„¢23 (250 participants) on Day 1.Randomization will be stratified b y 
participant age at enrollment (50 to 64 years, 65 to 74 years, and â‰¥75years)across the 
2vaccination groups . Safety  will be assessed via t elephone c ontact [ADDRESS_1214555] 50% of Phase [ADDRESS_1214556]: V116  32
PROTOCOL/AMENDMENT N O.:001-01 
V116 -001-01FINAL PROTOCOL 11-MAY -2020
Day 1 through Day 5 postvaccination .Informa tion for SAEs and deaths, re gardless of 
whether the events are considered to be vaccine related b y the investigator, will be collected 
from the time consent is signed through completion of participation in the study .
Blood samples for immunogenicity  assay s will be drawn immediatel y before vaccine 
administration (Day 1) and at 30 days postvaccination (Day 30).After completion of 
immunogenicit y testing to evaluate the stud y objectives and h ypotheses, serum samples will 
be stored to conduct an y additional study -related testing as requir ed by [CONTACT_63510]. For participants who provide optional consent for future biomedical research, 
leftover sera from the study  may  be used for other purposes, such as the development and/or 
validation of pneumococcal assay s after comp letion of all study -related immunogenicit y 
testing.
Specific procedures to be performed during the study , as well as their prescribed times and 
associated visit windows, are outlined in the SoA in Section 1.3. Details of each procedure 
are provided in Sect ion8.
4.[ADDRESS_1214557]-in-human Phase 1 portion of the study  will assess the safet y and tolerability of 
2different dosage levels of pPCV (pPCV -1 and pPCV -2)in adults 18to 49years of age .
Two different doses are being evaluated to assess antibody  concentrations related to 
polysaccharide antigen dose in a poly valent pneumococcal vaccine and to ensure confidence 
in the dose selected for further evaluation in Phase 2. The populat ion in Phase 1 includes 
adults who are in general good health and ,based on age ,are not at increased risk for 
pneumococcal disease.
The dose selection for Phase 2 will be based on Phase 1 safety  and immunogenicity  data .
The Phase 2 portion of the study  will assess safet y, tolerability, and immunogenicity of 
pPCV in adults â‰¥50 years of age . As the incidence of IPD is directl y related to age, with over 
half of all cases occurring in adults 50 years of age or older [Drijkoningen, J. J 2014] , this 
population is at increased risk for pneumococcal disease and its associated morbidity  and 
mortality .
4.2.1 Rationale for Endpoints
[IP_ADDRESS] Immunogenicity Endpoints
The immunogenicit y endpoints and associated comparative statisti cal criteria are consistent 
with previous early phase studies evaluating PCVs.
Sera from participants will be used to measure vaccine -induced, anti-PnP seroty pe-specific 
OPA GMTs and IgG GMCs f or all serot ypes included in pPCV using the MOPA and PnECL  
assay , respectivel y.Â 
Â  05H6VD
07XD6Y
PRODUCT: V116  33
PROTOCOL/AMENDMENT N O.:001-[ADDRESS_1214558] shown a positive correlation between serot ype-specific IgG antibody  
concentrations and OPA titers in children and adults [Centers for Disease Control and 
Prevention 2010] [Anttila, M., et al 1999] [Romero -Steiner, S., et al 1997] . OPA assesses 
levels of functional antibodies capable of opsonizing pneumococcal capsular poly saccharides 
for presentation to phagocytic cells for engulfme nt and subsequent killing, and therefore is 
considered an important immunologic surrogate for protection against I PD in adults. I t is 
noted that IgG antibod y and OPA titer threshold values that correlate with protection in 
adults have not been defined; how ever, the OPA functional assay  is considered a preferred 
endpoint in adults.
In the Phase 1 portion of this study , anti-PnP serotype -specific OPA GMTs and IgG GMCs 
will be evaluated as secondary  endpoints.
In the Phase 2 portion of this study , anti-PnP serotype-specific OPA GMTs will be evaluated 
as a primary  endpoint and seroty pe-specific IgG GMCs will be evaluated as a secondary  
endpoint.
Details on the immunogenicity  endpoints evaluated in this study  can be found in 
Section 9.4.1 and Section 9.4.2.
[IP_ADDRESS] Safet y Endpoints
The safet y endpoints (ie, AEs and temperature) evaluated in this study  were selected based 
on the anticipated product safet y profile and published data from marketed PCVs.
Vaccination report cards will be used to collect participant -reported events during the 
postvaccination period, as detailed in Section 8.1.9. Participants in Phase 1 will use paper 
VRCs and participants in Phase 2 will use eVRCs. The VRCs were structured as 
recommended in the final US Food and Drug Administration Patient -reported Outcome 
Guidance [U.S. Food and Drug Administration 2009] .
Details on the safet y endpoints evaluated in this study  can be found in Section 9.4.3.
Details on AEs, including definitions and reporting requirements, can be found in 
Appendix 3.
[IP_ADDRESS] Future Biomedical Research
The Sponsor will conduct future biomedical r esearch on specimens for which consent was 
provided during this study . This research may  include genetic anal yses (DNA), gene 
express ion profiling (RNA), proteomics, metabolomics (serum, plasma), and/or the 
measurement of other analy tes, depending on whi ch specimens are consented for future 
biomedical r esearch.
Such research is for biomarker testing to address emergent questions not des cribed elsewhere 
in the protocol (as part of the main study ) and will only  be conducted on specimens from 
appropriatel y consented participants. The objective of collecting/retaining specimens for Â 
Â  05H6VD
07XD6Y
PRODUCT: V116  34
PROTOCOL/AMENDMENT N O.:001-01 
V116 -001-01FINAL PROTOCOL 11-MAY -2020
future biomedical r esearch is to explore and identify  biomar kers that inform the scientific 
understanding of diseases and/or their therapeutic treatments. The overarching goal is to use 
such information to develop safer, more effective drugs/vaccines, and/or to ensure that 
participants receive the correct dose of t he correct drug/vaccine at the cor rect time. The 
details of future biomedical r esearch are presented in Appendix 6.
4.2.2 Rationale for t he Use of Comparator
Placebo -controlled clinical studies for new PCVs are no longer practical given the proven 
clinical efficacy  and widespread use of licensed pneumococcal vaccines worldwide.
PNEUMOVAXâ„¢23 was selected as the comparator for this study  based on the following 
rationale .Of the currently  licensed pneumococcal vaccines, PNEUMOVAXâ„¢[ADDRESS_1214559] seroty pes in common with pPCV, and antibody  responses to PNEUMOVAXâ„¢23 are 
generall y comparable to Prevnar 13â„¢ for the common seroty pes. Globally , 
PNEUMOVAXâ„¢23 is the primar y pneumococcal vaccine recommended for adults 65 years 
of age and older , and thus its use as a comparator in this study  will provide useful 
information for man y key regions . In the US , PNEUMOVAXâ„¢23 is indicated for use in 
persons 50 years of age or older, which is consistent with the population to be enrolled in 
Phase 2. Additionally , as of June 2019, ACI P changed their guideline to recommend that all 
adults 65 y ears of age and older should receive PNEUMOVAXâ„¢23 , and that vaccination 
with Prevnar 13â„¢ as part of a sequential regimen with PNEUMOVAXâ„¢[ADDRESS_1214560] an immunocompromis ing condition, but rather 
should be based on shared clinical decision between the health care provider and the patient.
4.3 Justification for Dose
4.3.1 Starting Dose for This Study
A dose of 2 Âµg/each PnP is proposed for clinical development ofpPCV , which is consistent 
with the dose used in other PCVs . The proposed human dose of pPCV is based on 
dose-ranging evaluation of pPCV in animal studies, as well as evaluation of other 
pneumococcal vaccines in humans. To gain confidence in the safet y and immunogenicit yof 
pPCV and to confirm the proposed human dose for pPCV clinical development , 2different 
doses will be evaluated in Phase 1: a 1.0 xdose with 2 Âµg/ each PnP, and a 2.0x dose with 
4Âµg/each PnP. For additional information related to dose, refer to the IB.
4.[ADDRESS_1214561] to follow -up (ie, the participant is unable to be contact[INVESTIGATOR_530] b y the 
investigator) .
For purposes of analy sis and reporting, the overa ll study  ends when the Sponsor receives the 
last laboratory  result or at the time of final contact [CONTACT_26355], whichever comes 
last.Â 
Â  05H6VD
07XD6Y
PRODUCT: V116  35
PROTOCOL/AMENDMENT N O.:001-01 
V116 -001-01FINAL PROTOCOL 11-MAY -2020
4.4.1 Clinical Criteria f orEarly Study Termination
The clinical stud y ma y be terminated early if the extent (inci dence and/or severit y) of 
emerging effects/clinical endpoints is such that the risk/benefit ratio to the study  population 
as a whole is unacceptable. In addition, further recruitment in the study  or at (a)particular 
study  site(s) may  be stopped due to insufficient compliance with the protocol, GCP, and/or 
other applicable regulatory requirements, procedure -related problems or the number of 
discontinuations for administrative reasons is too high .
5 STUDY POPULATION
Health y male and female participants between the ages of 18 and 49 years (inclusive) will be 
enrolled in Phase 1 of this study .
Health y male and female participants â‰¥50years of age will be enrolled in Phase 2 of this 
study .
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted.
5.1 Inclusion Criteria
A participant will be e ligible for inclusion in the study  if the participant :
1.In the opi[INVESTIGATOR_871], is in good health. Any underl ying chronic condition 
must be documented to be in stable condition according to the investigatorâ€™s judgment.
Demographics
2.For Phase 1:
â€¢Ismale or female , from 18yearsto 49yearsof age inclusive, at the time of signing 
the informed consent.
For Phase 2:
â€¢Is male or female â‰¥50years of age at the time of signing the informed consent.Â 
Â  05H6VD
07XD6Y
PRODUCT: V116  36
PROTOCOL/AMENDMENT N O.:001-[ADDRESS_1214562] 3months ( 90days [a spermatogenesis cy cle]) after the 
last dose of study  intervention:
â€¢Refrain from donating sperm
PLUS either:
â€¢Be abstinent from heterosexual intercourse as their preferred and usual lifesty le 
(abstinent on a long term and persistent basis) and agree to remain abstinent
OR
â€¢Must agree to use contraception unless confirmed to be azoospermic (vasectomized or 
secondary  to medical cause [Appendix 5]) as detailed below:
â—¦Agree to use a male condom plus partner use of an additional contraceptive 
method when having penile -vaginal intercourse with a WOCBP who is not 
currentl y pregnant. Note: Men with a pregnant or breastfeeding partner must 
agree to remain abstinent from penile -vaginal intercourse or use a male condom 
during each epi[INVESTIGATOR_19329] -vaginal penetration.
Female Participants
Contraceptive use b y women should be consistent with local regulations regarding the 
methods of contraception for those participating in clinical studies.
4.A female participant is eligible to participate if she is not pregnant or breastfeeding, and 
at least one of the following conditions applies:
-Is not a WOCBP
OR
-For Phase 1:
ï‚·Is a WOCBP and using a contraceptive method that is highly effective (with a 
failure rate of <1% per year), with low user dependency , or be abstinent from 
heterosexual intercourse as their pr eferred and usual lifesty le (abstinent on a long 
term and persistent basis), as described in Appendix [ADDRESS_1214563] dose of study  intervention and 
agrees not to donate eggs (ova, oocy tes) to other s or freeze/store for her own use 
for the purpose of reproduction during this period. The investigator should Â 
Â  05H6VD
07XD6Y
PRODUCT: V116  37
PROTOCOL/AMENDMENT N O.:001-01 
V116 -001-01FINAL PROTOCOL 11-MAY -2020
evaluate the potential for contraceptive method failure (ie, noncompliance, 
recentl y initiated) in relationship to the first dose of study interve ntion.
For Phase 2:
ï‚·Is a WOCBP and using a contraceptive method that is highly effective (with a 
failure rate of <1% per year), or be abstinent from heterosexual intercourse as 
their preferred and usual lifestyle (abstinent on a long term and persistent ba sis), 
as described in Appendix [ADDRESS_1214564] dose of study intervention. The investigator should 
evaluate the potential for contraceptive method failure (ie, noncompliance, 
recentl y initiated) in relationship to the first dose of study intervention.
-A WOCBP must have a negative highly  sensitive pregnancy  test (urine or serum as 
required b y local regulations) within [ADDRESS_1214565] cannot be conf irmed as negative (eg, an ambiguous result), a serum 
pregnancy  test is required. I n such cases, the participant must be excluded from 
participation if the serum pregnancy  result is positive.
â€¢Additional requirements for pregnancy  testing during and after st udy intervention are 
located in Appendix 2.
â€¢The investigator is responsible for review of medical history , menstrual history , and 
recent sexual activity  to decrease the risk for inclusion of a woman with an earl y 
undetected pregnancy .
Informed Consent
5.The participant provides written informed consent for the stud y. The participant may also 
provide consent for future biomedical research and/or assay  development sample 
collection. However, the participant may  participate in the main study  without 
participating in future biomedical research or assay  development sample collection .
5.[ADDRESS_1214566] be excluded from the study  if the participant:
Medical Conditions
1.Has a h istory  of IPD (positive blood culture, positive cerebrospi[INVESTIGATOR_63469], or 
positive culture at another sterile site) or known history of other culture -positive 
pneumococcal disease within 3 y ears of Visit 1 (Day 1).
2.Has a k nown h ypersensitivity  to any  component of the pneum ococcal pol ysaccharide 
vaccine, PCV , or any  diphtheria toxoid-containing vaccine.Â 
Â  05H6VD
07XD6Y
PRODUCT: V116  38
PROTOCOL/AMENDMENT N O.:001-01 
V116 -001-01FINAL PROTOCOL 11-MAY -2020
3.Has a k nown or suspected impairment of immunological function including, but not 
limited to, a history  of congenital or acquired immunodeficiency, documented HIV 
infection, functional or anatomic asp lenia, or history  of autoimmune disease (including 
but not limited to the autoimmune conditions outlined in the I nvestigator Trial File 
Binder for this study ).
4.Has a c oagulation disorder contraindicating intramuscular vaccination.
5.*Had a r ecent febrile ill ness (defined as oral or tympanic temperature â‰¥100.4Â°F 
[â‰¥38.0Â°C] or axillary or temporal temperature â‰¥99.4Â°F [â‰¥37.4Â°C]) or received antibiotic 
therap y for an y acute illness occurring within 72 hours before receipt of stu dy vaccine.
6.Has a known malignancy that is progressing or has required active treatment within the
3years prior to signing the informed consent . (Note : participants with basal cell 
carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ 
[eg,breast carcinoma, cervic al cancer in situ] that have undergone potentially  curative 
therap y are not excluded) .
7.A WOCBP who has a positive urine or serum pregnancy  test before vaccination at Visit 1
(Day 1).
Prior/Concomitant Therapy
8.Has received any pneumococcal vaccine or is expected to receive an y pneumococcal 
vaccine during the study ,outside of the protocol.
9.*Has r eceived s ystemic corticosteroids (prednisone equivalent of â‰¥20 mg/day) for 
â‰¥14consecutive day s and has not com pleted intervention at least 30 days prior to study  
vaccination.
10.*Has r eceived s ystemic corticosteroids exceeding phy siologic replacement doses 
(approximately  5mg/day p rednisone equivalent) starting from 14days prior to study  
vaccination. (Note : Topi[INVESTIGATOR_2855], ophthalmic, intra -articular or soft -tissue [e g, bursa, tendon 
steroid injections], and inhaled/nebulized steroids are permitted).
11.Is receiving immunosuppressive therap y, including chemotherapeutic agents used to treat 
cancer or other conditions, and interventions associated with organ or bone marrow 
transplan tation, or autoimmune disease.
12.*Has r eceived any  non- live vaccine starting from 14days prior to study  vaccin ation or is 
scheduled to receive any non-live vaccine through 30days following study  vaccination. 
Exception : Inactivated influenza vaccin e may  be administered but must be given at least 
7days before receipt of study  vaccine or at least 15 days after receipt of study  vaccine.
13.*Has r eceived any  live vaccine starting from 30days before study  vaccin ation or is 
scheduled to receive an y live va ccine through 30days following study  vaccin ation.Â 
Â  05H6VD
07XD6Y
PRODUCT: V116  39
PROTOCOL/AMENDMENT N O.:001-[ADDRESS_1214567] until the Day 30postvaccination blood draw is complete. Autologous 
blood transfusions are not considered an exclusion criterion.
Prior/Concurrent Clinical Study Experience
15.Is currently  parti cipating in or has participated in an interventional clinical study  with an 
investigational compound or device within 2 months of participating in this current stud y.
Other Exclusions
16.In the opi[INVESTIGATOR_871], has a history  of clinically  relevant drug or alcohol use 
that would interfere with participation in protocol -specified activities.
17.Has history or current evidence of an y condition, therap y, lab oratory abnormality ,or 
other circumstance that might expose the participant to risk by  [CONTACT_146296] , 
confound the results of the study , or interfere with the participant â€™s participation for the 
full duration of the study .
18.Is or has an immediate family  member (eg, spouse, parent/legal guardian, sibling, or 
child) who is investigationa l site or Sponsor staff directly  involved with this study .
For items with an asterisk (*), if the participant meets these exclusion criteria, the 
Day 1 Visit may be rescheduled for a time when these criteria are not met.
5.3 Lifestyle Considerations
No lifesty le restrictions are required.
5.4 Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study, but 
are not subsequently randomized in the study . A minimal set of screen failure information is 
required to ensure transparent reporting of screen failure participants to meet the CONSORT 
publishing requirements and to respond to queries from regulatory authorities. 
Minimal 
information includes demograph y, screen failure details, eligi bility  criteria, and any AEs or 
SAEs meeting reporting requirements as outlined in the data entry  guidelines.
5.5 Participant Replacement Strategy
A participant who withdraws from the stud ywill not be replaced.
6 STUDY INTERVENTION
Study  intervention is define d as an y investigational intervention(s), marketed product(s), 
placebo, or me dical device(s) intended to be administered to a study  participant according to 
the study  protocol .Â 
Â  05H6VD
07XD6Y
PRODUCT: V116  40
PROTOCOL/AMENDMENT N O.:001-01 
V116 -001-01FINAL PROTOCOL 11-MAY -2020
Clinical supplie s (pPCV and PNEUMOVAXâ„¢23 )will be packaged to support enrollment . 
Clinical supplies will be affixed with a clinical label in accordance with regulatory 
requirement s.
6.1 Study Intervention(s) Administered
The study intervention s to be used in this study are outlined inTable 1 (Phase 1) and Table 2
(Phase 2).Â 
Â  05H6VD
07XD6Y
PRODUCT: V116  41
PROTOCOL/AMENDMENT N O.:001-01 
V116 -001-01FINAL PROTOCOL 11-MAY -2020
Table 1 Study  Intervention sfor Phase 1
Arm Name [CONTACT_870046](s)Dosage 
Level(s)Route of 
Adm inVaccination 
Regim en UseIMP/
NIMP Sourcing
pPCV -1 Experimental pPCV Biological
/VaccineSterile 
SolutionRefer to I B 0.5 mL IM Single dose 
at Visit 1 
(Day 1)Experimental IMP Central
pPCV -2 Experimental pPCV Biological
/VaccineSterile 
SolutionRefer to IB 1.0 mL IM Single dose 
at Visit 1 
(Day 1)Experimental IMP Central
PNUEMOVAXâ„¢ 23 Active 
ComparatorPNEUMOVAXâ„¢23 Biological
/VaccineSterile 
SolutionRefer to 
product 
labeling0.5 mL IM Single dose 
at Visit 1 
(Day 1)Experimental IMP Central
Admin =administration; I B =Investigatorâ€™s Brochure; I M = intramuscular; I MP=investigational medicinal product; NI MP=non-investigational medicinal product ; pPCV =polyvalent pneumococcal 
conjugate vaccine .
Definition ofInvestigational Medicinal Product (I MP) and Non -Investigational Medicinal Product (NI MP) is based on guidance issued by [CONTACT_63512]. Regional and/or Country diff erences 
of the definition of I MP/NI MP may exist. I n these circumstances, local leg islation is followed.Â 
Â  05H6VD
07XD6Y
PRODUCT: V116  42
PROTOCOL/AMENDMENT N O.:001-01 
V116 -001-01FINAL PROTOCOL 11-MAY -2020
Table 2 Study  Interventions for Phase 2
Arm Name [CONTACT_870046](s)Dosage 
Level(s)Route of 
Adm inVaccination 
Regim en UseIMP/
NIMP Sourcing
pPCV Experimental pPCV Biological/
VaccineSterile 
SolutionRefer to I B Based on 
Phase 1 
ResultsIM Single dose at 
Visit 1 (Day 1)Experimental IMP Central
PNEUMOVAXâ„¢23 Active 
ComparatorPNEUMOVAXâ„¢23 Biological/
VaccineSterile 
SolutionRefer to 
product 
labeling0.5 mL IM Single dose at 
Visit 1 (Day 1)Experimental IMP Central
Admin =administration; I B =Investigatorâ€™s Brochure; I M = intramuscular; I MP=investigational medicinal product; NI MP=non-investigational medicinal product ; pPCV =polyvalent pneumococcal 
conjugate vaccine .
Definition of Investigational Medicinal Product (I MP) and Non -Investigational Medicinal Product (NI MP) is based on guidance issued by [CONTACT_63512]. Regional and/or Country diff erences 
of the definition of I MP/NI MP may exist. I n these circumstances, local legislation is followed.Â 
Â  05H6VD
07XD6Y
PRODUCT:   V116  43
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
All supplies indicated in Table 1 and Table 2will be provided per the "Sourcing" column
depending upon local country  operational requirements. If local sourcing, e very attempt 
should be made to source these supplies from a single lot/batch number .
Refer to Section 8.1.8 for details regarding administration of the study  intervention.
6.2 Preparati on/Handling/Storage/Accountability
6.2.[ADDRESS_1214568] be stored 
in a secure, environmentally  controlled, and monitored (manual or automated) area in 
accordance with the labeled storage conditions with access limited to the investigator and 
authorized sit e staff.
The investigator, institution, or the head of the medical institution (where applicable) is 
responsible for stud y intervention accountability , reconciliation, and record maintenance (ie, 
receipt, reconciliation, and final disposition records).
Forall study  sites, the local country  Sponsor personnel or designee will provide appropriate 
documentation that must be completed for drug accountability  and return, or local discard 
and destruction if appropriate. Where local discard and destruction is appr opriate, the 
investigator is responsible for ensuring that a local discard/destruction procedure is 
documented.
The study  site is responsible for recording the lot number, manufacturer, and expi[INVESTIGATOR_63470] y purchased product (if applicable) as p er local guidelines unless otherwise 
instructed by  [CONTACT_1034].
The investigator shall take responsibility  for and shall take all steps to maintain appropriate 
records and ensure appropriate supply, storage, handling, distribution, and usage of stud y 
interventions in accordance with the protocol and any  applicable laws and regulations .Â 
Â  05H6VD
07XD6Y
PRODUCT:   V116  44
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
6.3 Measures to Minimize Bias: Randomization and Blinding
6.3.1 Intervention Assignment
In Phase 1, intervention allocation/randomization will occur centrall y using an I RT sy stem. 
There are 3 study  intervention arms. Participants will be assigned randomly  in a 1:1 :1ratio to 
receive either pPCV -1, pPCV -2,or PNEUMOVAXâ„¢23 .
In Phase 2 , interven tionallocation/randomization will occur centrall y using an I RT sy stem. 
There are 2 study  intervention arms. Participants will be assigned randomly in a 1:1ratio to 
receive either pPCV or PNEUMOVAXâ„¢23 .
6.3.2 Stratification
Intervention allocation/randomization in Phase 1 will not be stratified.
Intervention allocation/randomization in Phase 2 will be stratified according to the following 
factors:
â€¢Participant age at time of randomization (50 to 64, 65 to 74, and â‰¥75years of age).
6.3.3 Blinding
In both Phase 1 and Phase 2, a double -blinding technique will be used. pPCV and 
PNEUMOVAXâ„¢23 will be prepared and/or dispensed in a blinded fashion by  [CONTACT_870021]. The participant, the investigator, and Sponsor 
personnel or delegate(s) who are involved in the study  intervention administration or clinical 
evaluation of the participants are unaware of the intervention assignments.
Because pPCV and PNEUMOVAXâ„¢[ADDRESS_1214569] a different appearance, a member of the study  
site staff will be unblinded for the purposes of receiving, maintaining, preparing and/or 
dispensing, and administering these stud y vaccines. Procedures for handling, preparing, and 
administering the unblinded vaccines are located in the I nvestigator Trial File Binder.
Toavoid bias, the unblinded study  personnel will have no further contact [CONTACT_870022] -related procedures/a ssessments after administration of study  
vaccines, which includes all safet y follow -up procedures . Addit ionall y, blinded site 
personnel will not be present in the examination room when study  vaccines are administered. 
Contact [CONTACT_703044]. Blinded site personnel will be responsible for all safety  and 
immunogenicit y follow -up procedures after vaccine administration.
An unblinded Clinical Research Associate will monitor vaccine accountability  at the study  
site. All other Sponsor personnel or delegate(s) and [COMPANY_006] Resea rch Laboratories employ ees 
directly  involved with the conduct of this study  will remain blinded to the participant-level 
intervention assignmen t.Â 
Â  05H6VD
07XD6Y
PRODUCT:   V116  45
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
See Section 8.1.13 for a description of the method of unblinding a participant during the 
study  should such action be warranted.
6.4 Study Intervention Compliance
Given that a single dose of pPCV or PNEUMOVAXâ„¢23 will be administered in this study , 
intervention compliance will n ot be assessed.
6.5 Concomitant Therapy
Medications or vaccinations specificall y prohibited in the exclusion criteria are not allowed
during the ongoing stud y(see Section 5.2). If there is a clinical indication for an y 
medications or vaccinations specificall yprohibited, di scontinuation from study  intervention 
may be required. The investigator should discuss any  questions regarding this with the 
Sponsor Clinical Director . The final decision on any supportive therap y or vaccination rests 
with the investigator a nd/or the participant â€™s primary  physician. However, the decision to 
continue the participant on study  intervention requires the mutual agreement of the 
investigator, the Sponsor, and the participant.
If the participant is scheduled to receive an y nonstudy  vaccine, the investigator should 
discuss this with the Sponsor Clinical Director as soon as possible. All nonstudy  vaccinations 
should be recorded on the appropriate eCRF.
Listed below are specific restrictions for concomitant therap y or vaccination:
â€¢Any administration of a nonstudy  pneumococcal vaccine is prohibited during the stud y.
â€¢Live and non -live vaccines may  only  be administered prior to or following the receipt of 
study  vaccine according to the time frames specified in Exclusion Criteria (Section 5.2). 
Exception : Inactivated influenza vaccine may  be administered but must be given at least 
7days before receipt of any  study  vaccine or at least 15 days after receipt of any  study  
vaccine.
â€¢Participants should not receive s ystemic corticosteroids (prednisone equivalent of 
â‰¥20mg/day  for â‰¥14consecutive day s) starting from 30 days prior to vaccination through 
30days following vaccination.
â€¢Participants should not receive s ystemic corticosteroids exceeding ph ysiologic 
replacement dose s (prednisone equivalent dose >5 mg/day ) starting from 14daysprior to
vaccination.
Note : Topi[INVESTIGATOR_2855], ophthalmic, intra -articular or soft -tissue (eg, bursa, tendon steroid 
injections), and inhaled/nebulized steroids are permitted.
Any deviation from the abov e requires consultation between the investigator and the Sponsor 
and written documentation of the collaborative decision on participant management.Â 
Â  05H6VD
07XD6Y
PRODUCT:   V116  46
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
6.5.1 Rescue Medications and Supportive Care
No rescue or supportive medications are specified for use in this study .
6.6 Dose Modification
No dose modification is allowed in this study .
6.7 Intervention After the End of the Study
There is no stud y-specified intervention following the end of the stud y.
6.8 Clinical Supplies Disclosure
This study  is blinded, but supplies are provided open label; therefore, an unblinded 
pharmacist or unblinded qualified study  site personnel will be used to maintain the blinding 
of study  staff w ho are directly  involved in the clinical evaluation of participants in the study . 
Study  intervention identity  (name, strength, or potency ) is included in the label text.
The emergency  unblinding call center will use the intervention/randomization schedule for 
the study  to unblind participants and to unmask study  intervention identity . The emergency  
unblinding call center should only  be used in cases of emergency (see Section 8.1.13 ). In the 
event that the emergency unblinding call center is not available fo r a given site in this study , 
the central electronic intervention allocation/randomization system (IRT) should be used to 
unblind participants and to unmask study  intervention identity . The Sponsor will not provide 
random code/disclosure envelopes or lists with the clinical supplies.
See Section 8.1.[ADDRESS_1214570]:   V116  47
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
Specific details regarding procedures to be performed at the time of withdrawal from the 
study ,as well as specific det ails regarding wit hdrawal from future biomedical r esearch, are 
outlined in Section 8.1.12 . The procedures to be performed should a participant repeatedl y 
fail to return for scheduled visits and/or if the study site is unable to contact [CONTACT_63517] 7.3.
7.[ADDRESS_1214571] t o Follow -up
If a participant fails to return to the clinic for a required study  visit and/or if the site is unable 
to contact [CONTACT_2299], the following procedures are to be performed:
â€¢The site must attempt to contact [CONTACT_19423]. I f the 
participant is contact[INVESTIGATOR_530], the participant should be counseled on the importance of 
maintaining the protocol -specified visit schedule.
â€¢The investigator or designee must make every  effort to regain contact [CONTACT_19424] (eg, telephone calls and/or a certified letter to the participantâ€™s last 
known mailing address or locally equivalent methods). These contact [CONTACT_19425]â€™s medical record.
â€¢Note: A participant is not considered lost to follow -up until the last scheduled visit for the 
individual participant. The missing data for the participant will be managed via the 
prespecified statistical data handling and anal ysis guidelines .
8 STUDY ASSE SSMENTS AND PROCEDUR ES
â€¢Study  procedures and their timing are summarized in the SoA.
â€¢Adherence to the stud y design requirements, including those specified in the SoA, is 
essential and required for study  conduct.
â€¢The investigator is responsible for ensuring that procedures are conducted by  
[CONTACT_11399] y qualified (by  [CONTACT_8640], training, and experience) staff. Delegation of study  
site personnel responsibilities will be docu mented in the I nvestigator Trial File Binder (or 
equivalent).
â€¢All study -related medica l decisions must be made by  [CONTACT_19427] a qualified 
physician.
â€¢All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility  criteria. The investigator will maintain a screening log to 
recor d details of all participants screened and to confirm eligibility  or record reasons for 
screening failure, as applicable.
â€¢Procedures conducted as part of the participantâ€™s routine clinical management (eg, blood 
count) and obtained before signing of ICF may be utilized for screening or baseline 
purposes provided the procedure met the protocol -specified criteria and were performed 
within the time frame defined in the SoA.Â 
Â  05H6VD
07XD6Y
PRODUCT:   V116  48
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
â€¢Additional evaluations/testing may  be deemed necessary  by [CONTACT_63519] y. In some cases, such evaluation/testing 
may be potentially  sensitive in nature (eg, HIV, Hepatitis C), and thus local regulations 
may require that additional informed consent be obtained from the participant. In these 
cases, such evaluations/testing will be performed in accordance with those regulations.
In Phase 1, the maximum amount of blood collected from each participant at each stud y visit 
will not exceed 105mL, and the total amount of blood collected over the duration of the 
study will not exceed 195mL(Table 3).
In Phase 2, the maximum amount of blood collected from each participant at each stud y visit 
will not exceed 80mL, and the total amount of blood collected over the duration of the study  
will not exceed 150 mL(Table 4 ).
Repeat or unscheduled samples may  be taken for safet y reasons or for technical issues with 
the samples.
Table 3 Appro ximate Blood Volumes Drawn b y Stud y Visit and by [CONTACT_655180] T ype 
(Phase 1)
Visit 1
Day 1Visit 2
Day 30Total
Param eter Approxim ate Blood Volume (mL)
Immunogenicity assessment (including retention 
samples)30 mL 30 mL 60 mL
Blood chemistry and hematology 13 mL 13 mL 26 mL
DNA for future biomedical researcha 8.5 mL N/A 8.5 mL
Assay developmenta 50mL 50 mL 100 mL
Expected total (mL) 101.5 mL 93 mL 194.5 mL
DNA =deoxyribonucleic acid.
aSamples for future biomedical research and assay development will only be obtained from participants who provide 
separate consent for collection of these optional samples.Â 
Â  05H6VD
07XD6Y
PRODUCT:   V116  49
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
Table 4 Approximate Blood Volumes Drawn b y Stud y Visit and by [CONTACT_655180] T ype 
(Phase 2)
Visit 1
Day 1Visit 3
Day 30Total
Param eter Approxim ate Blood Volume (mL)
Immunogenicity assessment (including retention 
samples)30 mL 30 mL 60 mL
DNA for Future Biomedical Researcha 8.5 mL N/A 8.5 mL
Assay developmenta 40 mL 40 mL 80 mL
Expected total (mL) 78.5 mL 70 mL 148.5 mL
DNA =deoxyribonucleic acid.
aSamples for future biomedical research and assay development will only be obtained from participants who provide 
separate consent for collection of these optional samples.
8.1 Administrative and General Procedures
8.1.1 Informed Consent
The investigator or medically  qualified designee (consistent with local requirements) must 
obtain documented consent from each potential participant prior to participating in a clinical 
study or future biomedical r esearch .If there are changes to the participantâ€™s status during the 
study  (eg, health or age of majority  requirements), the investigator or medically  qualified 
designee must ensure the appropriate consent is in place.
[IP_ADDRESS] General Informed Consent
Consent must be documented by [CONTACT_2299]â€™s dated signature [INVESTIGATOR_2394] a consent form along 
with the dated signature [CONTACT_63564].
A cop y of the signed and dated consent form should be given to the participant before 
participation in the study .
The initial I CF, any  subsequent revised written ICF, and an y written information provided to 
the participant must receive the IRB/IECâ€™s approval/favorable opi[INVESTIGATOR_19349]. The 
participant should be informed in a timely  manner if new information becomes available that 
may be relevant to the participantâ€™s willingness to continue participation in the study . The 
communication of this information will be provided and documented via a revised consent 
form or addendum to the original consent form that captures the participantâ€™s dated signature .
Specifics about a stud y and the study population will be added to the consent form template 
at the protocol level.Â 
Â  05H6VD
07XD6Y
PRODUCT:   V116  50
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
The informed consent will adhere to IRB/IEC requirements, applicable laws and regulations, 
and Sponsor requirements .
[IP_ADDRESS] Consent and Collection of Specimens for Future Biomedical Research
The investigator or medically  qualified designee will explain the future biomedical r esearch 
consent to the participant, answer all of his/her questions, and obtain wr itten informed 
consent before performin g any procedure related to future biomedical research. A cop y of the 
informed consent will be given to the participant.
[IP_ADDRESS] Consent and Collection of Blood Samples for Optional Assay Development
The investigator or medica lly qualified designee will explain the consent for the optional 
assay  development blood samples to the participant, answer all of his/her questions, and 
obtain written informed consent before performing any procedure related to the optional 
assay  developm ent blood samples collection. A copy  of the informed consent will be given to 
the participant.
8.1.2 Inclusion/Exclusion Criteria
All inclusion and exclusion criteria will be reviewed by [CONTACT_093] ,who is a qualified 
physician, to ensure that the participant qualifies for the study .
8.1.[ADDRESS_1214572] information (including direct 
telephone numbers) to be used in the event of an emergency . The investigator or qualified 
designee will provide the participant with a participant identification card immediately after 
the participant provides written informed consent. At the time of interventi onrandomization,
site personnel will add the treatment /randomization number to the participant identification 
card.
The participant identification card also contains contact [CONTACT_19430] a healthcare provide r can obtain information about study  
intervention in emergency  situations where the investigator is not available.
8.1.4 Medical History
A medical history  will be obtained by  [CONTACT_27404]. The participantâ€™s 
relevant medical history  for the 5 y ears prior to Visit 1 (Day 1) will be obtained to ensure that 
the participant satisfies the inclusion and exclusion criteria of the study . History  of tobacco 
use will be collected for all participants.Â 
Â  05H6VD
07XD6Y
PRODUCT:   V116  51
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
8.1.5 Prior and Concomitant Medications Revi ew
[IP_ADDRESS] Prior Medications
The investigator or qualified designee will review prior medication use and record prior 
medication taken b y the participant within 30 days before the stud y vaccination at Visit 1 
(Day 1).
[IP_ADDRESS] Concomi tant Medications
The investigator or qualified designee will record medication, if an y, taken by [CONTACT_63525] y.
The participant will use their paper VRC (Phase 1) or eVRC (Phase 2) (Section 8.1.9) to 
record n ew and/or concomitant medicat ions taken after Visit 1 (Day  1) and nonstudy  
vaccines received since Visit [ADDRESS_1214573] not be re -used for 
different participants.
8.1.7 Assignment of Treatment/Randomization Numb er
All eligible partici pants will be randomly  allocated and will receive a 
treatment /randomization number. The treatment/randomization number identifies the 
participant for all procedures occurring after treatment randomization . Once a 
treatment /randomization number is assigned to a participant, it can never be re -assigned to 
another participant.
A single participant cannot be assigned more than 1 treatment /randomization number.
8.1.[ADDRESS_1214574] of the study  will prepare 
and administer pPCV or PNEUMOVAXâ„¢23 .Study  vaccines should be prepared and 
administered b y appropriately qualified members of the study personnel (eg, ph ysician, 
nurse, ph ysicianâ€™s assistant, nurse practitioner, pharmacist, or medical assistant) as allowed 
by [CONTACT_5737]/state, country , and institutional guidance. Procedures for handli ng, preparing, and 
administering the unblinded vaccines are provided in the Investigator Trial File Binder. 
Unblinded study  personnel should follow the preparation and administration instructions for 
PNEUMOVAXâ„¢[ADDRESS_1214575] label.
Study  vaccines should be removed from the refrigerator no more than 1 hour before 
vaccination. The time of removal and time of vaccination should be documented in the 
participantâ€™s chart.Â 
Â  05H6VD
07XD6Y
PRODUCT:   V116  52
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
Study vaccine will be administered as a single IMinjection, preferabl y in t he deltoid region 
of the participantâ€™s arm . Adequate treatment provision, including epi[INVESTIGATOR_870009], should be available for immediate use should an anaph ylactic or 
anaph ylactoid reaction occur [Centers for Disease Control and Prevention 2015] .
Unblinded study  personnel should not have contact [CONTACT_870023] -related 
procedures/assessments after administration of study  vaccine, which includes all safet y 
follow -up procedures. All safet y and immunogenicity  assessments will be conducted b y 
blinded personnel, and the participant will be blinded to the study  vaccine received. 
Vaccination information, such as time of vaccination, must be recorded on the appropriate 
eCRF as per the d ata entry guidelines .
[IP_ADDRESS] Timing of Dose Administration
Vaccinations may  be administered at an y time of day and without regard to timing of meals.
Each participant â€™s bod y temperature must be taken before vaccine administration. Individuals 
who present with fever (oral or t ympanic temperature â‰¥100.4Â°F [â‰¥38.0Â°C] or axillary  or 
temporal temperature â‰¥99.4Â°F [â‰¥37.4Â°C]) will have the vaccination delay ed until fever is 
resolved for at least 72 hours.
The collection of blood samples and administration of pregnancy  tests (if applicable) must be 
done before vaccine administration.
All participants will be observed for at least [ADDRESS_1214576] be performed b y blinded site person nel for all study  
vaccines (Section 1.3 and Section 6.3.3).
8.1.[ADDRESS_1214577] (VRC)
Participants in Phase 1 will use a paper VRC and participants in Phase 2 will use an eVRC.
The information collected on the paper VRC will be consistent with the info rmation collected 
on the eVRC.
The paper VRCs/eVRCs are structured as recommended in the final Food and Drug 
Administration Patient -Reported Outcome Guidance [U.S. Food and Drug Administration 
2009] . The investi gator or delegate will train the participant in the use of the paper VRC 
(Phase 1) or eVRC (Phase 2) at Visit 1 (Day 1).
The participant will use the paper VRC/eVRC to record b ody temperature (Section 8.3.3);
concomitant medications and nonstudy  vaccinatio ns (Section [IP_ADDRESS]); and injection- site 
reactions, vaccine -specific complaints, andother complaints or illnesses (Section 8.4.8).
The investigator or delegate will discuss information entered into the paper VRC/eVRC with 
the participant at the telephone contact [INVESTIGATOR_106006] 15(Section 8.1.10) . A full review of the 
completed paper VRC/eVRC will occur at the Day 30postvaccination visit .Â 
Â  05H6VD
07XD6Y
PRODUCT:   V116  53
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
Any differences between paper VRC/eVRC data and the clinical database must be 
documented in the participantâ€™s source record.
8.1.[ADDRESS_1214578] on Day 15
The investigator or delegate will discuss any  information entered into the paper VRC
(Phase 1) or eVRC (Phase 2) with the participant at the telephone c ontact on Day 15. An y 
differences between the paper VRC/eVRC data and the clinical database must be 
documented in the participantâ€™s source record. A full review of the completed paper 
VRC/eVRC will occur at the Day  30postvaccination visit .
8.1.[ADDRESS_1214579] 
Questionnaire provided by [CONTACT_1034]. Data to be reported from this discussion will include 
SAE s and/or an y updates to previously reported safety information .
8.1.12 Discontinuation and Withdrawal
Participants who receive a single -dose intervention cannot discontinue study intervention 
(see Section 7.1).
When a participant withdraws from participation in t he study , all applicable activities 
scheduled for the final study  visit should be performed (at the time of withdrawal). An y AEs
that are present at the time of withdrawal should be followed in accordance with the safet y 
requirements outlined in Section 8.4.
[IP_ADDRESS] Withdrawal From Future Biomedical Resear ch
Participants may  withdraw their consent for future biomedical r esearch. Participants may  
withdraw consent at an y time by  [CONTACT_111954] . If medical 
records for the main study  are still available, the investigator will contact [CONTACT_111955] ([EMAIL_1250]). Subsequently ,the 
participant's consent for future biomedical r esearch will be withdrawn. A letter will be sent 
from the Sponsor to the investigator confirming the withdrawal. I t is the responsibility  of the 
investigator to inform the participant of completion of withdrawal. An y analy ses in progress 
at the time of request for withdrawal or alread y performed prior to the request being received 
by [CONTACT_443171]. 
No new analy ses would be generated after the request is received.
In the event that the medical records for the main study  are no longe r available (eg, if the 
investigator is no longer required b y regulatory authorities to retain the main study records) 
or the specimens have been completel y anon ymized, there will no longer be a link between 
the participantâ€™s personal information and their specimens. In this situation, the request for 
specimen withdrawal cannot be processed.Â 
Â  05H6VD
07XD6Y
PRODUCT:   V116  54
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
8.1.13 Participant Blinding/Unblindi ng
STUDY INTERVENT ION IDENT IFICATION INFORMAT ION IS TO BE UNMASKED 
ONLY IF NECESSARY FOR THE WELFARE OF THE PARTICIPANT. EVERY 
EFFORT SHOUL D BE MADE NOT TO UNBLIND.
For emergency  situations where the investigator or medically  qualified designee (consistent 
with local requirements) needs to identify  the intervention used by  a participant and /orthe 
dosage administered , he/she will contact [CONTACT_126537] a request for emergency  unblinding. As requested b y the investigator or medically  
qualified designee, the emergency  unblinding call center will provide the information to 
him/her promptly  and report unblinding to the Sponsor. Prior to contact[CONTACT_126538] a participantâ€™s intervention assignment, the 
investigator who is a qualified phy sician should make reasonable attempts to enter the 
intensity and tox icity grade of the AEs observed, the relation to study  intervention, the reason 
thereof , etc., in the medical chart. If it is not possible to record this assessment in the chart 
prior to the unblinding, the unblinding should not be delay ed.
In the event th at unblinding has occurred, the circumstances around the unblinding (eg, date, 
reason, and person performing the unblinding) must be documented promptly , and the 
Sponsor Clinical Director notified as soon as possible.
Once an emergency  unblinding has taken place, the investigator, site personnel, and Sponsor 
personnel may  be unblinded so that the appropriate follow -up medical care can be provided 
to the participant.
Participants whose trea tment assignment has been unblinded by  [CONTACT_2697] y 
qualified designee and/or nonstudy  treating ph ysician must be discontinued from study  
intervention, but should continue to be monitored in the study .
Additionally , the investigator or medically  qualified designee must go into the I RT sy stem 
and perform the unblind in the I RT sy stem to update drug disposition. In the event that the 
emergency  unblinding call center is not available for a given site in this study , the IRT 
system should be used for emergency  unblinding in the event that this is required for 
participant safety .
At the end of the stud y, random code/disclosure envelopes or lists and unblinding logs are to 
be returned to the Sponsor or designee.
8.1.14 Calibration of Equipme nt
The investigator or qualified designee has the responsibility  to ensure that any  device or 
instrument used for a clinical evaluation/test during a clinica l study  that provides information 
about inclusion/exclusion criteria and/or safety  or efficacy  parameters shall be suitably  
calibrated and/or maintained to ensure that the data obtained are reliable and/or reproducible. 
Documentation of equipment calibration must be retained as source documentation at the 
study  site.Â 
Â  05H6VD
07XD6Y
PRODUCT:   V116  55
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
8.2 Immunogenicity Assessmen ts
Sera from participants will be used to measure vaccine -induced OPA and IgG responses . 
These endpoints will be tested for all immunogenicity  blood draws specified in Section 1.3. 
Blood collection, storage, and shipment instructions for serum samples will be provided in 
the operations/laboratory manual.
The MOPA will be used for measuring OPA responses. Opsonization of pneumococci for 
phagocy tosis is an important mechanism by  [CONTACT_63531]. The OPA assay  is a useful tool for assessing the protective function 
of serot ype-specific antibodies and , therefore, the immunogenicit y of pneumococcal vaccine 
formulations.
Seroty pe-specific IgG will be measured using the PnECL  v2.0 assay  to assess the 
concentration of binding antibodies to capsular poly saccharide of S. pneumoniae.
8.2.1 Multiplex Opsonophagocytic Assay (MOPA)
The MOPA, developed and published by  [CONTACT_63532] (Director of the US World 
Health Organization pneumococcal serology  reference laboratory  and National I nstitutes of 
Health pneumococcal reference laboratories) [Burton, Robert L. and Nahm, Moon H. 2006] , is a 
multiplexed OPA assay  capable of measuring [ADDRESS_1214580] 4 seroty pes/run 
reduces the amount of serum needed for testing. The assay readout is the opsonization index, 
which is the reciprocal of the highest dilution that gives â‰¥50% bacterial killing, as 
determined b y comparison to assay background controls. MSD has developed and optimized 
the MOPA in a high throughput microcolon y platform. The MOPA assay  forpPCV will be 
qualified. The qualification studies will evaluate various performance parameters of the assay  
including precision, ruggedness, relative accuracy/dilutional linearity , andthe limi t of 
detection of the assay .
8.2.2 Pneumococcal Electrochemiluminescence (PnECL)
The Sponsor has developed and optimized a multiplex, ECL -based detection method for the 
quantitation of IgG serotype -specific antibodies to PnPseroty pes contained in pPCV . The 
PnEC L v2.0 assay  is based on the Meso -Scale Discovery  technology , which employ s 
disposable multi -spot microtiter plates. The benefits of the ECL  multiplex technology  over 
the prior enzy me-linked immunosorbent assay  methodology  include speed, equivalent or 
better sensitivity , increased dy namic range, the ability  to multiplex, and reduction in required 
serum sample and reagent volumes. The measurement of immune responses to the serot ypes 
contained in pPCV is performed using an assay  format consisting of 3 groups of 8, 9, and 
7seroty pes each. The PnECL  v2.0 assay  for pPCV will be qualified . The qualification
studies will evaluate various performance parameters of the assay  including precision, 
ruggedness, relative accuracy /dilutional linearity , and the limit of de tection of the assay .Â 
Â  05H6VD
07XD6Y
PRODUCT:   V116  56
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
8.3 Safety Assessments
Details regarding specific safet y procedures/assessments to be performed in this study  are 
provided. The total amount of blood to be drawn over the course of the study (from prestud y 
to poststudy  visits), including approximate blood volumes drawn b y visit and by [CONTACT_63533] t ype 
per particip ant, can be found in Section 8.
Planned time points for all safety assessments are provided in the SoA.
8.3.1 Physical Examinations
A complete ph ysical examination will be conducte d by [CONTACT_63534] (consistent with local requirements) before vaccination at Visit 1 (Day 1).
A complete ph ysical examination includes, but is not limited to, the assessment of general 
appearance, vital signs (heart rate, respi[INVESTIGATOR_2842], blood pressure, and body  temperature), 
eyes, throat, mouth, cardiovascular, respi[INVESTIGATOR_696] , gastrointestinal, skin, neurologic, and 
psychiatric s ystems, and other organ s ystems as indicated.
In the source documents, investigators should doc ument phy sical exam ination data and the 
status of all active medical conditions.
Investigators should pay  special attention to clinical signs related to previous serious
illnesses.
8.3.[ADDRESS_1214581] consistent with local requirements (sensitive to at least 25 IU Î² -hCG) must 
be performed before vaccination at Visit 1 ( Day 1)in WOCBP as described in Section 1.3. 
Urine or serum tests can be used, and results must be negative before vaccination can occur.
A detailed definition of WOCBP is provide d in Appendix 5.
8.3.3 Body Temperature Measurement
Each participantâ€™s bod y temperature must be taken before vaccination as described in 
Section 1.3.
Participants will also record o ral body temperatures using their paper VRC (Phase 1) or
eVRC (Phase 2) (Section 8.1.9) from Day 1 to Day 5 postvaccination.
For this study , any oral or tympanic temperature â‰¥100.4Â°F (â‰¥38.0Â°C) or axillary  or temporal 
temperature â‰¥99.4Â°F (â‰¥37.4Â°C) will be considered an AE of fever. All fevers must be 
reported Day [ADDRESS_1214582]:   V116  57
PROTOCOL/AMENDMENT N O.:  [ADDRESS_1214583] of clinical laboratory tests to be performed and to the SoA for 
the timing and frequency.
â€¢The investigator or medically  qualified designee (consistent with local requirements) 
must review the laboratory  report, document this review , and record an y clinically 
relevant changes occurring during the stud y in the AE section of the CRF. The laboratory 
reports must be filed with the source documents. Clinically  significant abnormal 
laboratory  findings are those which are not associated wit h the underl ying disease, unless 
judged b y the investigator to be more severe than expected for the participant's condition.
â€¢All protocol -required laboratory  assessments, as defined in Appendix 2, must be 
conducted in accordance with the laboratory  manual and the SoA .
â€¢If laboratory  values from nonprotocol -specified laboratory  assessments performed at the 
institutionâ€™s local laboratory  require a change in study  participant management or are 
considered clinically  significant by  [CONTACT_093] (eg, SAE or AE or dose 
modification), then the results must be recorded in the appropriate CRF (eg, SL AB).
â€¢For an y laboratory  tests with values considered clinically  significantl y abnormal during 
participation in the study , every  attempt should be made to perform repeat assessments 
until the values return to normal or baseline or if a new baseline is established as 
determined b y the investigator .
8.4 Adverse Events , Serious Adverse Events ,and Other Reportable Safety Events
The definitions of an AE or SAE, as well as the method of recording, evaluating, and 
assessing causalit y of AE and SAE and the procedures for completing and transmitting AE, 
SAE, and other reportable safet y event reports can be found in Appendix 3.
Adverse events, SAEs, and other reportable safety events will be reported by  [CONTACT_2299] 
(or, when appropriate, b y a caregiver, surrogate, or the participant's legall y authorized 
representative).
The investigator and an y designees are responsible for detecting, documenting, and reporting 
events that m eet the definition of an AE or SAE as well as other reportable safet y events. 
Investigators remain responsible for following up AEs , SAEs, and other reportable safety  
events for outcome according to Section 8.4.3.
The investigator, who is a qualified ph ysician, will assess events that meet the definition of 
an AE or SAE as well as other reportable safet y events with respect to seriousness, 
intensity /toxicity  and causality .Â 
Â  05H6VD
07XD6Y
PRODUCT:   V116  58
PROTOCOL/AMENDMENT N O.:  [ADDRESS_1214584] be reported b y the investigator if they cause the participant to 
be excluded from the study , or are the result of a protocol -specified intervention, including 
but not limited to washout or discontinuation of usual therap y, diet, placebo treatment, or a 
procedure.
ï‚·All nonserious AEs and other reportable safet y events (excluding pregnancy and 
lactation exposure) must be report ed by [CONTACT_870024] 30 day s postvaccination.
ï‚·All SAEs must be reported by [CONTACT_870025] , regardless of whether or not related to the 
Sponsorâ€™s product.
ï‚·All pregnancies and exposure during breastfeeding must be reported b y the 
investigator from the day of randomization through [ADDRESS_1214585] be reported immediatel y to the 
Sponsor if the event is either:
ï‚·A death that occurs prior to the participant completing the study.
OR
ï‚·An SAE that is considered by [CONTACT_2413], who is a qualified ph ysician, to be 
vaccine related.
Investigators are not obligated to activel y seek AE sor SAEs or other reportable safety  events 
in former stud y participants. However, if the investigator learns of an y SAE, including a 
death, at an y time after a participant has been discharged from the study , and he/she 
considers the event to be reasonabl y related to the study intervention or study  participation, 
the investigator must promptly  notify  the Sponsor.
All initial and follow -up AEs, SAEs, and other repo rtable safety  events will be recorded and 
reported to the Sponsor or designee within the time frames as indicated in Table [ADDRESS_1214586]:   V116  59
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
Table 5 Reporting Time Periods and Time Frames for A dverse Events and Other 
Reportable Safet y Events
Type of EventReporting Time 
Period:
Consent to 
Randomization/ 
AllocationReporting Time 
Period:
Randomization/ 
Allocation through 
Protocol- specified 
Follow -up PeriodReporting Time Period:
After the Protocol- specified 
Follow -up PeriodTime Frame 
to Report 
Event and 
Follow -up 
Information to 
Sponsor:
Nonserious Adverse 
Event (NSAE)Report if:
-due to protocol -
specified 
intervention
-causes exclusion
-participant is 
receiving placebo 
run-in or other run-
in treatmentReport all Not required Per data entry 
guidelines
Serious Adverse Event 
(SAE)Report if:
-due to protocol -
specified 
intervention
-causes exclusion
-participant is 
receiving placebo 
run-in or other run-
in treatmentReport all Report if:
-drug/vaccine related.
-any death until participant 
completion of study
(Follow ongoing to outcome)Within 24 
hours of 
learning of 
event
Pregnancy/Lactation 
ExposureReport if:
-due to intervention
-causes exclusionReport all Previously reported â€“Follow 
to completion/termination; 
report outcomeWithin [ADDRESS_1214587] in Phase 1
(require regulato ry 
reporting)Report if:
-due to intervention
-causes exclusionReport
-Potential drug -
induced liver injury 
(DILI)
-Require regulatory 
reportingNot required Within [ADDRESS_1214588] in Phase 2 (do 
not require regulatory 
reporting)There are no ECIs in Phase 2 of this study. Not applicable
Cancer Report if:
-due to intervention
-causes exclusionReport all Not required Within 5 
calendar days 
of learning of 
event
Overdose Report if:
- receiving placeb o 
run-in or other run-
in medication Report all Not required Within [ADDRESS_1214589]:   V116  60
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
8.4.2 Method of Detecting AE s, SAE s,and Other Reportable Safety Events
Care will be taken not to introduce bias when detecting AE sand/or SAEs and other 
reportable safet y events. Open -ended and nonleading verbal questioning of the participant is 
the preferred method to inquire about AE occurrence.
8.4.3 Follow -up of AE, SAE ,and Other Reportable Safety Event Information
After the initial AE/SAE report , the investigator is required to proactivel y follow each 
participant at subsequent visits/contacts. All AE s, SAE s, and other reportable safet y events ,
including pregnancy  and exposure during breastfeeding, ECI s, cancer, and overdose will be 
followed until resolution, stabilization, until the event is otherwise explained, or the 
participant is lost to follow -up (as defined in Section 7.3). In addition, the investigator will 
make every  attempt to follow all nonserious AEs that occur in randomized participants for 
outcome. Further information on follow -up procedures is given in Appendix 3.
8.4.4 Regulatory Reporting Requirements for SAE
Prompt notification (within 24 hours) by  [CONTACT_126543] y of participants and the 
safety of a stud y intervention under clinical investigation are met.
The Sponsor has a legal responsibility  to notify  both the local regulatory  authority  and other 
regulatory  agencies about the safet y of a stud y intervention under clinical investigation. The 
Sponsor will comply  with country -specific regulatory  requirements and global laws and 
regulations relating to safety  reporting to regulatory authorities, IRB/IECs, and investigators.
Investigator safety  reports must be prepared for S[LOCATION_003]R saccording to local regulatory  
requirements and Sponsor policy  and forwarded to investigators as necessary .
An investigator who receives an investigator safety report describing an SAE or other 
speci fic safet y information (eg, summary or listing of SAE) from the Sponsor will file it 
along with the I Band will notify  the IRB/IEC, if appropriate according to local requirements .
8.4.5 Pregnancy and Exposure During Breastfeeding
Although pregnancy  and infant ex posure during breastfeeding are not considered AEs, an y 
pregnancy  or infant exposure during breastfeeding in a participant (spontaneously  reported to 
the investigator or their designee) that occurs during the stud y are reportable to the Sponsor.
All reported pregnancies must be followed to the completion/termination of the pregnancy . 
Pregnancy  outcomes of spontaneous abortion, missed abortion, benign h ydatidiform mole, 
blighted ovum, fetal death, intrauterine death, miscarriage, and stillbirth must be reported as 
serious events (Important Medical Events). If the pregnancy continues to term, the outcome 
(health of infant) must also be reported.Â 
Â  05H6VD
07XD6Y
PRODUCT:   V116  61
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
8.4.6 Disease -related Events and/or Disease -related Outcomes Not Qualifying as 
AEs or SAEs
This is not applicable to this study .
8.4.[ADDRESS_1214590] for Phase 1 of this study  include:
a.An elevated AST or ALT lab value that is greater than or equal to 3X the upper limit of 
normal and an elevated total bilirubin lab value that is greater than or equal to 2X the 
upper limit of normal and, at the same time, an alkaline phosphatase lab value that is less 
than 2X the upper limit of normal, as determined b y wa y of protocol -specified laboratory  
testing or unscheduled laboratory  testing.*
*Note: These criteria are based upon available regulatory guidance documents. The 
purpose of the criteria is to specify  a threshold of abnormal hepatic tests that may  require 
an additional evaluation for an underl ying etiology. The study  site guidance for 
assessment and follow -up of these criteria can be found in the Investigator Study  File 
Binder (or equivalent).
There are no ECIs for Phase 2 of this study .
8.4.8 Adverse Eve nts Reported on the VRC
Participants will use a paper VRC (Phase 1) or eVRC (Phase 2) (Section 8.1.9) to report 
solicited and unsolicited AEs .
The definitions of solicited and unsolicited AEs can be found in Appendix 3.
[IP_ADDRESS] Solicited Adverse Events
Solicited A Es for this study  are summarized in Table 6.Â 
Â  05H6VD
07XD6Y
PRODUCT:   V116  62
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
Table 6 Solicited Adverse Events for V116 -001
Type of Solicited 
Adverse EventPredefined Solicited
Adverse EventsSolicited Time 
Period
Injection site â€¢Injection- site tenderness/pain
â€¢Injection- site redness/erythema
â€¢Injection -site swellingDay 1 to Day  5 
postvaccination
Systemic â€¢Headache
â€¢Muscle pain/my algia
â€¢Joint pain/arthralgia
â€¢Tiredness/fatigueDay 1 to Day  5 
postvaccination
All solicited injection -site AEs will be considered related to stud y intervention. The 
investigator will assess all solicited injection -site AEs for toxicity , and all solicited sy stemic 
AEs for both toxicity  and causality  (Appendix 3).
In addition, the investigator will review all solicited AEs for the following:
â€¢Is the event a s ymptom of another diagnosis?
â€¢Is the event ongoing at the end of the solicited period?
â€¢Does the event meet serious criteria?
A solicited AE that meets any of the above criteria must also be reported on the appropriate 
eCRF as specified in the data entry  guidelines.
Phase 1 :
Solicited injection -site AEs and solicited sy stemic AEs reported b y the participant using the 
paper VRC will be entered by  [CONTACT_870026].
Phase 2 :
Solicited injection -site AEs and solicited sy stemic AEs reported b y the participant using the 
eVRC will be transferred directly  to the Sponsor database.
[IP_ADDRESS] Unsolicited Adverse Events
Unsolicited AEs for this study  are events that are 1) not pr edefined in Table 6, or 
2)predefined in Table 6but reported at an y time outside of the solicited time period . In 
Phase [ADDRESS_1214591] to seriousness, intensity /toxicity ,and causalit y.Â 
Â  05H6VD
07XD6Y
PRODUCT:   V116  63
PROTOCOL/AMENDMENT N O.:  [ADDRESS_1214592] be reported b y the investigator within 5 calendar d ays to the 
Sponsor either by [CONTACT_26365]. Electronic reporting procedures can be found in 
the EDC data entry  guidelines. Paper reporting procedures can be found in the Investigator 
Trial File Binder (or equivalent) .
8.6 Pharmacokinetics
PK parame ters will not be evaluated in this study .
8.7 Pharmacodynamics
Pharmacod ynamic parameters will not be evaluated in this study .
8.8 Biomarkers
Biomarkers are not evaluated in this study .
8.9 Future Biomedical Research Sample Collection
If the participant signs the future biomedical r esearch consent, the following specime ns will 
be obtained as part of future biomedical r esearch:
â€¢DNA for future research
â€¢Leftover stud y serum after completion of immunogenicity testing store dfor future 
research
8.10 Optional Assay Development Bl ood Sample Collection
If the participant signs the consent for the optional assay development blood samples, these 
additional blood samples will be obtained at Day 1 and Day 30. These blood samples will be 
used to support future development work on improvi ng bioanal ytical measurements , which 
requires high- volume single -donor samples to monitor performance of the assay  over time.
Sample collection, storage, and shipment instructions for the optional assay development 
blood samples will be provided in the operations/laboratory  manual.
8.[ADDRESS_1214593]:   V116  64
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
8.12 Visit Requirements
Visit requirements are outlined in Section 1.3. Specific procedure -related details areprovided 
inSection 8.
8.12.1 Screening
Screening procedures will be conducted at Visit 1 (Day 1) as outlined in Section 1.3.
In the event that Day 1 is rescheduled (see Section 5.2), a review of prior 
medications/vaccinations and medical history , a complete phy sical examination, and a bod y 
temperature measurement must be repeated prior to vaccination .
8.12.2 Treatment Period/Vaccination Visit
Requirements during the treatment period are outlined in Section 1.3.
9 STATISTICAL ANALYSIS PLAN
This section outlines the statistical analy sis strategy  and procedures for the study . If, after the 
study  has begun, but prior to any  unblinding, changes are made to primary  and/or key  
secondary  hypotheses, or the statistical methods related to those hy potheses, then the 
protocol will be amended (consistent with I CH Guideline E9). Changes t o exploratory  or 
other non -confirmatory  analy ses made after the protocol has been finalized, but prior to 
unblinding, will be documented in a n sSAP and referenced in the CSR for the study . Post hoc 
exploratory  anal yses will be clearly  identified in the CSR .
9.1 Statistical Analysis Plan Summary
Key elements of the statistical anal ysis plan are summarized below; the comprehensive plan 
is provided in Section 9.2through Section 9.12.
Study Design Overview A Phase 1/Phase 2, Randomized, Double -blind Study to Eval uate the 
Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal 
Conjugate Vaccine in Adults.
Treatm entAssignment In Phase 1, participants will be randomly assigned in a 1:1:1 ratio to 
receive either pPCV -1, pPCV -2, or PNEUMOVAXâ„¢23 .
In Phase 2, participants will be randomly assigned in a 1:1 ratio to receive 
either pPCV or PNEUMOVAXâ„¢23 . Randomization in Phase 2 will be 
stratified by [CONTACT_870027] (50 to 64 years, 65 to 74 years, and 
â‰¥75years).
Analysis Populations Safety : APaT population
Prim ary Immunogenicity : PP population
Supportive Immunogenicity : FAS populationÂ 
Â  05H6VD
07XD6Y
PRODUCT:   V116  65
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
Prim ary Endpoint sin 
Phase 1The primary safety endpoints in Phase 1 include:
ï‚·Proportion of participants with solicited injection -site AEs
ï‚·Proportion of participants with solicited systemic AEs
ï‚·Proportion of participants with vaccine -related SAEs
Key Secondary Endpoints 
in Phase 1The key secondary imm unogenicity endpoints in Phase 1 include:
ï‚·Ratio of serotype -specific OPA GMTs for the common serotypes in 
pPCV and PNEUMOVAXâ„¢23
ï‚·Ratio of serotype -specific OPA GMTs of pPCV and 
PNEUMOVAXâ„¢23 for the serotypes unique to pPCV
ï‚·Ratio of s erotype -specific IgG GMCs for the common serotypes in 
pPCV and PNEUMOVAX â„¢23
Prim ary Endpoints in 
Phase 2Theprimary safety endpoints in Phase 2 include:
ï‚·Proportion of participants with solicited injection -site AEs
ï‚·Proportion of participants with solicited systemic AEs
ï‚·Proportion of participants with vaccine -related SAEs.
The primary imm unogenicity endpoints in Phase 2 include:
ï‚·Ratio of s erotype -specific OPA GMTs for the common serotypes in 
pPCV and PNEUMOVAXâ„¢23
ï‚·Ratio of serotype -specific OPA GMTs of pPCV and 
PNEUMOVAXâ„¢23 for the serotypes unique to pPCV
Key Secondary Endpoints 
in Phase 2Thekey secondary imm unogenicity endpoints in Phase 2 include:
ï‚·Ratio of s erotype -specific IgG GMCs for the common serotypes in 
pPCV and PNEUMOVAXâ„¢23
ï‚·Ratio of serotype -specific IgG GMCs of pPCV and 
PNEUMOVAXâ„¢23 for the serotypes unique to pPCV
Statistical Methods for Key 
Immunogenicity Analyses 
in Phase 1Immunogenicity analyses will be conducted separately for each serotype .
Immunogenicity endpoints will be analyzed at 30days postvaccination 
compared with prevaccination (Day 1) to describe the IgGantibody 
concentrations in response to the vaccination. The ratio of OPA GMTs
and IgG GMCs (pPCV -1/PNEUMOVAXâ„¢23 and 
pPCV -2/PNEUMOVAXâ„¢23) will be presented along with 95% CIsby 
[CONTACT_43108] .
The OPA GMT ratio estimation and 95% CI will be calculated using a 
cLDA method.
Statistical Methods for Key 
Immunogenicity Analyses 
in Phase 2Immu nogenicity analyses will be conducted separately for each serotype.
To address the primary noninferiority hypothesis (H1), a noninferiority 
test comparing OPA GMTs for the common serotypes inpPCV and 
PNEUMOVAXâ„¢23 (control group) w ill be conducted. A noninferiority 
margin of 0.33 corresponding to a 3.0-fold lower OPA GMT in the pPCV
group compared w ith the control group w ill be used. Rejecting the null 
hypothesis at the 1 -sided Î±=0.[ADDRESS_1214594]:   V116  66
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
the 2 -sided 95% CI on the GMT ratio ( pPCV /control) being >0.33 and 
would lead to the conclusion that the OPA GMT for pPCV is noninferior 
to that of the cont rol vaccine, for the given common serotype.
To address the second primary hypothesis (H2), a test comparing OPA 
GMTs for the serotypes unique to pPCV will be conducted. Rejecting the 
null hypothesis at the 1 -sided Î±=0.025 level corresponds to the low er 
bound of the 2 -sided 95% CI on the GMT ratio ( pPCV /control) being 
>1.0 and w ould lead to the conclusion that the OPA GMT for pPCV is 
statistically significantly greater than that of the control vaccine, for the 
given unique serotype.
The statistical margin sspecified for H1 and H2 are consistent with
previous early phase comparative studies [Jackson, L. A., et al 2013] .
The OPA GMT ratio estimation, 95% CI, and the hypothesis test 
(ie,1-sided p-value) will be calculated using a cLDA method.
Statistical Methods for Key 
Safety Analyses in Phase 1 
and Phase 2The analysis of safety will follow  a tiered approach. No Tier 1 events are 
defined in this study. For Tier 2 events, 95% C Is will be provided for 
betw een-group differences in the proportion of participants with events; 
these analyses will be performed using the M&N method [Miettinen, O. 
and Nurminen, M. 1985] .
Interim Analyses (IA) There are 2interim analys esplanned for this study :
Phase 1 Interim Analysis :
An interim analysis will be performed once the primary 30 -day 
postvaccination safety and immunogenicity data are available for all 
Phase 1 participants. At this point, the database will be locked and an 
analysis will be performed to summarize the safety and immunogenicity 
data. The siDMC will review unblinded Phase 1 safety and 
immunogenicity data reports and evaluate the benefit and risk profile to 
make a recommendation regarding proceeding to Phase 2. The Sponsor 
study team will review the Phase 1 safety and immunogenicity aggregate 
data reports to inform the cl inical development decision to proceed to 
Phase 2. The study team will not be unblinded to participant -level data. 
The unblinded Phase 1 data will be provided by [CONTACT_870028], and the clinical database will 
remain blinded to both the Sponsor study team and participating sites 
throughout the duration of the Phase 1/Phase 2 study.
Phase 2Interim Analysis :
An interim analysis is planned to support clinical development decisions 
prior to the completion of the Phase [ADDRESS_1214595] 50% of Phase [ADDRESS_1214596]:   V116  67
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
unblinded to participant -level data, and the clinical database will remain 
blinded to both the Sponsor study team and participating sites throughout 
the duration of the Phase 1/Phase [ADDRESS_1214597] controls the overall type I error at the 1 -sided 
0.025 level w ithin each group; therefore, no multiplicity adjustment will be 
required.
The overall alpha level for the secondary immunogenicity objectives, 
relating to both the set of common and unique serotypes, as measured by
[CONTACT_202132], is also controlled at the 1-sided 0.025 level.
No m ultiplicity adjustments will be made for the safety comparisons.
Sample Size and Power In Phase 1, approximately 90participants will be enrolled, with 
approximately 30 participants in each of the 3vaccination groups.
In Phase 2, Approximately 500 participants will be enrolled, w ith 
approximately 250participants in each of the 2vaccination groups. 
Assuming 90% evaluability ( approximately 225participants per group), 
there is 98.7% pow er to declare primary noninferiority to 
PNEUMOVAXâ„¢23 for the common serotypes and 99.2% pow er to 
declare pPCV is statistically significantly greater than 
PNEUMOVAXâ„¢[ADDRESS_1214598] of 
the pow ers for the set of noninferiority hypotheses and the set of 
superiority (ie,statistically significantly greater) hypotheses, is 98%. This 
sample size also provides adequate pow er for the secondary hypotheses. 
Specifically, there is 87 % power for the secondary noninferiority 
hypothesis and 92% pow er for the secondary superiority (ie,statistically 
significantly greater) hypothesis . The overall pow er for the secondary 
hypotheses is 80%.
9.2 Responsibility for Analyses/In -house Blinding
The statistical anal ysis of the data obtained from this study  will be the responsibility  of the
Clinical Biostatistics department of the Sponsor. This study  will be conducted as a 
double -blind study  under in- house blinding procedures. At the time of the interim analy ses, 
the unblinded Phase 1and Phase 2data will be provided by  [CONTACT_870029], and the clinical database will remain blinded to both the 
Sponsor study  team and participating sites throughout the duration of the Phase 1/Phase 2 
study .
Section 6.3.3 specifies the roles and responsibilities of the site and Sponsor personnel who 
will be unblinded during the study . 
The Clinical Biostatistics department will generate the randomized allocation schedule(s) for
study  treatment assignment. Randomization will be implemented in an IRT.
Blinding details related to the planned interim analyses are described in Section 9.7.Â 
Â  05H6VD
07XD6Y
PRODUCT:   V116  68
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
9.3 Hypotheses/Estimation
Objectives and h ypotheses of the stud y are stated in Section 3.
9.4 Analysis Endpoints
Immunogenicit y and safety analysis endpoints are listed below.
9.4.1 Immunogenicity Endpoints in Phase 1 
There are no primary  immunogenicit y analysis endpoints in Phase 1.
Secondary  immunogenicity  anal ysis endpoints in Phase 1include :
â€¢Ratio of s eroty pe-specific IgG GMCs for the common s eroty pesin pPCV and 
PNEUMOVAXâ„¢23 at 30 days postvaccination.
â€¢Ratio of s eroty pe-specific OPA GMTs for the common seroty pes in pPCV and 
PNEUMOVAXâ„¢23 at 30days postvaccination.
â€¢Ratio of s eroty pe-specific OPA GMTs of pPCV and PNEUMOVAXâ„¢23 for the 
seroty pes unique to pPCV at 30 days postvaccination.
â€¢Seroty pe-specific GMFRs from prevaccination (Day 1) to 30 days postvaccination 
(Day 30) for both OPA and IgG responses .
The specific sets of serotypes described as common or unique will be clearly  defined in the 
sSAP to be written prior to database lock.
9.4.2 Immunogenicity Endpoints in Phase 2
Primary  immunogenicit y analysis endpoints in Phase 2 include :
â€¢Ratio of s eroty pe-specific OPA GMTs for the common seroty pes in pPCV and 
PNEUMOVAXâ„¢23 at30dayspostvaccination.
â€¢Ratio of s eroty pe-specific OPA GMTs of pPCV and PNEUMOVAXâ„¢23 for the 
seroty pes unique to pPCV at 30 days postvaccination.
Secondary  immunogenicity  anal ysis endpoints in Phase 2 include :
â€¢Ratio of s eroty pe-specific IgG GMCs for the common seroty pes in pPCV and 
PNEUMOVAXâ„¢23 at 30 days postvaccination.
â€¢Ratio of s eroty pe-specific IgG GMCs of pPCV and PNEUMOVAXâ„¢[ADDRESS_1214599]:   V116  69
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
â€¢Seroty pe-specific GMFRs from prevaccination (Day 1) to 30 day s postvaccination 
(Day 30) for both OPA and IgG responses.
â€¢Difference in the proportion of participants who achieve a â‰¥4 -fold increase in 
seroty pe-specific OPA responses from prevaccination (Day 1)to 30days
postvaccination.
The specific sets of serotypes described as common or unique will be clearly defined in the 
sSAP to be written prior to database lock.
9.4.3 Safety Endpoints in Phase 1 and Phase 2
Safety  anal yses will be conducted separatel y for Ph ase1 and Phase 2. Safety  and tolerability  
will be assessed b y clinical review of all relevant parameters ,including AEs and 
postvaccination bod y temperature measurements.
The safet y analysis endpoints that address the primary  objective include:
â€¢Proportion of participants with solicited injection- site AEs ( redness/ery thema, swelling, 
and tenderness/pain) from Day 1 through Day 5 postvaccination
â€¢Proportion of participants with solicited sy stemic AEs (musc le pain/m yalgia, joint 
pain/arthralgia, headache, and tiredness/fatigue) from Day 1 through Day 5
postvaccination
â€¢Proportion of participants with vaccine -related SAEs from Day 1 through the duration of 
participation in the study .
Additional Safety  anal ysisendpoints include:
â€¢Proportions of participants with the broad AE categories consisting of an y AE and an y 
vaccine -related AE from Day 1 through Day 30 postvaccination
â€¢Proportions of participants with the broad AE categories consisting of an y SAE and death 
from Day 1 through the duration of participation in the study
â€¢Proportion of participants with maximum temperature measurements meeting the 
Brighton Collaboration cut points from Day [ADDRESS_1214600] the results o f the immunogenicit y endpoint(s) . 
Potential deviations include but are not limited to:Â 
Â  05H6VD
07XD6Y
PRODUCT:   V116  70
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
â€¢Failure to receive correct clinical material as per the randomization schedule at Visit 1 
(Day 1) (ie, participants who were cross -treated)
â€¢Having no valid serology results (ie, participants who are m issing serology  results for 
both Day  1 and Day  30 [30 to 44 day sfollowing vaccination]).
Determinations onprotocol deviations will be made by  [CONTACT_870030] 1 interim anal ysis(Section 9.7.1) , prior to the planned Phase 2 interim 
analysis (Section 9.7.2 ), and prior to the final unblinding of the database .Participants will be 
included in the vaccination group to which they  are randomized for the analy sis of 
immunogenicit y data using the PP population .
The FAS population will be used for supplementary  analy sis of the immunogenicity  data . 
The FAS population consists of all randomized participants who received at least 
1vaccination and have at least 1serology  result. Participants will be included in the
vaccination group to which they  are randomized for the anal ysis of immunogenicity  data
using the FAS population.
Details on the approach to handling missing data are provided in Section 9.6.
9.5.[ADDRESS_1214601] clinical material will 
be included in the group correspond ing to the clinical material actually  received.
Details on the approach to handling missing data are provided in Section 9.6.
9.6 Statistical Methods
No statistical hy pothesis testing is planned for Phase 1, but rather estimation will be
performed for both the safety  and immunogenicity data.
For immunogenicity  analy ses in Phase 2, unless otherwise specified, all statistical tests will 
be conducted at theÎ±=0.05 level ( 2-sided). Results that will be considered statistically
significant (versus nominally significant) after consideration of the strategy  for controlling
type-I errors are described in Sectio n9.8.
9.6.1 Statistical Methods for Immunogenicity Analyses in Phase 1
The immunogenicit y analy ses will be conducted for each serot ype separately .
The geometric mean ratios and 95% CI sof IgG GMC sandOPA GM Tswill be calculated
using a cLDA method proposed by  [CONTACT_165381] [Liang, K -Y and Zeger, S. L . 2000]
utilizing data from all 3vaccination groups. In t hismodel , the response vector consists of the Â 
Â  05H6VD
07XD6Y
PRODUCT:   V116  71
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
log-transformed prevaccination (Day 1) and postvaccination (Day 30) antibody  titers. The 
repeated measures model will include terms for time, the interaction of time -by-vaccination 
group (with a restriction of the same baseline mean across groups). The treatment difference 
in terms of a geometric mean ratio at a given postvaccination time point will be estimated 
and tested from this model. The term for time will be treated as a categorical variable. An 
unstructured covariance matrix will be used to model the correlation among repeated 
measurements. This model allows the inclusion of participants who are missing either the 
baseline or postbas eline measurements, thereb y increasing efficiency .The GMFRs from 
prevaccination to 30days postvaccination for both OPA and IgG response will be estimated 
by [CONTACT_43108], and the corresponding 95% CI s will be based on the sample t -
distribution. 
Theanalysis strateg yfor key immunogenicit y variables in P hase 1is listed i n Table 7.
Table 7 Analy sis Strategy  for Key Immunogenicit y Variables in Phase 1
Endpoint/Variable
(Description, Time point)Statistical
MethodAnalysis
PopulationMissing Data 
Approach
Secondary Endpoints
Ratio of IgG GMCs at 30 days postvaccination for 
common serotypescLDAa
(point estimate, 
95% CI)PP/FAS Model -based
Ratio of OPA GM Tsat 30 days postvaccination for 
common serotypescLDAa
(point estimate, 
95% CI)PP/FAS Model -based
Ratio of OPA GM Ts at 30 days postvaccination for 
unique serotypes in pPCVcLDAa
(point estimate, 
95% CI)PP/FAS Model -based
GMFRs from prevaccination to 30 days 
postvaccination for both OPA and IgG responsesDescriptive Statistics 
(point estimate, 
95% CI)PP/FASMissing data will 
not be imputed
CI=confidence interval; cLDA = constrained longitudinal data analysis; FAS =Full Analysis Set; GMC =geometric 
mean concentration; GMFR =geometric mean fold rise; GMT =geometric mean titer; IgG=immunoglobulin G; 
OPA =opsonophagocytic activity; PP=Per-protocol .
acLDA model with terms for time andthe interaction of time -by-vaccination group.
9.6.2 Statistical Methods for Immunogenicity Analyses in Phase 2
This section describes the statistical methods that address the primary  and secondary  Phase 2 
immunogenicit y objectives. The margins of noninferiorit y and superiority (ie,statistically  
significantl y greater) presented below are consistent with previous early phase comparative 
studies [Jackson, L . A., et al 2013] .Â 
Â  05H6VD
07XD6Y
PRODUCT:   V116  72
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
The immunogenicit y analy ses will be conducted for each serot ype separately .
Primary Endpoints/Hypotheses
For the common seroty pes, the primary  noninf eriority  hypotheses (H1) regarding OPA GMT 
levels between recipi[INVESTIGATOR_870010]â„¢23 is:
H0: GMT 1/GMT 2â‰¤0.33 versus
H1: GMT 1/GMT 2>0.33
where GMT 1is the serotype -specific OPA GMT for the pPCV group and GMT 2is the 
seroty pe-specific OPA GMT for the PNEUMOVAXâ„¢23 group. A ratio of 0.33 corresponds 
to a 3.0- fold lower OPA GMT in the pPCV group compared with the PNEUMOVAXâ„¢23
group. Rejecting the null hy pothesis (H 0) at the 1- sided Î±=0.025 level corresponds to the
lower bound of the 2 -sided 95% CI on the GMT ratio (pPCV /PNEUMOVAXâ„¢23 ) being 
>0.33 and would lead to the conclusion that the OPA response to pPCV for the common 
seroty pe is noninferior to that of PNEUMOVAXâ„¢23 .
For the serot ypes that are unique to pPCV , the primary superiorit y (ie,statistically  
significantl y greater) hypotheses (H 2) regarding OPA levels between recipi[INVESTIGATOR_870011]â„¢23 group is :
H0: GMT 1/GMT 2â‰¤1.0 versus
H1: GMT 1/GMT 2>1.0
where GMT 1is the OPA GMT for the pPCV group and GMT 2is the OPA GMT for the 
PNEUMOVAXâ„¢23 group . Rejecting the null h ypothesis (H 0) at the 1- sided Î±=0.025 level 
corresponds to the lower bound of the 2- sided 95% CI  on the GMT ratio 
(pPCV /PNEUMOVAXâ„¢23 ) being >1.0 and would lead to the conclusion that the OPA 
response to pPCV for the unique serot ype is statistically  significantly  greater than that of 
PNEUMOVAXâ„¢23 .
The GMT ratio estimation, 95% CI , and the hy pothesis test (ie, 1- sided p- value) will be 
calculated using a cLDA method proposed b y Liangand Zeger [Liang, K -Y and Zeger, S. L. 
2000] utilizing data from both vaccination groups. I n this model, the response vector consists 
of the log- transformed prevaccination (Day 1) and postvaccination (Day 30) antibody  titers.
The repeated measures model will include terms for time, the interaction of 
time-by-vaccination group (with a restriction of the same baseline mean across groups), age 
stratum (ie, 50 to 64 years, 65 to 74 years, a nd â‰¥75 years) at vaccination, and age
stratum -by-time interaction. This model will allow for different baseline means for each age
stratum, but restrict the baseline mean within each age stratum to be the same for all
vaccination groups. The treatment diff erence in terms of a geometric mean ratio at a given 
postvaccination time point will be estimated and tested from this model. The term for time 
will be treated as a categorical variable. An unstructured covariance matrix will be used to 
model the correlati onamong repeated measurements. The Kenward -Roger adjustment will 
be used with REML  to make proper statistical inference. This model allows the inclusion of Â 
Â  05H6VD
07XD6Y
PRODUCT:   V116  73
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
participants who are missing either the baseline or postbaseline measurements, thereb y 
increasing e fficiency .
For titer measurements that are smaller than the lower bound of the assay â€™sdetectable range,
half of the lower bound will be used as the value of the titer.
Secondary Endpoints/Hypotheses
The same statistical approach as used for the primary  endpoints will be used to address the 
secondary  immunogenicity  hypotheses (H3 and H4) that compare the IgG GMC responses of 
pPCV with PNEUMOVAXâ„¢23 , except that a noninferior ity margin of 0.5 will be use dto 
evaluate noninferiorit y of the common serot ypes, which corresponds to a 2.0 -fold lower
IgGGMC in the pPCV group compared with the PNEUMOVAXâ„¢23 group. The GMFRs 
from prevaccination to 30 days postvaccination for both OPA and IgG response will be 
estimated by  [CONTACT_43108], and the corresponding 95% CIs will be based on sample 
t-distribution. The d ifference between the pPCV group and the PNEUMOVAXâ„¢23 group in 
the proportion of participants with â‰¥4-fold increase in serot ype-specific OPA responses from 
prevaccination ( Day 1)to 30 day s postvaccination will be estimated. The corresponding 95% 
CIs about these differences will be calculated using the M&N method, stratify ing by  [CONTACT_48965] (50 to 64 years, 65 to 74 years, and â‰¥75years)[Miettinen, O. and Nurminen, M. 
1985] .
The anal ysis strateg yfor key immunogenicit y variables in P hase [ADDRESS_1214602]:   V116  74
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
Table 8 Analy sis Strategy  for Key Immunogenicit y Variables in Phase 2
Endpoint/Variable
(Description, Time point )Statistical MethodAnalysis 
PopulationMissing Data 
Approach
Prim ary Endp oints
Ratio of OPA GMTs at 30 days 
postvaccination for common 
serotypescLDAa
(point estimate, 95% CI, p -valueb)PP/FAS Model -based
Ratio of OPA GMTs at 30 days 
postvaccination for unique serotypescLDAa
(point estimate, 95% CI, p -valueb)PP/FAS Model -based
Secondary Endpoints
Ratio of IgG GMCs at 30 day s 
postvaccination for common 
serotypescLDAa
(point estimate, 95% CI, p -valueb)PP/FAS Model -based
Ratio of IgG GMCs at 30 day s 
postvaccination for unique serotypescLDAa
(point estimate, 95% CI, p -valueb)PP/FAS Model -based
GMFRs from prevaccination to 
30days postvaccination for both 
OPA and IgG responsesDescriptive Statistics
(point estimate, 95% CI)PP/FASMissing data 
will not be 
imputed
Difference in p roportion of 
participants with a â‰¥4-fold increase 
in serotype -specific OPA responses
from prevaccination to 30 days 
postvaccinationDescriptive Statistics
(point estimate, 95% CI)PP/FASMissing data 
will not be 
imputed
CI=confidence interval; cLDA =constrained longitudinal data analysis; FAS =Full Analysis Set; GMC =geometric 
mean concentration; GMFR =geometric mean fold rise; GMT =geometric mean titer; IgG =immunoglobulin G; 
OPA =opsonophagocytic activity; PP =Per-protocol.
acLDA model with terms for time, the interactio n of tim e-by-vaccination group, age stratum, and the interaction of age 
stratum -by-time.
bp-values for noninferiority or superiority (ie,statistically significantly greater) hypothesis.
9.6.3 Statistical Methods for Safety Analysis (Phase 1 and Phase 2)
Safety  and tolerability  will be assessed b y clinical review of all relevant parameters ,
including AEs, postvaccination temperature measurements , and laboratory  measurements 
(Phase 1 only ).Safet y analy ses will be conducted separately for Phase [ADDRESS_1214603]:   V116  75
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
The anal ysis of AEs and temperature measurements will follow a tiered approach (Table 9).
The tiers differ with respect to the anal yses that will be performed. Events are either 
prespecified as Tier 1 events or will be classified as belonging to Tier 2 or Tier 3 based on 
the numbe r of events observed.
Laboratory  measurements collected during Phase 1 (see Appendix 2) will be summarized 
separately . Details regarding the anal ysis of laboratory  measurements will be provided in the 
sSAP.
Tier [ADDRESS_1214604] to inferential testing for statistical significance with p -values and 95% CIs 
provided for between -treatment differences in the proportion of participants with events .
No Tier [ADDRESS_1214605] clinical study  of pPCV, no data exists around which a comparative, data -driven safet y 
hypothesis can be formulated a nd tested. As a result, the solicited injection- site and sy stemic 
AEs reported in this study will be anal yzed as Tier 2 events.
Tier 2 Events
Tier 2 events will be assessed via point estimates and risk differences with 95% C Isprovided 
for differences in the proportion of participants with events ; these anal yses will be performed 
using the M&N method [Miettinen, O. and Nurminen, M. 1985] , an unconditional, 
asymptotic method .
For this study , solicited injection -site AEs from Day [ADDRESS_1214606] AE categories consisting of the percentage of participants with 
any AE, a nyvaccine -related AE, any solicited injection -site AE, an y solicited systemic AE, 
anySAE, a nyvaccine -related SAE, and death will be considered Tier 2 events. Nonserious 
AEs will be followed for 30days postvaccination, while SAEs will be followed through the 
duration of participation in the study .
Adverse events (specific terms as well as SOC terms) will be classified as belonging to Tier [ADDRESS_1214607] 
4events was chosen because the 95% CI for the between -group difference in percent 
incidence will alway s include zero when vaccination groups of equal size each have less than 
4events and thus would add little to the interpretation of potentially meaningful differences. 
Because many 95% CIs for Tier [ADDRESS_1214608]:   V116  76
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
Tier 3 Events
Events not defined above are considered Tier 3 events. Only  point estimates by  [CONTACT_870031] 3 events.
Table 9 Analy sis Strategy for Safety  Parameters
Safety 
Tier Safety Endpoints95% CI for 
Between -group 
Comparison aDescriptive
Statistics
Tier 2 Injection -site redness/erythema (Days 1 to 5) X X
Injection -site swelling (Days 1 to 5) X X
Injection -site tenderness/pain (Days 1 to 5) X X
Muscle pain/myalgia (Days 1 to 5) X X
Joint Pain/arthralgia (Days 1 to 5) X X
Headache (Days 1 to 5) X X
Tiredness/fatigue (Days 1 to 5) X X
Any AEbX X
Any vaccine -related AEbX X
Any solicited injection -site AE (Days 1 to 5)bX X
Any solicited systemic AE (Days 1 to 5)bX X
Any serious AEbX X
Any vaccine -related SAEbX X
DeathbX X
Maximum temperature measurements meeting the 
Brighton Collaboration cut points (Days 1 to 5)X X
Specific AEs by [CONTACT_870032] (incidence 
â‰¥4participants in at least 1 of the vaccination groups)X X
Tier 3 Specific AEs by [CONTACT_870032] (incidence 
<4participants in all of the vaccination groups)X
AE=adverse event; CI =confidence interval; M&N =Miettinen and Nurminen PT =preferred term; SAE =serious 
adverse event; SOC =system organ class; X =results will be provided.
Note: AEs includes both clinical and laboratory AEs (laboratory AEs will be collected in Phase 1 only).
aThese analyses will be performed using the M&N method [Miettinen, O. and Nurminen, M. 1985] .
bThese endp oints are broad AE categories. For example, descriptive statistics for the safety endpoint of â€œAny AEâ€ will 
provide the number and percentage of participants with at least [ADDRESS_1214609]:   V116  77
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
performed on these ch aracteristics. The number and percentage of participants randomized 
and vaccinated, and the reasons for discontinuation, will be display ed by [CONTACT_19313].
Demographic variables (eg, age) andprior and concomitant therapi[INVESTIGATOR_870012]. Separate summaries will be provided for Phase 1 and Phase 2.
No other anal yses are planned for this study .
9.7 Interim Analyses
Areview of Phase 1 and Phase 2 safet y and tolerability  data will be conducted by  [CONTACT_870033]. Immunogenicity  data willalso be provided to the siDMC to enable a 
benefit -risk assessment. A description of the structure and function of the siDMC, along with 
the timing and content of the safet y review, will be outlined in the siDMC charter. 
Information regarding the composition of the siDMC is provided in Appendix 1.
Blinding to intervention assignment will be maintained at all investigational sites. 
Participant -level unblinding will be restricted to an internalunblinded statistician and 
statistical programmer performing any planned or requested safet y reviews by [CONTACT_766094] .
Any safet y reviews conducted while the study  is ongoing will be provided by  [CONTACT_870034]. Prior to final study  unblinding, the internal unblinded 
statistician will not be involved in any discussions regarding modifications to the protocol, 
statistical methods, identification of protocol deviations, or data validation efforts after the 
safet y reviews .
Two prespecified analyses are planned prior to the completion of this study , as described 
below.
9.7.1 Phase 1 Interim Analysis
An interim anal ysis will be performed once the primary  30-day postvaccination safet y and 
immunogenicit y data are available for all Phase 1 participants. At this point, the database will 
be locked and an analy sis will be performed to summarize the safet y and immunogenicit y 
data. This anal ysis will not occur until medical/scientific review of the data has been 
performed and protocol deviations have been identified .The siDMC will review unblinded 
Phase 1 safet y and immunogenicity data reports and evaluate the benefit and risk profile to 
make a recommendation regarding proceeding to Phase 2. The Sponsor study  team will 
review the Phase 1 safety and immunogenicit y aggregate data reports to inform the clinical 
development decision to proceed to Phase 2. The Sponsor study  team will not be unblinded 
to participant- level data. The unblinded Phase 1 data will be provided b y an unblinded 
statistician who is not part of the blinded study  team, and the clinical database will remain 
blinded to both the Sponsor study  team and participating sites throughout the duration of the 
Phase 1/Phase [ADDRESS_1214610]:   V116  78
PROTOCOL/AMENDMENT N O.:  [ADDRESS_1214611] 50% of Phase [ADDRESS_1214612] sfor the Phase 2 
immunogenicit y anal ysis: (1) a separate noninferiority  test for each of the common seroty pes 
between pPCV and PNEUMOVAXâ„¢23 , and (2) a separate superiority  (ie,statistically  
significantl y greater) test for each of the serot ypes thatare un ique to pPCV . This study  will 
be considered to have met its primary  immunogenicity  objective if success is demonstrated 
for all common serot ypes and all unique serot ypes included in the primary  immunogenicit y 
hypotheses. The intersection -union test control s the overall t ype Ierror at the 1-sided 
0.025 level within each group; t herefore ,no multiplicity  adjustment will be required within 
each group [Berger, R. L. 1982] .The intersection- union test refers to the fact that the set of 
statistical null hy potheses to be tested can be expressed as a union, and the set of statistical 
alternative h ypotheses as an intersection. Thus, the overall statistical null hy pothesis can only  
be rejected if each of the set of statistical null hy potheses are rejected.
The same multiplicity  strategy  will be applied to the 2secondary  study  hypotheses for which 
there is also a noninferiority  hypothesis for the common seroty pes between pPCV and 
PNEUMOVAXâ„¢23, and a superiorit y (ie,statistically  significantly  greater) hypothesis for 
the serot ypes unique to pPCV, as measured b y IgG. In this way ,for the secondary  hypotheses 
to be supported by [CONTACT_26739], all statistical tests will have to be statistically significant . This 
approach controls the t ypeI error at 0.025 (1-sided) for the set of primary  hypothesis tests 
and separatel y at 0.025 (1-sided) for the set of secondary  hypothesis tests.
No multiplicity  adjustments will be made for the safet y comparisons.
9.[ADDRESS_1214613]:   V116  79
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
In Phase 2, Approximately  500 participants will be enrolled, with approximately  
250participants in each of the 2 vaccination groups. Assuming 90% ev aluability  
(approximately  225 participants per group), there is 98.7% power to declare primary
noninferiority  to PNEUMOVAXâ„¢23 for the common seroty pes and 99.2% power for
superiority  (ie,statistically  significantl y greater) for the unique serot ypes based on OPA
GMT ratios . The overall estimate of power for the primary hypothesis , as the product of the 
power sfor the set of noninferiority hypotheses an d the set of superiorit y (ie,statistically  
significantl y greater) hypotheses, is 98%. This sample size also provides adequate power for 
the secondary  hypotheses. Specificall y, there is 87% power for the secondary  noninferiorit y 
hypothesis and 92% power for the secondary  superiority  (ie,statistically  significantly  
greater) hypothesis. The overall power for the secondary  hypotheses is 80%. The sample size 
and power calculations are based on the following assumptions:
â€¢The standard deviation of natural log -transformed OPA assay  and IgG results are 2.2 and 
1.73, respectivel y.These assumptions are based on observations from previous studies 
with PNEUMOVAXâ„¢23.
â€¢For the common seroty pes, the assumed true geometric mean ratios of OPA GMTs and 
IgG GMCs are 1 .
â€¢For the unique serot ypes, the assumed true geometric mean ratios of OPA GMTs andIgG 
GMCs are 3 and 2 , respectively .
â€¢90% evaluability  rate (approxi mately  225 participants per group) .
9.9.2 Safety Analyses
For safet y comparisons, all participants are expected to be evaluable.
In Phase 1, if no SAEs are observed among the 30 participants in each vaccination group, this 
study  provides 68.7% confidence that the true SAE rate is <1.2% (1 out of every  
83participants). In Phase 2, if no SAEs are observed among the 250 participants in each 
vaccination group, this study  provides 97.9% confidence that the true SAE rate is <1.5% 
(1out of every 67participants).
The probability  of observing at least 1SAE in this study  depends on the number of 
participants enrolled and the incidence rate of SAEs in the general population. In Phase 2, if 
the incidence rate of a nSAE is 1of every 143recipi[INVESTIGATOR_870013] (0.7%), then there is 
an 80% chance of observing at least 1such SAE among 250 participants in the pPCV group. 
If the incidence rate is 1 of every  332 recipi[INVESTIGATOR_870013] (0.3%), then there is a 50% 
chance of observing at least 1SAE among 2 50participants in the pPCV group .
For the Phase 2 safet y comparisons, risk differences between the 2vaccination groups that 
could be detected with an 80% probability  are summarized in Table 10 for a variet y of 
hypothetical true incidence rates. These calculations assume thatthere are 250 evaluable 
participants in both groups and are based on a 2 -sided significance level of Î±=0.05. N o 
multiplicity  adjustments were made in these calculations.Â 
Â  05H6VD
07XD6Y
PRODUCT:   V116  80
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
Table 10 Differences in the Incidence of Adverse Event Rates Between the 2Vaccination 
Groups in Phase 2 That Can be Detected With Approximately  80% Probability
Incidence o f Adverse Event Risk Difference
pPCV (%) PNEUMOVAXâ„¢23 (%) Percentage Points
3.6 0.1 3.5
7.6 2.0 5.6
12.3 5.0 7.3
19.2 10.0 9.2
25.5 15.0 10.5
31.4 20.0 11.4
42.5 30.0 12.5
The incidence rates for each vaccination group are hypothetical and do not represent actual adverse events in either 
group.
The incidences assume a 2 -sided 5% alpha level with 250 participants in each group. No multiplicity adjustments 
were made.
The calculations are based on an asymptotic method proposed by [CONTACT_870035] n and Manning [Farrington, C. P. 1990] .
9.10 Subgroup Analyses
Subgroup anal yses will be provided for Phase 2, where t he geometric mean ratio between 
pPCV and PNEUMOVAXâ„¢23 as assessed by [CONTACT_870036] (ie, 50 to 64 years, 65 to 74 years, and â‰¥75 years).
Further details of subgroup anal yses will be documented in the sSAP .
9.11 Compliance (Medication Adherence)
Given that participants will receive a single dose of pPCV or PNEUMOVAXâ„¢23, 
compliance will not be calculated. However, the number and proportion of randomized 
participants receiving pPCV or PNEUMOVAXâ„¢23 will be summarized (Section 9.12).
9.12 Extent of Exposure
In Phase 1, the extent of exposure will be summarized by  [CONTACT_870037] -1, pPCV -2, or PNEUMOVAXâ„¢23.
In Phase 2, the extent of exposure will be summarized by [CONTACT_870038]â„¢23.Â 
Â  05H6VD
07XD6Y
PRODUCT:   V116  81
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
10 SUPPORTING DOCU MENTATION AND OPERAT IONAL 
CONSIDERATIONS
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.[ADDRESS_1214614] for Clinical Trials
[COMPANY_006] Sharp and Dohme Corp., a subsidiary of [COMPANY_006] & Co., Inc. (MSD)
Code of Conduct for Interventional Clinical Trials
I. Introduction
A.Purpose
MSD, through its subsidiaries, conducts clinical trials worldwide to evaluate the safety and effectiveness of our 
products. As such, we are committed to designing, implementing, conducting, analyzin g, and reporting these trials 
in compliance with the highest ethical and scientific standards. Protection of participants in clinical trials is the 
overriding concern in the design and conduct of clinical trials. In all cases, MSD clinical trials will be c onducted 
in compliance with local and/or national regulations (including all applicable data protection regulations), and 
International Council for Harmonisation Good Clinical Practice (ICH -GCP), and also in accordance with the 
ethical principles that have their origin in the Declaration of Helsinki.
B.Scope
Highest ethical and scientific standards shall be endorsed for all clinical interventional investigations sponsored by 
[CONTACT_19481] (parties) employed for their execution ( e.g., contra ct research organizations, 
collaborative research efforts). This Code is not intended to apply to trials that are observational in nature, or 
which are retrospective. Further, this Code does not apply to investigator -initiated trials , which are not under t he 
full control of M SD.
II.Scientific Issues
A.Trial Conduct
1.Trial Design
Except for pi[INVESTIGATOR_19354], clinical trial protocols will be hypothesis -driven to assess safety, efficacy
and/or pharmacokinetic or pharmacodynamic indices of MSD or comparator products. Alternatively, M SD
may conduct outcomes research trials, trials to assess or validate various endpoint measures, or trials to 
determine patient preferences, etc.
The design (i.e., participant population, duration, statistical power) must be adequate to address the specific
purpose of the trial. P articipants must meet protocol entry criteria to be enrolled in the trial. 
2.Site Selection
MSD selects investigative sites based o n medical expert[INVESTIGATOR_18700], access to appropriate participants, adequacy of 
facilities and staff, previous performance in clinical trials, as well as budgetary considerations. Prior to trial 
initiation, sites are evaluated by [CONTACT_26397] (or individuals acting on behalf of MSD) to assess the ability 
to successfully conduct the trial.
3.Site Monitoring/Scientific Integrity
Investigative t rial sites are monitored to assess compliance with the trial protocol and Good Clinical Practice 
(GCP). MSD reviews clinical data for accuracy, completeness, and consistency. Data are verified versus 
source documentation according to standard operating procedures. Per M SD policies and procedures, if fraud, Â 
Â  05H6VD
07XD6Y
PRODUCT:   V116  82
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
scientific/research misconduct or serious GCP -non-compl iance issuspected, the issues are investigated. 
When necessary, the clinical site will be closed, the responsible regulatory authorities and ethics review 
committees notified .
B. Publication and Authorship
Regardless of trial outcome, MSD commits to publi sh the primary and secondary results of its registered trials of 
marketed products in which treatment is assigned, according to the pre-specified plans for data analysis. To the 
extent scientifically appropriate, M SDseeks to publish the results of other a nalyses it conducts that are important 
to patients, physicians, and payers. Some early phase or pi[INVESTIGATOR_26346] -generating rather 
than hypothesis testing ;in such cases, publication of results may not be appropriate since the tri al may be 
underpowered and the analyses complicated by [CONTACT_19482].
MSDâ€™s policy on authorship is consistent with the re commendations published by [CONTACT_26399] (ICMJE). In summary, autho rship should reflect significant contribution to the design and 
conduct of the trial, performance or interpretation of the analysis, and/or writing of the manuscript. All named 
authors must be able to defend the trial results and conclusions. M SD funding o f a trial will be acknowledged in 
publications.
III.Participant Protection
A. Regulatory Authority and Ethics Committee Review (Institutional Review Board [IRB]/Independent Ethics 
Committee [IEC])
All protocols and protocol amendments will be submitted by [CONTACT_88708]/authorization prior to implementation of the trial or amendment, in compliance with local and/or 
national regulations.
The protocol, protocol amendment(s), informed consent form, investigatorâ€™s brochure, and other relevant trial 
documents must be reviewed and approved by [CONTACT_2717]/IEC before being implemented at each site, in compliance 
with local and/or national regulations. Changes to the protocol that are required urgently to eliminate an 
immediate hazard and to protect participant safety may be enacted in anticipation of ethics committee approval.  
MSD will inform regulatory authorities of such new measures to protect participant safety, in compliance with 
local and/or national regulations.
B. Safety
The guiding principle in decision -making in clinical trials is that participant welfare is of primary importance. 
Potential participants will be informed of the risks and benefits of, as well as alternatives to, trial participation. At 
a minimum, trial designs will take into account the local stand ard of care.
All participation in M SD clinical trials is voluntary. Participants enter the trial only after informed consent is 
obtained . Participants may withdraw from a n MSD trial at any time, without any influence on their access to, or 
receipt of, medical care that may otherwise be available to them.
C. Confidentiality
MSD is committed to safeguarding participant confidentiality, to the greatest extent possible. Unless required by 
[CONTACT_2371], only the investigator, Sponsor (or individuals acting on behalf of MSD ), ethics committee, and/or regulatory 
authorities will have access to confidential medical records t hat might identify the participant by [CONTACT_2300].
D. Genomic Research
Genomic research will only be conducted in accordance with a protocol and informed consent authorized by [CONTACT_63544] c ommittee.Â 
Â  05H6VD
07XD6Y
PRODUCT:   V116  83
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
IV. Financial Considerations
A. Paym ents to Investigators
Clinical trials are time -and labor -intensive. It is M SDâ€™s policy to compensate investigators (or the sponsoring 
institution) in a fair manner for the work performed in support of M SD trials. M SD does not pay inc entives to 
enroll participants in its trials. However, when enrollment is particularly challenging, additional payments may be 
made to compensate for the time spent in extra recruiting efforts.
MSD does not pay for participant referrals. However, M SDmay compensate referring physicians for time spent 
on chart review and medical evaluation to identify potentially eligible participants.
B.Clinical Research Funding
Informed consent forms will disclose that the trial is sponsored by M SD, and that the investiga tor or sponsoring 
institution is being paid or provided a grant for performing the trial. However, the local ethics committee may 
wish to alter the wording of the disclosure statement to be consistent with financial practices at that institution. As 
noted above, all publications resulting from M SD trials will indicate M SD as a source of funding.
C. Funding for Travel and Other Requests
Funding of travel by [CONTACT_19488] ( e.g., to scientific meetings, investigator meetings, etc.) will be 
consistent with local guidelines and practices.
V. Investigator Commit ment
Investigators will be expected to review M SDâ€™s Code of Conduct as an appendix to the trial protocol, and in signing the 
protocol, agree to support these et hical and scientific standards .
10.1.2 Financial Disclosure
Financial Disclosure requirements are outlined in the US Food and Drug Administration 
Regulations, Financial Disclosure b y Clinical I nvestigators (21 CFR Part 54). I t is the 
Sponsor's responsibility  to determine, based on these regulations, whether a request for 
Financial Disclosure information is required. It is the investigator's/subinvestigator's 
responsibility  to comply  with any  such request.
The investigator/subinvestigator(s) agree, if requested by  [CONTACT_19489] 21 
CFR Part 54, to provide his/her financial interests in and/or arrangements with the Sponsor to 
allow for the submission of complete and accurate certification and disclosure statements. 
The investigator/subinvestigator(s) further ag ree to provide this information on a 
Certification/Disclosure Form, commonly  known as a financial disclosure form, provided b y 
the Sponsor. The investigator/subinvestigator(s) also consent to the transmission of this 
information to the Sponsor in the Unite d States for these purposes. This may  involve the 
transmission of information to countries that do not have laws protecting personal data.Â 
Â  05H6VD
07XD6Y
PRODUCT:   V116  84
PROTOCOL/AMENDMENT N O.:  [ADDRESS_1214615] this study  in compliance with all applicable data protection 
regulations.
Participants will be assigned a unique identifier by [CONTACT_1034]. An y participant records or 
datasets that are transferred to the Sponsor will contain the identifier only; participant names 
or an y information that would make the participant identifiable wi ll not be transferred.
The participant must be informed that his/her personal study -related data will be used by  [CONTACT_19490]. The level of disclosure must also be 
explained to the participant. 
The participant must be informed that his/her medical records may  be examined by  [CONTACT_126560] S ponsor, by  
[CONTACT_6667]/IEC members, and b y inspectors from regulatory authorities.
[IP_ADDRESS] Confiden tiality of Data
By [CONTACT_12570], the investigator affirms to the Sponsor that information furnished to 
the investigator b y the Sponsor will be maintained in confidence, and such information will 
be divulged to the IRB, IEC,or similar or expert committee; affiliated institution and 
employ ees, only  under an appropriate understanding of confidentialit y with such board or 
committee, affiliated institution and employ ees. Data generated b y this study will be 
considered confidential by [CONTACT_093], except to the extent that it is included in a 
publication as provided in the Publications section of this protocol.
[IP_ADDRESS] Confidentiality of Participant Records
By [CONTACT_12570], the investigator agrees that the Sponsor (or Sponsor representative), 
IRB/IEC, or regulatory  authority  representatives may  consult and/or cop y study  documents to 
verify  worksheet/ CRF data. By  [CONTACT_17317], the participant agrees to this 
process. If study  documents will be photocopi[INVESTIGATOR_75311]/ CRF information, the participant will be identified b y unique code only; full 
names/initials will be masked prior to transmission to the Sponsor.
By [CONTACT_12570], the investigator agrees to treat all participant data used and 
disclosed in connection with this study  in accordance with all applicable privacy  laws, rules 
and regulations.
[IP_ADDRESS] Confidentiality of IRB/IEC Information
The Sponsor is required to record the name [CONTACT_19525]/IEC that reviews and 
approves this study . The Sponso r is also required to document that each IRB/IEC meets 
regulatory  and ICH GCP requirements b y requesting and maintaining records of the names 
and qualifications of the IRB/IEC members and to make these records available for 
regulatory  agency  review upon re quest b y those agencies.Â 
Â  05H6VD
07XD6Y
PRODUCT:   V116  85
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
10.1.4 Committees Structure
[IP_ADDRESS] Internal Data Monitoring Committee
To supplement the routine monitoring outlined in this protocol, a separate siDMC will 
monitor the interim data from this study . The siDMC is comprise d of members of Sponsor 
Senior Management, none of whom are directly  associated with the conduct of this study . 
The siDMC will monitor the study  at an appropriate frequency  (Section 9.7[Interim 
Analy ses] ) for evidence of adverse effects of study  intervention and immunogenicity  data, as 
described in the detailed monitoring guidelines. The siDMC will determine whether the stud y 
should continue (or other modifications, prespecified or otherw ise, should be made) 
according to the protocol, considering the overall risk and benefit to stud y participants. The 
siDMC will also make recommendations to the Sponsor protocol team regarding steps to 
ensure both participant safety and the continued ethica l integrit y of the study.
Specific details regarding responsibilities of the siDMC will be described in a separate 
charter that is reviewed and approved b y the siDMC.
10.1.[ADDRESS_1214616] 
proprietary  inform ation and to provide comments.
Authorship will be determined by  [CONTACT_11403] I nternational Committee 
of Medical Journal Editors authorship requirements .
10.1.6 Compliance with Study Registra tion and Results Posting Requirements
Under the terms of the FDAAA of 2007 and the EMA clinical trial Directive 2001/20/EC, the 
Sponsor of the study  is solely  responsible for determining whether the study and its results 
are subject to the requirements for submission to http://www.clinicaltrials.gov, 
www.clinicaltrialsregister.eu or other local registries. MSD, as Sponsor of this study , will 
review this protocol and submit the information necessary  to fulfill these requirements. MSD 
entries are not limited to FDAAA or the EMA clinical trial directive mandated trials. 
Information posted will allow participants to identify  potentiall y appropriate studies for their 
disease conditions and pursue participation b y calling a central contact [CONTACT_870039].
By [CONTACT_12570], the investigator acknowledges that the statutory  obligations under 
FDAAA, the EMA clinical trials directive ,or other locally  mandated registries are that of the Â 
Â  05H6VD
07XD6Y
PRODUCT:   V116  86
PROTOCOL/AMENDMENT N O.:  [ADDRESS_1214617] the study  in an efficient and 
diligent manner and in conformance with this protocol; generall y accepted standards of GCP
(eg, International Conference on Harmonization of Technical Requirements for Registration 
of Pharmaceuticals for Human Use GCP : Consolidated Guideline and other generally  
accepted standards of GCP ); and all applicable federal, state and local laws, rules and 
regulations relating to the conduct of the clinical study .
The Code of Conduct, a collection of goals and considerations that gov ern the ethical and 
scientific conduct of clinical investigations sponsored b y MSD, is provided i n this appendix 
under the Code of Conduct for Clinical Trials.
The investigator agrees not to seek reimbursement from participants, their insurance 
providers, or from government programs for procedures included as part of the study 
reimbursed to the investigator b y the Sponsor.
The investigator will promptly  inform the Sponsor of an y regulatory authority inspection 
conducted for this study .
The invest igator agrees to provide the Sponsor with relevant information from inspection 
observations/findings to allow the Sponsor to assist in responding to an y citations resulting 
from regulatory  authority inspection and will provide the Sponsor with a copy  of the 
proposed response for consultation before submission to the regulatory  authority . 
Persons debarred from conducting or working on clinical studies by  [CONTACT_63550]â€™s studies. The investigator 
will immediately  disclose in writing to the Sponsor if an y person who is involved in 
conducting the study  is debarred or if any  proceeding for debarment is pending or, to the best 
of the investigatorâ€™s knowledge, threatened .
10.1.8 Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the Sponsor or designee electronically  (eg, laboratory  data). The investigator 
or qualified designee is responsible for verify ing that data entries are accurate and correct b y 
physicall y or electronically signing the CRF.
Detailed information regarding Data Management procedures for this protocol will be 
provided separatel y.
The investigator must maintain accurate documentation (s ource data) that supports the 
information entered in the CRF.Â 
Â  05H6VD
07XD6Y
PRODUCT:   V116  87
PROTOCOL/AMENDMENT N O.:  [ADDRESS_1214618] permit study -related monitoring, audits, IRB/IEC review, and 
regulatory  agency  inspections and provide direct access to source data documents.
Study  documentation will be p romptly  and fully  disclosed to the Sponsor by [CONTACT_63551], 
copy ing, review, and audit at reasonable times b y representatives of the Sponsor or an y 
regulatory  authorities. The investigator agrees to promptly  take an y reasonable steps that are 
requested b y the Sponsor or an y regulatory  authorit ies as a result of an audit or inspection to 
cure deficiencies in the stud y documentation and worksheets/CRFs .
The Sponsor or designee is responsible for the data management of this study  including 
quality  checking of the data.
Study  monitors will perform ongoing source data review and verification to confirm that data 
entered into the CRF b y authorized site personnel are acc urate, complete, and verifiable from 
source documents; that the safet y and rights of participants are being protected; and that the 
study  is being conducted in accordance with the currentl y approved protocol and an y other 
study  agreements, ICH GCP, and all applicable regulatory requirements.
Records and documents, including signed ICF, pertaining to the conduct of this study  must 
be retained b y the investigator for 15 years after study  completion unless local regulations or 
institutional policies require a longer retention period. No records may  be destroy ed during 
the retention period without the written approval of the Sponsor. No records may  be 
transferred to another location or part y without written notification to the Sponsor .
10.1.9 Source Documents
Source do cuments provide evidence for the existence of the participant and substantiate the 
integrit y of the data collected. The investigator/institution should maintain adequate and 
accurate source documents and study  records that include al lpertinent observation s on each 
of the siteâ€™s participants. Source documents and data should be attributable, legible, 
contemporaneous, original, accurate, and complete. Changes to source data should be 
traceable, should not obscure the original entry , and should be explained i f necessary  (eg, via 
an audit trail). Source documents are filed at the investigatorâ€™s site.
Data reported on the CRF or entered in the eCRF that are transcribed from source documents 
must be consistent with the source documents or the discrepancies must be explained. The 
investigator /institution may need to request previous medical records or transfer records, 
depending on the study . Also, current medical records must be available .
10.1.[ADDRESS_1214619]:   V116  88
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
In the event the Sponsor prematurel y terminates a particular stud y site, the Sponsor or 
designee will promptly  notify  that study  siteâ€™s IRB/IEC as specified b y applicable regulatory 
requirement(s).Â 
Â  05H6VD
07XD6Y
PRODUCT:   V116  89
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
10.2 Appendix 2: Clinical Laboratory Tests
â€¢The tests detailed in Table 11will be performed by  [CONTACT_2237] .
â€¢Local laboratory  results are only  required in the event that the central laboratory  results 
are not available in time for either stud y intervention administration and/or response 
evaluation. If a local sample is required, it is important that the sample for central 
analysis is obtained at the same time. Additionally , if the local laboratory  results are used 
to make either a stud y intervention decision or response evaluation, the results must b e 
entered into the CRF.
â€¢Protocol -specific requirements for inclusion or exclusion of participants are detailed in 
Section 5of the protocol.
â€¢Additional tests may  be performed at an y time during the study as determined necessary 
by [CONTACT_870040].
â€¢Pregnancy  testing:
-Pregnancy  testing requirements for study  inclusion are described in Section 5.1.
-Pregnancy  testing (urine or serum as required b y local regulations) should be 
conducted [ADDRESS_1214620]'s participation in the study .Â 
Â  05H6VD
07XD6Y
PRODUCT:   V116  90
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
Table 11 Protocol -require d Safet yLaboratory  Assessments
Laboratory 
AssessmentsParameters
Hem atology
(Phase 1 only)Platelet Count RBC Indices:
MCV
MCHWBC count with 
Differential:
Neutrophils
Lymphocytes
Monocytes
Eosinophils
BasophilsRBC Count
Hem oglobin
Hem atocrit
Chemistry
(Phase 1 only)Blood Urea 
Nitrogen (BUN)Potassium Aspartate 
Aminotransferase
(AST)/ Serum 
Glutamic -Oxaloacetic 
Transaminase (SGOT)Total bilirubin (and 
direct bilirubin, if 
total bilirubin is 
elevated above the 
upper limit of 
normal)
Albumin Bicarbonate Chloride Creatinine
Alkaline 
phosphataseSodium Alanine 
Aminotransferase
(ALT)/ Serum 
Glutamic -Pyruvic 
Transaminase (SGPT)Total Protein
Glucose 
(nonfasting )
Other Screening 
Testsâ€¢Follicle -stimulating hormone (as needed in women of nonchildbearing potential only)
â€¢Serum or urine Î² human chorionic gonadotropin (Î² hCG) pregnancy test (as needed for 
WOCBP)
â€¢All study -required laboratory assessments will be performed by a central laboratory, 
with the exception of pregnancy tests.
The i nvestigator (or medically  qualified designee) must document their review of each 
laboratory  safet y report.Â 
Â  05H6VD
07XD6Y
PRODUCT:   V116  91
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
10.3.1 Definition of AE
AE definition
â€¢An AE is an y untoward medical occurrence in a clinical study  participant, temporally  
associated with the use of study  intervention, whether or not considered related to the 
study  intervention.
â€¢NOTE: An AE can therefore be an y unfavorable and unintended sign (including an 
abnorm al laboratory  finding), s ymptom, or disease (new or exacerbated) temporally  
associated with the use of a study intervention.
â€¢NOTE: For purposes of AE definition, study  intervention (also referred to as Sponsorâ€™s 
product) includes an y pharmaceutical product , biological product, vaccine, diagnostic 
agent, or protocol specified procedure whether investigational or marketed (including 
placebo, active comparator product, or run -in intervention) , manufactured by , licensed 
by, provided by , or distributed by  [CONTACT_63553] .
Events meeting the AE definition
â€¢Any abnormal laboratory test results (hematology , clinical chemistry, or urinaly sis) or 
other safet y assessments (eg, ECG, radiological scans, vital signs measurements), 
including those that worsen from baseline, considered clinicall y significant in the medical 
and scientific judgment of the investigator.
â€¢Exacerbation of a chronic or intermittent pre -existing condition including either an 
increase in frequency  and/or intensity  of the condition.
â€¢New conditions detected or diagnosed after stud y intervention administration even 
though it may  have been present before the start of the study .
â€¢Signs, sy mptoms, or the clinical sequelae of a suspected drug -drug interaction.
â€¢Signs, sy mptoms, o r the clinical sequelae of a suspected overdose of either study  
intervention or a concomitant medication.
â€¢For all reports of overdose (whether accidental or intentional) with an associated AE, the 
AE term should reflect the clinical s ymptoms or abnormal te st result. An overdose 
without any  associated clinical sy mptoms or abnormal laboratory  results is reported using 
the terminology  â€œaccidental or intentional overdose without adverse effect.â€
â€¢Any new cancer or progression of existing cancer.Â 
Â  05H6VD
07XD6Y
PRODUCT:   V116  92
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
Events NOT meeting the AE d efinition
â€¢Medical or surgical procedure (eg, endoscop y, appendectom y): the condition that leads to 
the procedure is the AE.
â€¢Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
â€¢Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present or 
detected at the start of the study  that do not worsen.
â€¢Surgery  planned prior to informed consent to treat a pre -existing condition that has not 
worsened.
â€¢Refe r to Section 8.4.6 for protocol -specific exceptions.
Definition of Unsolicited and Solicited AE
â€¢An unsolicited AE is an AE that was not solicited using a VRC and that is communicated 
by a participant who has signed the informed consent. Unsolicited AEs inc lude serious 
and nonserious AEs.
â€¢Solicited AEs are predefined local (at the injection site) and s ystemic events for which 
the participant is specifically  questioned, and which are noted b y the participant in their 
VRC.
10.3.[ADDRESS_1214621] medical occurrence that, at any dose:
a.   Results in death
b.   Is life -threatening
â€¢The term â€œ life-threatening â€in the definition of â€œseriousâ€ refers to an event in which 
the participant was at risk of death at the time of the event. It does not refer to an 
event, which h ypothetically  might have caused death, if it were more severe.
c.   Requires inpatient hospi[INVESTIGATOR_31007]
â€¢Hospi[INVESTIGATOR_19357], regardless of length of stay, even 
if the hospi[INVESTIGATOR_2138] a precautionary  measure for continued observation. (Note: 
Hospi[INVESTIGATOR_19358] a pre -existing condition that has not 
worsened is not an SAE. A pre -existing condition is a clinical condition that is 
diagnosed prior to the use of an MSD product and is documented in the participantâ€™s 
medical history .Â 
Â  05H6VD
07XD6Y
PRODUCT:   V116  93
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
d.    Results in persistent or significant disability/incapacity
â€¢The term disability  means a substantial disruption of a personâ€™s ability  to conduct 
normal life functions.
â€¢This definition is not intended to include experiences of relativel y minor medical 
signifi cance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, 
and accidental trauma (eg, sprained ankle) that may interfere with or prevent 
every day life functions but do not constitute a substantial disruption.
e.    Is a congenital anomaly /birth defect
â€¢In offspring of participant taking the product regardless of time to diagnosis.
f.    Other important medical events
â€¢Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that may  
not be immediately  life-threatening or result in death or hospi[INVESTIGATOR_43193] 1 
of the other outcomes listed in the above definition. These events should usually  be 
considered serious.
Examples of such events include invasive or malignant cancers, intensive treatment in 
an emergency  room or at home for allergic bronchospasm, blood dy scrasias or 
convulsions that do not result in hosp italization, or development of drug dependency 
or drug abuse.
10.3.3 Additional Events Reported
Additional events that require r eporting
In addition to the above criteria, AEs meeting either of the below criteria, although not 
serious per ICH definition, are reportable to the Sponsor.
â€¢Is a cancer
â€¢Is associated with an overdoseÂ 
Â  05H6VD
07XD6Y
PRODUCT:   V116  94
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
10.3.4 Recording AE and SAE
AE and SAE r ecording
â€¢When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation (eg, hospi[INVESTIGATOR_1088], laboratory , and diagnostics reports) related to 
the event.
â€¢The investigator will record all relevant AE/SAE information on the AE 
CRFs /worksheets at each examination.
â€¢It is not acceptable for the investigator to send photocopi[INVESTIGATOR_10914]â€™s medi cal 
records to the Sponsor in lieu of completion of the AE CRF page.
â€¢There may  be instances when copi[INVESTIGATOR_63475] b y 
the Sponsor. I n this case, all participant identifiers, with the exception of the participant 
number, will be blinded on the copi[INVESTIGATOR_19361].
â€¢The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. I n such cases, the diagnosis (not the 
individual signs/sy mptoms) will be documented as the AE/SAE.
Assessment of i ntensity /toxicity
â€¢An event is defined as â€œseriousâ€ when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, not when it is rated as severe.
â€¢The investigator will make an assessment of intensity  for each AE and SAE (and other 
reportable safet y event) reported during the stud y and assign it to 1 of the following 
categories: 
-Mild: An event that is easily  tolerated b y the partic ipant, causing minimal discomfort 
and not interfering with every day activities (for pediatric studies, awareness of 
symptoms, but easily  tolerated).
-Moderate: An event that causes sufficient discomfort to interfere with normal 
every day activities (for pedi atric studies definitely acting like something is wrong).
-Severe: An event that prevents normal everyday  activities. An AE that is assessed as 
severe should not be confused with an SAE. Severe is a category  utilized for rating 
the intensity  of an event; an d both AE and SAE can be assessed as severe (for 
pediatric studies, extremely  distressed or unable to do usual activities).
â€¢Injection site ery thema/redness or swelling from the day  of vaccination through Day  [ADDRESS_1214622]:   V116  95
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
â€¢The investigator will make an assessment of toxicity for each AE and SAE (and other 
reportable event) reported during the stud y. A toxicity  grade will be assigned to 
injection- site AEs, specific sy stemic AEs , other s ystemic AEs, and vital sign 
(temper ature) AEs as shown in the following tables. The toxicity  grading scales used in 
this study  are adapted from the â€œFDA Guidance for Industry : Toxicity  Grading Scale for 
Health y Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, 
September 2007.â€
Injection -Site AE Toxicity Grading Scale
Injection Site 
Reaction to Study 
Vaccine/PlaceboaGrade 1 Grade 2 Grade 3 Grade 4
Injection -site AEs occurring Days 1 through 5 following receipt of study vaccine/placebo
Pain/Tenderness Does not interfere 
with activityRepeated use of 
non-narcotic pain 
reliever >24 hours 
or interferes with 
activityAny use of narcotic 
pain reliever or 
prevents daily 
activityER visit or 
hospi[INVESTIGATOR_2666]/Redness Size measured as
BSize measured as
C or DSize measured as
Eâ†’Necrosis or 
exfoliative 
dermatitis or 
results in ER 
visit or 
hospi[INVESTIGATOR_63477]/Swelling Size measured as 
BSize measured as
C or DSize measured as
Eâ†’Necrosis or ER 
visit or 
hospi[INVESTIGATOR_870014]-narcotic pain 
reliever >24 hours 
or interferes with 
activityAny use of narcotic 
pain reliever or 
prevents daily 
activityER visit or 
hospi[INVESTIGATOR_63479] -site reaction that begins â‰¥6 days after receipt of study vaccine/placebo
Pain/tenderness
Erythema/Redness
Induration/Swelling
OtherDoes not interfere 
with activityRepeated use of 
non-narcotic pain 
reliever >24 hours 
or interferes with 
activityAny use of narcotic 
pain reliever or 
prevents daily 
activityER visit or 
hospi[INVESTIGATOR_93275] = adverse event; ER = emergency room; eVRC = electronic Vaccine Report Card; SAE = serious adverse event ; 
VRC =vaccination report card.
aBased upon information provided by [CONTACT_31823] t on the paper VRC/ eVRC and verbally during VRC review. 
Erythema/Redness and Induration/Swelling are specific injection -site AEs with size designations of letters A through E â†’, 
based upon a graphic in the paper VRC/ eVRC. Size A is not assigned a toxicity g rade; however, injection -site AEs that 
measure size A should be reported as adverse experiences. If the participant has an ER visit or is hospi[INVESTIGATOR_870015] -site AE, that AE is to be assigned a toxicity grade of 4, regardless of the size measur ed.Â 
Â  05H6VD
07XD6Y
PRODUCT:   V116  96
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
Specific Systemic AE Toxicity Grading Scale
Systemic (General)Mild 
(Grade 1)Moderate 
(Grade 2)Severe 
(Grade 3)Potentially Life 
Threatening
(Grade 4)
Headache No interference 
with activityRepeated use of non -
narcotic pain reliever 
>24hours or some 
interference with 
activitySignificant; any use 
of narcotic pain 
reliever or prevents 
daily activityER visit or 
hospi[INVESTIGATOR_93276]; 
prevents daily 
activityER visit or 
hospi[INVESTIGATOR_93277]; 
prevents daily 
activityER visit or 
hospi[INVESTIGATOR_93278] = emergency room
Other Systemic AE Toxicity Grading Scale
Systemic IllnessaMild 
(Grade 1)Moderate 
(Grade 2)Severe 
(Grade 3)Potentially Life 
Threatening
(Grade 4)b
Illness or clinical AE 
(as defined 
according to 
applicable 
regulations)No interference 
with activitySome interference 
with activity not 
requiring medical 
interventionPrevents daily 
activity and 
required medical 
interventionER visit or 
hospi[INVESTIGATOR_93278] = emergency room; eVRC = electronic Vaccine Report Card; SAE = serious adverse event ; VRC =vaccination report 
card.
aBased upon information provided by [CONTACT_870041]/ eVRC and verbally during the eVRC review during the 
primary safety follow -up period. For SAEs reported beyond the primary safety follow -up period, grading will be based upon 
the initial report and/or follow -up of the event.
bAEs resulting in death will be assessed as Grade 4.
Vital Sign (Temperature) Toxicity Grading Scale
Vital SignsaMild 
(Grade 1)Moderate 
(Grade 2)Severe 
(Grade 3)Potentially Life 
Threatening
(Grade 4)
Fever (Â°C)b
(Â°F)b38.0 to 38.4
100.4 to 101.138.5 to 38.9
101.2 to 102.039.0 to 40.0
102.1 to 104.0>40.0
>104.[ADDRESS_1214623] for all vital sign requirements.
bOral temperature; no recent hot or cold beverages or smoking.Â 
Â  05H6VD
07XD6Y
PRODUCT:   V116  97
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
Assessment of c ausality
â€¢Did the Sponsorâ€™s product cause the AE?
â€¢The determination of the likelihood that the Sponsorâ€™s product caused the AE will be 
provided b y an investigator who is a qua lified ph ysician. The investigatorâ€™s signed/dated 
initials on the source document or worksheet that supports the causalit y noted on the AE 
form, ensures that a medically  qualified assessment of causalit y was done. This initialled 
document must be retained for the required regulatory  time frame. The criteria below are 
intended as reference guidelines to assist the investigator in assessing the likelihood of a 
relationship between the test product and the AE based upon the available information.
â€¢The following components are to be used to assess the relationship between the 
Sponsorâ€™s product and the AE; the greater the correlation with the components and 
their respective elements (in number and/or intensity ), the more likel y the Sponsorâ€™s 
product caused the AE:
-Exposure: Is there evidence that the participant was actuall y exposed to the 
Sponsorâ€™s product such as: reliable history, acceptable compliance assessment (diary , 
etc.), seroconversion or identification of vaccine virus in bodily  specimen?
-Time Course: Did the AE follow in a reasonable temporal sequence from 
administration of the Sponsorâ€™s product? I s the time of onset of the AE compatible 
with a vaccine -induced effect?
-Likely Cause: Is the AE not reasonabl y explained by  [CONTACT_63556], other drug(s)/vaccine(s), or other host or environmental factors?
-Rechallenge: Was the participant re -exposed to the Sponsorâ€™s product in the study ?
-If yes, did the AE recur or worsen?
-If yes, this is a positive rechallenge.
-If no, this is a negative rechallenge.
(Note: This criterion is not applicable if: (1) the initial AE resulted in death or permanent 
disability , or (2) the study  is a single -dose vaccine study ; or (3) Sponsorâ€™s product(s) is/are 
used only  1 time.)
NOTE: IF A RECHALLENGE IS PLANNED FOR AN AE THAT WAS SERI OUS AND 
MAY HAVE BEEN CAUSED BY [CONTACT_26370]â€™S PRODUCT, OR I F RE -EXPOSURE 
TO THE SPONSORâ€™S PRODUCT POSES ADDITIONAL POTENTIAL SI GNIFICANT 
RISK TO THE PARTI CIPANT THEN THE RECHALLENGE MUST BE APPROVED I N 
ADVANCE BY [CONTACT_93333], AND IF REQUI RED, THE 
IRB/IEC.Â 
Â  05H6VD
07XD6Y
PRODUCT:   V116  98
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
-Consistency with study intervention profile: Is the clinical/pathological 
presentation of the AE consistent with previous knowledge regarding the Sponsorâ€™s 
product or drug class pharmacology  or toxicology?
-The assessment of relationship will be reported on the CRFs/worksheets b y an 
investigator who is a qualified phy sician according to his/her best clinical judgment, 
including consideration of the above elements.
-Use the following scale of criteria as guidance (not all criteria must be present to be 
indicative of a Sponsorâ€™s product relationship).
-Yes, there is a reasonable possibility  of Sponsorâ€™s product relationship:
-There is evidence of exposure to the Sponsorâ€™s product. The temporal sequence of 
the AE on set relative to the administration of the Sponsorâ€™s product is reasonable. 
The AE is more likely explained by [CONTACT_1034]â€™s product than b y another cause.
-No, there is not a reasonable possibility  of Sponsorâ€™s product relationship:
-Participant did not rece ive the Sponsorâ€™s product OR temporal sequence of the 
AE onset relative to administration of the Sponsorâ€™s product is not reasonable OR 
the AE is more likely  explained by  [CONTACT_26372]â€™s product. 
(Also entered for a participant with overdose without an associated AE.)
â€¢For each AE/SAE, the investigator must document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causalit y.
â€¢There may  be situations in which an SAE has occurred and the investigator ha s minimal 
information to include in the initial report to the Sponsor. However, it is very important 
that the investigator always make an assessment of causalit y for every event before the 
initial transmission of the SAE data to the Sponsor.
â€¢The investigat or may  change his/her opi[INVESTIGATOR_19954] -up 
information and send an SAE follow -up report with the updated causality  assessment.
â€¢The causality  assessment is 1 of the criteria used when determining regulatory  reporting 
requirements.
Follow-up of AE and SAE
â€¢The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically  indicated or as requested b y Sponsor to 
elucidate the nature and/or causalit y of the AE or SAE as fully as possible. This may  
include additional laboratory  tests or investigations, histopathological examinations, or 
consultation with other health care professionals.Â 
Â  05H6VD
07XD6Y
PRODUCT:   V116  99
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
â€¢New or updated information will be recorded in the CRF.
â€¢The investigator will submit any  updated SAE data to the Sponsor within 24 hours of 
receipt of the information.
10.3.5 Reporting of AE s, SAE s, and Other Reportable Safety Events to the Sponsor
AE, SAE, and o ther reportable safety e vent reporting to Sponsor via electronic d ata 
collection t ool
â€¢The p rimary  mechanism for reporting to the Sponsor will be the EDC tool.
â€¢Electronic reporting procedures can be found in the EDC data entry guidelines (or 
equivalent).
â€¢If the electronic s ystem is unavailable for more than 24 hours, then the site will use 
the paper AE Reporting form.
â€¢Reference Section 8.4.1 for reporting time requirements.
â€¢The site will enter the SAE data into the electronic sy stem as soon as it becomes 
available.
â€¢After the stud y is completed at a given site, the EDC tool will be taken off -line to prevent 
the entry  of new data or changes to existing data.
â€¢If a site receives a report of a new SAE from a study  participant or receives updated data 
on a previousl y repor ted SAE after the EDC tool has been taken off -line, then the site can 
report this information on a paper SAE form or by [CONTACT_756] (see next section).
â€¢Contacts for SAE reporting can be found in the Investigator Stud y File Binder (or 
equivalent).
SAE reporti ng to the Sponsor via paper CRF
â€¢If the EDC tool is not operational, facsimile transmission or secure e -mail of the SAE 
paper CRF is the preferred method to transmit this information to the Sponsor.
â€¢In rare circumstances and in the absence of facsimile equi pment, notification by  
[CONTACT_9337] a cop y of the SAE data collection tool sent by [CONTACT_19515].
â€¢Initial notification via telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages w ithin the designated reporting time frames.
â€¢Contacts and instructions for SAE reporting and paper reporting procedures can be found 
in the Investigator Study  File Binder (or equivalent) .Â 
Â  05H6VD
07XD6Y
PRODUCT:   V116  100
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
10.4 Appendix 4: Device Events, Adverse Device Events, and Medical Device 
Incidents: Definition s, Collection, and Documentation
Not applicable.Â 
Â  05H6VD
07XD6Y
PRODUCT:   V116  101
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
10.5 Appendix 5: Contraceptiv e Guidance
10.5.1 Definitions
Women of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanentl y sterile (see below):
If fertility  is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cy cle cannot 
be confirmed before first dose of study  intervention, additional evaluation should be 
considered.
Women in the following categories are not considered WOCBP:
â€¢Premenarchal
â€¢Premenopausal female with 1 of the following:
- Documented h ysterectomy
-Documented bilateral salpi[INVESTIGATOR_1656]
-Documented bilateral oophorectom y
For individuals with permanent infertility  due to an alternate medical cause other than the 
above (eg, Mullerian agenesis, androgen insensitivity), investigator discretion should be 
applied to determining study  entry .
Note: Documentation can come from the site personnelâ€™s review of the participantâ€™s 
medical records, medical examination, or medical history  interview.
â€¢Postmenopausal female
-A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause.
â—¦A high FSH level in the postmenopausal range may  be used to confirm a 
postm enopausal state in women not using hormonal contraception or HRT. 
However, in the absence of [ADDRESS_1214624]:   V116  102
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
10.5.2 Contracepti on Requirements
[IP_ADDRESS] Contraception Requirements in Phase 1
Female Participants
Contraceptives allowed during the study includea:
Highly Effective Contraceptive Methods That Have Low User Dependency
Failure rate of <1% per year when used consistently and correct ly.
â€¢Progestogen -only subdermal contraceptive implantb
â€¢IUSc
â€¢IUD
â€¢Bilateral tubal occlusion
â€¢Azoospermic partner (vasectomized or secondary to medical cause)
This is a highly effective contraception method provided that the partner is the sole male sexual 
partner of the WOCBP and the absence of sperm has been confirmed. If not, an additional highly 
effective method of contraception should be used. A spermatogenesis cycle is approximately 90 days.
Note: Documentation of azoos permia can come from the site personnelâ€™s revie w of the participantâ€™s 
medical records, medical examination, or medical history intervie w.
Sexual Abstinence
â€¢Sexual abstinence is considered a highly effective method only if defined as refraining from 
heterosexual intercourse during the entire period of risk associated w ith the study intervention. The 
reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the 
preferred and usual lifestyle of the participant.
aContraceptive use by [CONTACT_93339].
bIf locally required, in accordance with CTFG guidelines, acceptable contraceptive implants are l imited to 
those which inhibit ovulation.
cIUS is a progestin releasing IUD .
Note: The follow ing are not acceptable methods of contraception:
-Periodic abstinence (calendar, symp tothermal, post -ovulation methods), withdraw al (coitus interruptus), 
spermicides only, and LAM.
-Male condom with cap, diaphragm, or sponge with spermicide.
-Male and female condom should not be used together (due to risk of failure with frictio n).
Male Participants
Male participants with female partners of childbearing potential are eligible to participate if 
they agree to 1 of the following during the protocol -defined time frame in Section 5.1:
â€¢Be abstinent from penile -vaginal intercourse as their usual and preferred lifesty le 
(abstinent on a lo ng-term and persistent basis) and agree to remain abstinent.Â 
Â  05H6VD
07XD6Y
PRODUCT:   V116  103
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
â€¢Use a male condom plus partner use of an additional contraceptive method when having 
penile -vaginal intercourse with a WOCBP who is not currentl y pregnant.
-The following are not acceptable meth ods of contraception:
â€¢Periodic abstinence (calendar, s ymptothermal, postovulation methods), 
withdrawal (coitus interruptus), spermicides only , and LAM.
â€¢Male condom with cap, diaphragm, or sponge with spermicide.
1. Male and female condom cannot be used togeth er.
-Note: Men with a pregnant or breastfeeding partner must agree to remain abstinent 
from penile -vaginal intercourse or use a male condom during each epi[INVESTIGATOR_191202].
[IP_ADDRESS] Contraception Requirements in Phase 2
Contraceptives allowed during the study includea:
Highly Effective Contraceptive Methods That Have Low User Dependencyb
Failure rate of <1% per year when used consistently and correctl y.
â€¢Progestogen -only subdermal contraceptive implantc
â€¢IUSd
â€¢Non-hormonal IUD
â€¢Bilateral tubal occlusion
â€¢Azoospermic partner (vasectomized or secondary to medical cause)
This is a highly effective contraception method provided that the partner is the sole male sexual partner of 
the WOCBP and the absence of sperm has been confirmed. If not, an addit ional highly effective method 
of contraception should be used. A spermatogenesis cycle is approximately 90 day s.
Note: Documentation of azoospermia can come from the site personnelâ€™s revie w of the participantâ€™s 
medical records, medical examination, or med ical history intervie w. 
Highly Effective Contraceptive Methods That Are User Dependentb
Failure rate of <1% per year when used consistently and correctly .
â€¢Com bined (estrogen -and progestogen -containing) hormonal contraceptionc
-Oral
-Intravaginal
-Transdermal
-Injectable
â€¢Progestogen -only hormonal contraceptionc
-Oral
-InjectableÂ 
Â  05H6VD
07XD6Y
PRODUCT:   V116  104
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
Sexual Abstinence
â€¢Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual 
intercourse during the entire period of risk associated with the study intervention. The reliability of sexual 
abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual 
lifestyle of the participant.
a   Contraceptive use by [CONTACT_870042] w ith local regulations regarding the use of 
contraceptive methods for participants of clinical studies.
b   Typi[INVESTIGATOR_63485] -use failure rates (ie, when used consistently and 
correctly).
c   If locally required, in accordance w ith CTFG guidelines, acceptable contraceptive implants are limited to 
those which inhibit ovulation.
d   IUS is a progestin releasing IUD.
Note: The follow ing are not acceptable methods of contraception:
-  Periodic abstin ence (calendar, symptothermal, post -ovulation methods), w ithdrawal (coitus 
interruptus), spermicides only, and LAM.
-  Male condom with cap, diaphragm, or sponge with spermicide.
-  Male and female condom should not be used together (due to risk of failure with friction).
Male Participants
Male participants with female partners of childbearing potential are eligible to participate if 
they agree to 1 of the following during the protocol -defined time frame in Section 5.1:
â€¢Be abstinent from penile -vaginal intercourse as their usual and preferred lifesty le 
(abstinent on a long -term and persistent basis) and agree to remain abstinent.
â€¢Use a male condom plus partner use of an additional contraceptive method when having 
penile -vaginal intercourse with a WOCBP who is not currentl y pregnant.
-The following are not acceptable methods of contraception:
â€¢Periodic abstinence (calendar, s ymptothermal, postovulation methods), 
withdrawal (coitus interruptus), spermicides only , and LAM.
â€¢Male condom with cap, diaphragm, or sponge with spermicide.
2. Male and female condom cannot be used together.
-Note: Men with a pregnant or breastfeeding partner must agree to remain abstinent 
from penile -vaginal intercourse or use a male condom during each epi[INVESTIGATOR_870016].Â 
Â  05H6VD
07XD6Y
PRODUCT:   V116  105
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
10.6 Appendix 6: Collection and Management of Specimens for Future Biomedical 
Research
1.  Definitions
a.Biomarker: A biological molecule found in blood, other bod y fluids, or tissues that is a 
sign of a normal or abnormal process or of a condition or disease. A biomarker may be 
used to see how well the body  responds to a treatment for a disease or condition .1
b.Pharmacogenomics: The investigation of variations of DNA and RNA characteristics as 
related to drug/vaccine response.2
c.Pharmacogenetics: A subset of pharmacogenomics, pharmacogenetics is the influence of 
variations in DNA sequence on drug/vaccine response.2
d.DNA: Deox yribonucleic acid.
e.RNA: Ribonucleic acid.
2.  Scope of Future Biomedical Research
The specimens consented and/or collected in this study  as outlined in Section 8. 9will be 
used in various experiments to understand:
â—¦The biology  of how drugs/vaccines work
â—¦Biomarkers responsible for how a drug/vaccine enters and is removed b y the body
â—¦Other pathway s with which drugs/vaccines m ay interact
â—¦The biology  of disease
The specimen(s) may  be used for future assay  development and/or drug/vaccine 
development.
It is now well recognized that information obtained from studying and testing clinical 
specimens offers unique opportunities to enhance our understanding of how individuals 
respond to drugs/vaccines, enhance our understanding of human disease and ultimately  
improve public health through development of novel treatments targeted to populations 
with the greatest need. All specimens will be used by  [CONTACT_63558].
3.  Summary of Procedures for Future Biomedical Research.
a.   Participants for Enrollment
All participants enrolled in the clinical study  will be considered for enrollment in 
future biomedic al research.Â 
Â  05H6VD
07XD6Y
PRODUCT:   V116  106
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
b.   Informed Consent
Informed consent for specimens (ie, DNA, RNA, protein, etc.) will be obtained 
during screening for protocol enrollment from all participants or legal guardians, at a 
study  visit by  [CONTACT_63559] d esignate. Informed consent for future 
biomedical r esearch should be presented to the participants on the visit designated in 
the SoA. If delay ed, present consent at next possible Participant Visit. Consent forms 
signed b y the participant will be kept at the clinical study  site under secure storage for 
regulatory  reasons.
A template of each stud y siteâ€™s approved informed consent will be stored in the 
Sponsorâ€™s clinical document repository .
c.   eCRF Documentation for Future Biomedical Research Specimens
Docu mentat ion of participant consent for future biomedical research will be captured 
in the eCRFs . Any specimens for which such an informed consent cannot be verified 
will be destroy ed.
d.   Future Biomedical Research Specimen(s)
Collection of specimens for fu ture biomedical research will be performed as outlined 
in the SoA. I n general, if additional blood specimens are being collected for future 
biomedical r esearch, these will usually  be obtained at a time when the participant is 
having blood drawn for other s tudy purposes.
4.  Confidential Participant Information for Future Biomedical Research
In order to optimize the resea rch that can be conducted with future biomedical r esearch 
specimens, it is critical to link participant' clinical information with future test results. I n 
fact little or no research can be conducted without connecting the clinical study data to 
the specimen. The clinical data allow specific analyses to be conducted. Knowing 
participant characteristics like gender, age, medical history  and int ervention outcomes are 
critical to understanding clinical context of anal ytical results.
To maintain privacy  of information collect ed from specimens obtained for future 
biomedical r esearch, the Sponsor has developed secure policies and procedures. All 
specimens will be single -coded per ICH E15 guidelines as described below.
At the clinical study  site, unique codes will be placed on the future biomedical r esearch 
specimens. This code is a random number which does not contain an y personally 
identify ing inform ation embedded within it. The link (or key) between participant 
identifiers and this unique code will be held at the study  site. No personal identifiers will 
appear on the specimen tube.Â 
Â  05H6VD
07XD6Y
PRODUCT:   V116  107
PROTOCOL/AMENDMENT N O.:  [ADDRESS_1214625] party  (eg, a university  investigator) designated b y 
the Sponsor. The investigato r conducting the anal ysis will follow the Sponsorâ€™s privacy 
and confidentialit y requirements. An y contracted third part y anal yses will conform to the 
specific scope o f anal ysis outlined in future biomedical research protocol and consent. 
Future biomedical research specimens remaining with the third party  after specific 
analysis is performed will be reported to the Sponsor.
6.  Withdrawal From Future Biomedical Research
Participants may  withdraw their consent for future biomedical r esearch and ask that thei r 
biospecimens not be used for future biomedical r esearch. Participants may withdraw 
consent at an y time b y contact[CONTACT_491494]. If medical records 
for the main study  are still available, the investigator will contact [CONTACT_111972] ([EMAIL_1250]). Subsequently, the 
participant's specimens will be flagged in the biorepository and restricted to main study 
use only . If specimens were collected from study participants specifical ly for future 
biomedical r esearch, these specimens will be removed from the biorepository and 
destroy ed. Documentation will be sent to the investigator confirming withdrawal and/or 
destruction, if applicable. I t is the responsibility  of the investigator to inform the 
participant of completion of the withdrawal and/or destruction, if applicable. Any 
analyses in progress at the time of request for withdrawal/destruction or alread y 
performed prior to the request being received b y the Sponsor will continue to b e used as 
part of the overall research study  data and results. No new analy ses would be generated 
after the request is received.
In the event that the medical records for the main study  are no longer available (eg, if the 
investigator is no longer required by [CONTACT_870043]) or the specimens have been completel y anonymized, there will no longer be a 
link between the participantâ€™s personal information and their specimens. In this situation, 
the request for withdrawal of consent and/or destruction cannot be processed.
7.  Retention of Specimens
Future biomedical r esearch specimens will be stored in the biorepository  for potential 
analysis for up to [ADDRESS_1214626]:   V116  108
PROTOCOL/AMENDMENT N O.:  [ADDRESS_1214627] results are accessible only  to the 
authorized Sponsor representatives and the designated study administrator research 
personnel and/or collaborators. Database user authentication is highl y secure, and is 
accomplished using network securit y policies and practices based on international 
standards to protect against unauthorized access.
9.  Reporting of Future Biomedical Research Data to Participants
No information obtained from exploratory  laboratory  studies will be reported to the 
participant, famil y, or physicians. Principle reasons not to inform or return results to the 
participant include: Lack of relevance to participant health, limitations of predictive 
capability , and concerns regarding misinterpretation.
If important research findings are discovered, the Sponsor may  publish results, present 
results in national meetings, and make results accessible on a public website in order to 
rapi[INVESTIGATOR_252314]. Participants will not be 
identified by  [CONTACT_63561].
10. Future Biomedical Research Study Population
Every  effort will be made to recruit all participants diagnosed and treated o n Sponsor 
clinical studies for f uture biomedical r esearch.
11.Risks Versus Benefits of Future Biomedical Research
For future biomedical research, risks to the participant have been mini mized and are 
described in the future biomedical r esearch inf ormed consent.
The Sponsor has developed strict security, policies, and procedures to address participant 
data privacy  concerns. Data privacy  risks are largely  limited to rare situations involving 
possible breach of confidentiality . In this highl y unlikely situation, there is risk that the 
information, like all medical information, may  be misused.
12.Questions
Any questions related to the future biomedical research should be e mailed directly  to 
[EMAIL_1250].Â 
Â  05H6VD
07XD6Y
PRODUCT:   V116  109
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
13.References
1.  National Cancer Institute [I nternet]: Available from 
https://www.cancer.gov/publications/dictionaries/cancer -terms?cdrid=[ZIP_CODE]
2.  International Conference on Harmonization [Internet] : E15: Definitions for Genomic 
Biomarkers, Pharmacogenomics, Pharma cogenetics, Genomic Data and Sample Coding 
Categories. Available from http://www.ich.org/products/guidelines/efficacy/efficacy -
single/article/definitions -for-genomic -biomarkers- pharmacogenomics -pharmacogenetics -
genomic -data-and-sample -cod.html 
3.  Industry Pharmacogenomics Working Group [Internet]: Understanding the I ntent, Scope 
and Public Health Benefits of Exploratory  Biomarker Research: A Guide for I RBs/IECs 
and Investigational Site Staff. Available at http://i -pwg.org/ 
4.  Industry  Pharmacogenomics Working Group [Internet]: Pharmacogenomics 
Informational Brochure for I RBs/IECs and Investigational Site Staff. Available at http://i-
pwg.org/Â 
Â  05H6VD
07XD6Y
PRODUCT:   V116  110
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
10.7 Appendix 7: Country -specific Requirements
Not applicable.Â 
Â  05H6VD
07XD6Y
PRODUCT:   V116  111
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
10.8 Appendix 8: Abbreviations
Abbreviation Expanded Term
ACIP Advisory Committee on Immunization Practices
AE adverse event 
ALT Alanine Aminotransferase
APaT All-Participants -as-Treated
AST Aspartate Aminotransferase
Î²-hCG Î²-human chorionic gonadotropin
CFR Code of Federal Regulations
CI confidence interval
cLDA constrained longitudinal data analysis
CONSORT Consolidated Standards of Reporting Trials
CRF Case Report Form
CSR Clinical Study Report
CTFG Clinical Trials Facilitation Group
DNA deoxyribonucleic acid
ECG electrocardiogram
ECI events of clinical interest
ECL electrochemiluminescence
eCRF electronic Case Report Form
EDC electronic data collection
EMA European Medicines Agen cy
EU European Union
eVRC electronic Vaccination Report Card
FAS Full Analysis Set
FDAAA Food and Drug Administration Amendments Act
FSH follicle -stimulating hormone
GCP Good Clinical Practice
GMC geometric mean concentration
GMFR geometric mean fold rise
GMT geometric mean titer
HIV human immunodeficiency virus
HRT hormone replacement therapy
IB Investigatorâ€™s Brochure
ICF Informed Consent Form
ICH International Council for Harmonisation
IEC Independent Ethics Committee
IgG immunoglobulin G
IM intramuscular
IPD invasive pneumococcal disease
IRB Institutional Review Board
IRT interactive response technology
IU intersection -union
IUD intrauterine device
IUS intrauterine hormone -releasing system
LAM lactational amenorrhea method
M&N Miettinen and Nurminen
MOPA multiplexed opsonophagocytic assay
MSD [COMPANY_006] Sharp & Dohme Corp.
OPA opsonophagocytic activity
PCV pneumococcal conjugate vaccine
PK pharmacokineticÂ 
Â  05H6VD
07XD6Y
PRODUCT:   V116  112
PROTOCOL/AMENDMENT N O.:  [ADDRESS_1214628]
WOCBP woman (or w omen) of childbearing potentialÂ 
Â  05H6VD
07XD6Y
PRODUCT:   V116  113
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
11 REFERENCES
[Anttila, M., et al 1999] Anttila M, Voutilainen M, JÃ¤ntti V, Eskola J, 
KÃ¤yhty H. Contribution of serot ype-specific 
IgG concentration, IgG subclasses and 
relative antibod y avidit y to 
opsonophagocy tic activity  against 
Streptococcus pneumoniae. Clin Exp 
Immunol 1999;118(3):402- 7.03QY70
[Berger, R. L. 1982] Berger RL. Multiparameter h ypothesis 
testing and acceptance sampling. 
Technometrics. 1982 Nov;24(4):295 -300.0575BK
[Burton, Robert L . and Nahm, 
Moon H. 2006]Burton RL, Nahm MH. Development and 
validation of a fourfold multiplexed 
opsonization assay  (MOPA4) for 
pneumococcal antibodies. Clin Vaccine 
Immunol 2006;13(9):1004- 9.03QT2R
[Castiglia P. 2014] Castiglia P. Recommendations for 
pneumococcal immunization outside routine 
childhood immunization programs in 
Western Europe. Adv Ther. 
2014Oct;31(10):1011 -44.04P7L W
[Centers for Disease Control 
and Prevention (CDC) 2013]Centers for Disease Control and Prevention 
(CDC). Use of 13 -valent pneumococcal 
conjugate v accine and 23 -valent 
pneumococcal poly saccharide vaccine 
among children aged 6- 18 years with 
immunocompromising conditions: 
recommendations of the Advisory  
Committee on I mmunization Practices 
(ACI P). MMWR Morb Mortal Wkly  Rep. 
2013 Jun 28;62(25):521- 4.043QRD
[Centers for Disease Control 
and Prevention 2010]Centers for Disease Control and Prevention. 
Prevention of Pneumococcal Disease 
Among Infants and Children - Use of 13-
Valent Pneumococcal Conjugate Vaccine 
and 23- Valent Pneumococcal 
Polysaccharide Vac cine; Recommendations 
of the Advisory  Committee on 
Immunization Practices (ACI P). MMWR 
2010;59(RR -11):1- 19.03RSB6Â 
Â  05H6VD
07XD6Y
PRODUCT:   V116  114
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
[Centers for Disease Control 
and Prevention 2010]Centers for Disease Control and Prevention. 
Updated recommendations for prevention of 
invasive pneumococcal disease among 
adults using the 23 -valent pneumococcal 
polysaccharide vaccine (PPSV23). MMWR 
2010;59(34):1102 -6.03RCFX
[Centers for Disease Control 
and Prevention 2015]Centers for Disease Control and Prevention. 
Epi[INVESTIGATOR_528850] -
preventable diseases. 13th ed. Hamborsk y J, 
Kroger A, Wolfe S, editors. Washington 
(DC): Department of Health and Human 
Services (HHS); c2015. Chapter 6, Vaccine 
administration; p. 79 -106.0508PV
[Centers for Disease Control 
and Prev ention 2019]Centers for Disease Control and Prevention. 
Advisory  Committee on Immunization 
Practices (AC IP), summary  report, October 
24-25, 2018. Washington (DC): Department 
of Health and Human Services (HHS); 2019. 
190 p.057YZL
[Centre for Disease Cont rol 
and Prevention 2016]Centre for Disease Control and Prevention. 
Active Bacterial Core surveillance (ABCs) 
report emerging infections program network 
Streptococcus pneumoniae, 2016. Atlanta 
(GA): Department of Health and Human 
Services (HHS); 2016. 1 p.052RDB
[Demczuk, W. H. B., et al 
2013]Demczuk WHB, Martin I, Griffith A, 
Lefebvre B, McGeer A, Lovgren M, et al. 
Seroty pe distribution of invasive 
Streptococcus pneumoniae in Canada after 
the introduction of the 13 -valent 
pneumococcal conjugate vaccine, 2010 -
2012. Can J Microbiol 2013;59:778 -88.03XKZ6
[Drijkoningen, J. J 2014] Drijkoningen JJ, Rohde GG. Pneumococcal 
infection in adults: burden of disease. Clin 
Microbiol I nfect. 2014 May ;[ADDRESS_1214629] 5:45-
51.04NFHN
[European Center for Disease 
Prevention and Control 2018]European Center for Disease Prevention and 
Control. Surveillance report: annual 
epi[INVESTIGATOR_93282] 2016: invasive 
pneumococcal disease. Stockholm 
(Sweden): European Center for Disease 052RH8Â 
Â  05H6VD
07XD6Y
PRODUCT:   V116  115
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
Prevention and Control (ECDC) 2018 Aug. 
12 p.
[Farrington, C. P. 1990] Farrington CP, Manning G. Test Statistics 
and Sample Size Formulae for Comparative 
Binomial Trials with Null Hy pothesis of 
Non- Zero Risk Difference or Non -Unity 
Relative Risk. Stat Med Vol. 9,1447- 1454 
(1990)04FS6L
[Golden, A. R., et al 2016] Golden AR, Adam HJ, Zhanel GG. Invasive 
Streptococcus pneumoniae in Canada, 2011 -
2014: Characterization of new candidate 15 -
valent pneumococcal conjugate vaccine 
seroty pes 22F and 33F. Vaccine. 2016 May  
17;34(23):2527- 30.04KWF0
[Hicks, L . A., et al 2007] Hicks LA, Harrison LH, Flannery B, Hadler 
JL, Schaffner W, Craig AS, et al. Incidence 
of Pneumococcal Disease Due to Non -
Pneumococcal Conjugate Vaccine (PCV7) 
Seroty pes in the [LOCATION_002] during the Era 
of Widespread PCV7 Vac cination, [ADDRESS_1214630] Dis 2007;196:1346- 54.03QT0G
[Jackson, L . A., et al 2013] Jackson L A, Gurtman A, van Cleeff M, 
Jansen KU, Jay awardene D, Devlin C, et al. 
Immunogenicit y and safety of a 13 -valent 
pneumococcal conjugate vaccine compared 
to a 2 3-valent pneumococcal pol ysaccharide 
vaccine in pneumococcal vaccine -naive 
adults. Vaccine. 2013 Aug 2;31(35):3577 -
84.043QMS
[Janssens, J. P. 2004] Janssens JP, Krause KH. Pneumonia in the 
very old. Lancet Infect Dis. 2004 Feb;4:112 -
24.04VTNJ
[Kobay ashi, M., et al 2015] Kobay ashi M, Bennett NM, Gierke R, 
Almendares O, Moore MR, Whitney  CG, et 
al. Intervals Between PCV13 and PPSV23 
Vaccines: Recommendations of the 
Advisory  Committee on Immunization 
Practices (AC IP). MMWR Morb Mortal 
Wkly  Rep. 2015 Sep 4;64(34):944- 7.04P7L HÂ 
Â  05H6VD
07XD6Y
PRODUCT:   V116  116
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
[Liang, K -Y and Zeger, S. L . 
2000]Liang K -Y, Zeger SL. Longitudinal data 
analysis of continuous and discrete 
responses for pre -post designs. Sanky ha: 
The Indian Journal of Statistics 
2000;62(Series B, Part 1):134- 48.00V5V6
[Miettinen, O. and Nurminen, 
M. 1985]Miettinen O, Nurminen M. Comparative 
Analy sis of Two Rates. Stat Med 
1985;4:213- 26.03QCDT
[Miller, Elizabeth, et al 2011] Miller E, Andrews NJ, Waight PA, Slack 
MP, George RC. Herd immunity  and 
seroty pe replacement 4 years after seven-
valent pneumococcal conjugate vaccination 
in England and Wales: an observational 
cohort study . Lancet Infect Dis 
2011;11(10):760 -8.03RKY7
[Moore, M. R., et al 2015] Moore MR, L ink-Gelles R, Schaffner W, 
Lynfield R, Lexau C, Bennett NM, et al. 
Effect of use of 13 -valent pneumococcal 
conjugate vaccine in children on invasive 
pneumococcal disease in children and adults 
in the [LOCATION_003]: analy sis of multisite, 
population -based surveillance. Lancet Infect 
Dis. 2015 Feb 3. [Epub ahead of print].043MRP
[Pi[INVESTIGATOR_63466], T. 2015] Pi[INVESTIGATOR_63466] T, Bennett NM. Pneumococcal 
disease prevention among adults: strategies 
for the use of pneumococcal vaccines. Am J 
Prev Med. 2015 Dec;49([ADDRESS_1214631] 4):S383 -90.04WP9S
[Pi[INVESTIGATOR_63466], Tamara, et al 
2010]Pi[INVESTIGATOR_63466] T, Lexau C, Farley  MM, Hadler J, 
Harrison LH, Bennett NM, et al. Sustained 
reductions in invasive pneumococcal disease 
in the era of conjugate vaccine. J I nfect Dis 
2010;201(1):32- 41.03R5S4
[Romero -Steiner, S., et al 
1997]Romero- Steiner S, L ibutti D, Pais LB, 
DykesJ, Anderson P, Whitin JC, et al. 
Standardization of an opsonophagocy tic 
assay  for the measurement of functional 
antibody  activity  against streptococcus 
pneumoniae using differentiated HL -60 
cells. Clin Diagn Lab Immunol 
1997;4(4):415- 22.03NWQ5Â 
Â  05H6VD
07XD6Y
PRODUCT:   V116  117
PROTOCOL/AMENDMENT N O.:  001 -01  
V116 -001-01FINAL PROTOCOL 11-MAY -2020
[Simonsen, L ., et al 2014] Simonsen L , Tay lor RJ, Schuck- Paim C, 
Lustig R, Haber M, Klugman KP. Effect of 
13-valent pneumococcal conjugate vaccine 
on admissions to hospi[INVESTIGATOR_307] 2 y ears after its 
introduction in the [LOCATION_003]: a time series 
analysis. Lancet Respir Med. 2014 
May;2(5):387 -94.04KVRV
[U.S. Food and Drug 
Administration 2009]U.S. Food and Drug Administration (CDER, 
CBER, CDRH). Guidance for industry  
patient -reported outcome measures: use in 
medical product development to support 
labeling claims [I nternet]. Washin gton: U.S. 
Department of Health and Human Services; 
2009. Available from: 
https://www.fda.gov/downloads/drugs/guida
nces/ucm193282.pdf04MG9J
[van der L inden, M., et al 
2015]van der Linden M, Falkenhorst G, Perniciaro 
S, Imohl M. Effects of infant pneumoc occal 
conjugate vaccination on seroty pe 
distribution in invasive pneumococcal 
disease among children and adults in 
German y. PLoS One. 2015 Jul 
1;10(7):e0131494.04KVRY
[Waight, P. A., et al 2015] Waight PA, Andrews NJ, L adhani SN, 
Sheppard CL, Slack MP, Miller E. Effect of 
the 13 -valent pneumococcal conjugate 
vaccine on invasive pneumococcal disease 
in England and Wales 4 years after its 
introduction: an observational cohort study . 
Lancet Infect Dis. 2015 May ;15(5):535 -43.04KTF2Â 
Â  05H6VD
07XD6Y